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Doxorubicin, as one of the most efficacious cytotoxic anticancer drugs, has been 
clinically used for more than thirty years. Despite its long history of use, the efficacy 
of treatment and the severity of myelosuppression after chemotherapy vary greatly 
from patient to patient, thus posing a major obstacle for clinical treatment of patients 
with doxorubicin. Understanding the sources of this pharmacodynamic variability, 
especially in terms of pharmacokinetic variability, potentially enhances the prospect 
of predicting toxicity, and individualising dosing for optimal outcome. Therefore, in 
the studies we have focused on investigation of the associations of the 
pharmacodynamics of doxorubicin (doxorubicin-induced hematologic toxicities and 
the tumour response) with the pharmacokinetic parameters and the genetic variants in 
CBR1 and CBR3 which encode the two main metabolizing enzymes that extensively 
reduce doxorubicin to doxorubicinol, the less hematologic and tumoural active 
metabolite.  
 
In this clinical study, ninety-nine female breast cancer patients (64 Chinese, 26 
Malays, 7 Indians and 2 other ethnic origins) received the first-line doxorubicin at 
75mg/m2 per dose every 3 weeks. Intra-tumoral CBR1 and CBR3 expressions had 
been investigated before the patients received chemotherapy. Pharmacokinetic data, 
toxicities, and tumour reductions were evaluated after the first cycle of doxorubicin 
treatment. Comprehensive sequencing of all coding regions, including the splice-site 
junctions of CBR1 and CBR3, was performed in the breast cancer patients. The allele 
frequencies of the important variants identified in the breast cancer patients were also 
examined in larger cancer-free Asian groups. 
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We found that the patient’s body surface area was not associated with the 
pharmacokinetics and pharmacodynamics of doxorubicin. However, the wide inter-
patient variations observed in leukocyte suppression at nadir may be correlated with 
the plasma concentration ratios of doxorubicinol to doxorubicin at 1 hr after 
doxorubicin administration and the non-synonymous coding region variant in CBR3, 
C4Y (11G>A); whereas the doxorubicin-induced tumour reduction may be related to 
the pharmacokinetics parameter, K21, (the rate constant of peripheral tissue 
compartment to central blood compartment)  and the genetic variant, CBR3, C4Y 
(11G>A).  
 
The most influential variant of CBR3 (11G>A) appeared to be associated with lower 
doxorubicinol AUC and lower doxorubicinol AUC/doxorubicin AUC metabolic 
ratios, suggesting that patients with the G allele may have greater catalytic conversion 
of doxorubicin to the less active metabolite, doxorubicinol. Consistently, patients with 
the G allele experienced significantly less leukocyte suppression at nadir and less 
tumour reduction. Higher intra-tumoral transcriptional expression of CBR3 mRNA 
was found in patients with the G allele, which indicates that this variant may function 
on CBR3 expression. It was further found that this variant was the only genotype 
contributory to the final multiple linear regression model of leukocyte suppression at 
nadir, thus indicating its potential use for doxorubicin dosage individualization. The 
correlations of this genotype-phenotype in the subgroup of Chinese patients were 
found to be similar to the main cohort. The result suggests that the observed 
genotype-phenotype correlations were consistent because of the internal validation in 
the largest subgroup-Chinese. Chinese patients experienced more hematologic 
  X
toxicities than Malays and Indians. The G allele frequency of CBR3, C4Y (11G>A) in 
Chinese was also significantly lower than that in Indians and in Caucasians. 
Therefore, the CBR3 11G>A genotype may account for the greater doxorubicin-
induced myelosuppression observed in Chinese. The reported functional allele CBR3 
V244M (730G>A) and the intronic variant CBR1 397+125G>T had significantly 
higher doxorubicinol AUC.  
 
The research described in this dissertation has extended our understanding on the 
inter-patient variation in doxorubicin caused hematologic toxicities and efficacy. The 
analysis of PK and PG of CBRs could provide useful information for individualized 
chemotherapy with doxorubicin. 
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Anticancer chemotherapy began in the 1940s with the first use of mustine as an 
anticancer drug to treat a patient with leukemia (Goodman, et al., 1946). In the 
following half a century after that event, many cytotoxic anticancer drugs, such as 
anthracyclines, platinum-based agents, campotothecins, and taxanes, had been 
successfully discovered and developed in clinical cytotoxic chemotherapy. Preclinical 
researches have gradually revealed the mechanisms of action of these cytotoxic 
anticancer drugs. The target of these cytotoxic anticancer drugs is on DNA. These 
drugs disrupt cell proliferation (William, et al., 2004). In order to provide better cares 
for cancer patients, clinical researchers have concentrated on finding the best 
chemotherapy regimens for these cytotoxic anticancer drugs to achieve higher 
anticancer efficacies but lower risk of severe adverse effects.  
 
In the later years, cancer researches have revealed essential traits of cancer cells 
compared to normal cells. These include: the capability of proliferation because of 
self-sufficiency in growth signals; insensitivity to growth-inhibitory signals; evasion 
of apoptosis and senescence; limitless replicative potential; sustained angiogenesis 
and potential to invade tissue and to metastasize (Hanahan, et al., 2000). Novel 
molecular disease-specific targets have been identified along with the key traits of 
cancer cells. At present, some molecular targeted anticancer drugs have been 
developed and are undergoing preclinical studies and clinical trials (William, et al., 
2004). For example, nuclear factor-kappa B (NF-κB), as an antipopototic transcription 
factor, was found to increase the activity or over-expression in many types of cancer 
cells. Specific NF-κB inhibitors like curcumin and BAY11-7082 are promising drugs 
in clinical treatments of cancer patients (Van Waes, 2007; Freudlsperger, et al., 2008).  
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The development of the novel molecular targeted anticancer drugs is a potential 
strategy today. However, improvement in the use of these existing cytotoxic 
anticancer drugs is equally important for more effective care of cancer patients. After 
consideration of the costs, availability and benefits, 17 existing cytotoxic anticancer 
drugs (bleomycin, chlorambucil, cisplatin, cyclophosphamide, doxorubicin, etoposide, 
5-fluorouracil, methotrexate, prednisolone, procarbazine, tamoxifen, vincristine, 
vinblastine, cytarabine, dactinomycin, daunorubicin, and 6-mercaptopurine) with two 
antiemetics (a dopamine receptor and a 5-HT3 receptor antagonist) as well as 
dexamethasone have been listed in the highest priority and considered as the most 
essential anticancer drugs in clinical anticancer chemotherapy, announced in a World 
Health Organization consultation (Sikora, et al., 1999; http://www.who.int/emlib/).  It 
is possible that the existing cytotoxic anticancer drugs will be continuously used in 
clinical cancer chemotherapy for the next few decades (Gurney, 2002).  
 
The existing cytotoxic anticancer drugs are efficient in killing off cancer cells by 
disrupting the proliferation of cancer cells. However, they, at the same time, also 
disrupt the proliferation of healthy normal cells. In this regard, therapeutic window 
between anticancer efficacy and severe adverse effects of the existing cytotoxic 
anticancer drugs is very narrow. It means that there may not have enough difference 
between the effective dose to kill cancer cells and the dose to cause the severe adverse 
effects in the same patient. Using inappropriate dosage to treat patients may lead to 
unpredictable effects. High-dosage would give rise to severe or fatal adverse effects, 
while under-dosage would reduce the anticancer efficacy. To find out the appropriate 
dosage to achieve high anticancer efficacy with low risk of severe adverse effects has 
been one of the most important issues in clinical cancer chemotherapy.   
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Conventionally, dose in cytotoxic anticancer chemotherapy often uses a maximum 
tolerated dose (MTD), where the highest drug dose does not cause unacceptable 
adverse effects. In 1958, a pediatrician, Pinkel, examined previous studies on five 
cytotoxic anticancer drugs (mechlorethamine, methotrexate, 6-mercaptopurine, 
actinomycin D and triethylenethiophosphoramide) and found that when the MTDs of 
the five drugs were normalized by body surface area (BSA), they were similar among 
different animals and between pediatric and adult human (Pinkel, 1958). Together 
with other findings that BSA was proportional to some physiological functions such 
as blood volume, basal metabolic rate and liver volume, the use of patient’s BSA to 
calculate the starting dosage of the cytotoxic anticancer drugs was recommended at 
that time and this method has become a standard practice clinically for most cytotoxic 
anticancer drugs.  However, the accuracy of this method was questioned because 
many further researches found that inter-patient’s BSA failed to correlate with wide 
inter-patient variations in the pharmacokinetics of the most cytotoxic anticancer drugs 
(William, et al., 2004).  
 
 
Clinical pharmacokinetics (PK) is a study of the time course of drug absorption, 
distribution, metabolism and elimination in human body (William, et al., 2004). The 
area under the plasma concentration-time curve (AUC), the highest observed plasma 
concentration (Cmax) or the steady-state concentration for continuous infusion (Css), 
clearance (Cl), as well as the elimination half-life (t1/2) are commonly used 
pharmacokinetic parameters to describe drug disposition in patients (Goh, et al., 
2000).   
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Clinical pharmacodynamics (PD) is a study of the action or effects of drugs in patients 
(William, et al., 2004). Clinical pharmacodynamics of cytotoxic anticancer drugs 
mostly focuses on the drug induced toxicities and efficacy.  
 
Although BSA failed to correlate with inter-patient variations in the pharmacokinetics 
of the most cytotoxic anticancer drugs, many previous investigations showed that 
cytotoxic anticancer drugs induced toxicities had been correlated with 
pharmacokinetic parameters such as AUC, Css, Cmax, and Cl. And some anticancer 
efficacy had been correlated with pharmacokinetic parameters (Desoize, et al., 1994, 
Newell, 1994, Canal, et al., 1998; William, et al., 2004). These pharmacokinetic-
pharmacodynamic (PK-PD) correlations provide a background that dose optimisation 
for individual patients could be calculated from the PK-PD correlations (Canal, et al., 
1998). For example, our early studies have demonstrated that docetaxel AUC was 
significantly correlated with the docetaxel induced hematologic toxicity, neutropenia 
(r=-0.48 and p= 0.01 between docetaxel AUC and nadir neutrophil count (ANC)) 
(Goh, et al., 2002). Docetaxel AUC together with two other parameters, alanine 
aminotransferase levels (ALT) and alpha-1-acid glycoprotein (A1AG), could predict 
the inter-patient’s nadir neutrophil counts (the final model: log(nadirANC)=0.54-
2.5310-2ALT+ 0.41A1AG-1.3310-4AUCdocetaxel, r2=0.736, and p<0.001) (Goh, 
et al., 2002).  Nowadays, this approach of dose optimisation for individuals based on 
PK-PD correlations has even been a subject of investigation in cancer therapy.  
 
Pharmacogenetics (PG), another rapidly developing field in clinical research, is the 
study of genetic variants that may influence the absorption, distribution, metabolism 
and elimination of a drug (PK) and the consequence of its efficacy and toxicity (PD) 
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(Roses, 2000; Blackhall, et al., 2006). It aims not only to understand inter-patient 
variations, but also to identify the bio-markers to predict drug toxicity and/or efficacy 
in individual patients.  
 
When patients received standard BSA-based dosage of a cytotoxic anticancer drug, 
wide inter-patient variations in anticancer drug efficacy, toxicities and 
pharmacokinetic parameters were observed. The inter-patient variations in cytotoxic 
anticancer drug PD and PK are due to non-genetic factors and genetic factors. Non-
genetic factors include drug-drug interactions, patients’ age, liver and renal function, 
concomitant diseases, nutritional status, smoking, and alcohol consumption. Genetic 
factors are due to genetic variants located at the genes that encode drug metabolizing 
enzymes, drug transporters and drug targets. These genetic variants would alter the 
gene expression and/or gene function, thus, affecting the PK and PD outcomes of 
patients (McLeod, 2004, Lee, et al., 2005, Bosch, 2008).  
 
Many studies have demonstrated the correlation of genetic variants with the PK and 
PD of individual patients. Usually, about 15-30% of the inter-patient variations in PK 
and PD may be due to genetic variants; in some special cases, nearly up to 95% of 
inter-patient variations would be influenced by genetic variants (Evans, et al., 2003; 
Eichelbaum, et al., 2006). In anticancer chemotherapy, the two best studied examples 
are thiopurine methyltransferase (TPMT) genetic variants and uridine diphosphate 
glucuronosyltransferase 1A1*28 (UGT1A1*28) genetic variant. TPMT is the 
predominant enzyme to catalyze the S-methylation of the thiopurine drugs, 6-
mercaptopurine. Patients with TPMT deficiency or lower TPMT activity are at high 
risk of severe hematologic toxicity after receiving standard dose of 6-mercaptopurine. 
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Genetic variants in TPMT are highly related to TPMT deficiency or lower TPMT 
activity, and are thus used to adjust 6-mercaptopurine dose intensity (Yates, et al., 
1997). Another good example is UGT1A1*28.  UGT1A1 catalyzes SN-38, which is 
an active metabolite of anticancer drug irinotecan, to SN-38G, which is an inactive 
conjugated metabolite of irinotecan. Diarrhea and leucopenia are the dose-limiting 
toxicities of irinotecan. Both toxicities are associated with higher levels of SN-38 in 
patients. Genetic variant UGT1A1*28 has shown to be highly correlated with SN-38 
glucuronidation, diarrhea and leucopenia as well. Thus, UGT1A1*28 is a useful 
biomarker in dose optimisation of irinotecan (Iyer, et al., 2002). Recently, based on 
validated results, the food and drug administration (FDA) has approved changing 
labels on the two cytotoxic anticancer drugs: 6-mercaptopurine and irinotecan. The 
genetic tests have been recommended for applications in adjusting the safer dosage 
for individual patients who need to be treated with either of the two anticancer drugs 
(http://www.fda.gov/cder/genomics/genomic_biomarkers_table.htm). However, to 
date, the genetic biomarkers of most other cytotoxic anticancer drugs commonly used 
for treatment of cancer patients haven’t been studied clearly and completely. Future 
studies to evaluate genetic variant effects on cytotoxic anticancer drugs will likely 
yield important results that may be used to predict treatment outcome and/ or may be 
implemented in individualized drug therapy.    
 
Briefly, it is well known that inter-patient variations in anticancer drug efficacy and 
toxicities are wide when cancer patients receive a BSA standardized dose of cytotoxic 
anticancer drugs. Anticancer drug PK-PD correlations could provide useful 
information for therapy optimization. Furthermore, pharmacogenetics is a useful way 
to identify influential genetic variants to be used to explain and predict inter-patient 
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variations in PK and PD. In this study, therefore, we will focus on doxorubicin (trade 
name Adriamycin), one of the seventeen anticancer drugs listed in the highest priority 
announced by World Health Organization. Doxorubicin, as a highly efficacious 
anticancer drug, has been commonly used as the first line anticancer drug for breast 
cancer. Doxorubicin clinical dosage is based on a patient’s BSA, and its use is limited 
because of its severe hematologic toxicities, neutropenia and leukopenia. Knowledge 
about the PK-PD correlations of doxorubicin is scarce. Moreover, there is no clinical 
report available on the association of genetic variants in the doxorubicin metabolic 
pathway with doxorubicin-induced hematologic toxicities. Thus, in this thesis we will 
try to establish the correlation of doxorubicin-induced efficacy and hematologic 
toxicities in Singaporean breast cancer patients with the pharmacokinetics of 
doxorubicin, and the correlation of the genetic variants in the main metabolizing 
enzymes of doxorubicin with PK and PD.  
 
In this thesis, Chapter 2 summarizes various findings on the pharmacodynamics (drug 
response of toxicity and efficacy), pharmacokinetics and pharmacogenetics of 
doxorubicin. Chapter 3 describes the clinical trial used in this study, methodologies 
for the PK, PG and statistic analysis. Chapter 4 assesses the PD, PK and PG of 
doxorubicin in our patients, and the correlations of the toxicity and the efficacy with 
the PK and PG. Chapter 5 reviews all findings raised in this thesis. Finally, Chapter 6 












2.1 Introduction of doxorubicin  
The first anthracycline antibiotics was daunorubicin isolated early in 1957 from the 
actinobacterium Streptomyces peucetius (Di Marco, et al., 1981). Later in 1969, 
Arcamone et al. further discovered doxorubicin, a daunorubicin analogue, from 
Streptomyces peucetius var. caesius, a mutagenic Streptomyces peucetius (Arcamone, 
et al., 1969). Since then, many research reports related to pharmacodynamics and 
pharmacokinetics of doxorubicin have been published. This literature review will 
focus on the molecular structure, pharmacodynamics, pharmacokinetics and 
pharmacogenetics of doxorubicin.   
 
2.2 Molecular structure of doxorubicin 
The molecular structure of doxorubicin is shown in Figure 2.1. Doxorubicin consists 
of a tetracyclic aglycone structure linked to an amino sugar, called daunosamine, by a 
glycosidic bond at the C-7 in ring A. This amino sugar produces a hydrophilic center 
for doxorubicin. A short chain with a carbonyl group at C-13 and a hydroxyl group at 
C-14 attaches to ring A at C-9. A quinine group presents in ring C and a 
hydroquinone group presents in ring B. A methoxyl substituent at C-4 links to ring D. 
(Arcamone, et al., 1969; Minotti, et al., 2004). The only structural difference between 
doxorubicin and daunorubicin is that it is a hydroxyl group at C-14 in doxorubicin, 
whereas it is a methyl group at C-14 in daunorubicin. The complex structure of 




























Figure 2.1 The molecular structure of doxorubicin 
(C27H29NO11; Molecular Mass=543.52) 
 
2.3 Main mechanisms of anticancer cytotoxicity action 
Since the introduction of doxorubicin into clinical practice in the early 1970s, it has 
become one of the most effective chemotherapy treatments for a broad range of 
malignant tumours such as lymphomas and various solid tumours such as breast 
cancer, small cell lung cancer and ovarian cancer (Ogura, 2001). Various mechanisms 
of action of doxorubicin–induced anticancer cytotoxicity have been discovered. 
However, some issues remain as a matter of debate and are unclear. Thus, the 
mechanisms of action have been the centre of intensive investigations. Recently, Dr 
Giorgio Minotti and his colleagues had reviewed the existing findings and 
summarized the main mechanisms of action of anticancer cytotoxic activities which 
include inhibition of topoisomerase II (topo II) triggered by DNA intercalation, 
oxidative damage mediated by generation of free radicals, apoptosis induced by 
tumour protein p53-dependent and/or tumour protein p53-independent pathway and 
interactions with proteasome to mediate-transport doxorubicin into the nucleus 
(Minotti, et al., 2004). Figure 2.2 published on pharmacogenomics knowledge base, 
shows the main mechanisms of doxorubicin anticancer cytotoxicity action (Klein, et 
al., 2004; http://www.pharmgkb.org/) . 
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Figure 2.2 Main mechanisms of doxorubicin anticancer cytotoxicity action.  





Dox-doxorubicin; Topo2A-topoisomerase II; ROS-reactive oxygen species, like 
superoxide anion (O2·−), hydrogen peroxide (H2O2) and hydroxyl adicals (OH·); Dox-
semiquinone-doxorubicin-semiquinone; ABC transporters-ATP-binding cassette 
transporters; RALBP1-ralA binding protein 1; SLC22A16-solute carrier family 22 
(organic cation/carnitine transporter), member 16; CAT-catalase; SOD1-superoxide 
dismutase 1, soluble; GPX1-glutathione peroxidase 1; NOS3- nitric oxide synthase 3 
(endothelial cell); NQO1-NAD(P)H dehydrogenase, quinone 1; XDH-xanthine 
dehydrogenase; ERCC2-excision repair cross-complementing rodent repair 
deficiency, complementation group 2; MLH1-DNA mismatch repair protein Mlh1; 
MSH2-mutS homolog 2; TP53-tumor protein p53; NFKB1-nuclear factor kappa-B, 
subunit 1.   
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Firstly, the inhibition of topoisomerase II triggered by DNA intercalations as the first 
mechanism was characterized (Tewey, et al., 1984; Cortés-Funes, et al., 2007). 
During cell replication, topoisomerase II, as a nuclear enzyme functions to alter the 
topological state of double-stranded DNA, causing the transient double-stranded DNA 
to break and then rejoin DNA after changing the twisting status of the double helix. 
However, if cells are treated with doxorubicin, topoisomerase II function is inhibited. 
In the nucleus, doxorubicin directly intercalates into the DNA double-stranded helix. 
Doxorubicin’s rings B and C overlap with the base pairs; ring D passes through the 
intercalation site; and the amino sugar located in the DNA minor groove interacts 
with flanking base pairs immediately adjacent to the intercalation site (Minotti, et al., 
2004). Intercalation of doxorubicin with DNA stabilizes the topoisomerase II-DNA 
complex, preventing the DNA double-stranded helix from rejoining after the breakage 
of transient double-stranded DNA by topoisomerase II, and thereby disrupting cell 
replication. 
 
This mechanism has been observed when cancer cells were exposed to doxorubicin 
concentration as low as 1-2µM (equivalent to 0.544-1.087µg/ml) in vitro. In clinical 
setting, after bolus administration of doxorubicin, the peak plasma concentrations 
(Cmax) and the tumor tissue concentrations of doxorubicin in patients could achieve 
the in vitro concentration (Lee, et al., 1980). The concentrations of doxorubicin in 
lymphoma cells in patients with lymphoma and in nucleated blood cells in patients 
with multiple myeloma have been found to be above the concentration for a few days 
(Speth, et al., 1987; Andersen, et al., 1999).  Therefore, this mechanism is considered 




Secondly, when the concentrations of doxorubicin in vitro in cancer cells are much 
higher than 2µM, generation of free radicals can be detected in the cells and oxidative 
damage mediated by the generation of free radicals may play a key role in cell death. 
A number of NAD(P)H (nicotinamide adenine dinucleotide phosphate reduced form) 
-oxidoreductases, including cytochrome P450 or -b5 reductases, mitochondrial 
NADH dehydrogenase, xanthine dehydrogenase, endothelial nitric oxide synthase 
(reductase domain), catalyze the quinine group in doxorubicin ring C to accept a free 
electron to form semiquinine doxorubicin. This resulting free radical semiquinine 
reacts with molecular oxygen to produce the superoxide anion (O2·−), hydrogen 
peroxide (H2O2) and hydroxyl radicals (OH·). These free radicals have been reported 
to contribute to the anticancer toxicity of doxorubicin through direct DNA cleavage, 
the production of lipid peroxidation to damage cell membrane and the increase of 
ceramide generation to activate proapoptotic cycle (Speth et al., 1988; Minotti, et al., 
2004).  
 
Thirdly, doxorubicin as an extracellular signal to induce apoptosis has been found to 
activate tumour protein p53-dependent pathway and/or tumour protein p53-
independent pathway. The tumour protein p53 is a DNA binding protein. Doxorubicin 
could increase the level of the tumour protein p53. This results in up-regulation of the 
cyclin-dependent kinase inhibition protein p21waf1/cip1, and thus inhibiting DNA 
synthesis and causing G1 arrest (Minotti, et al., 2004). On the other hand, 
doxorubicin-induction of apoptosis has been demonstrated through several tumour 
protein p53-independent pathways. One pathway is that doxorubicin directly 
stimulates sphingomyelinases (SMases) to hydrolyze sphingomyelin (SM) and 
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generate ceramide. This ceramide as a second messenger induces apoptosis by 
activating JNK (c-Jun N-terminal kinase) pathway and blocking serine-threonine 
Akt/PKB (protein kinase B) survival pathway (Kolesnick, 2002; Minotti, et al., 2004). 
The other pathway is that doxorubicin directly damages mitochondria to cause 
cytochrome c release, resulting in cancer cell apoptosis (Minotti, et al., 2004).   
 
Fourthly, proteasomes transport doxorubicin into the nucleus. Since the primary 
anticancer cytotoxicity mechanism of topoisomerase II inhibition occurs in the 
nucleus, accumulation of doxorubicin in the nucleus becomes more important. Recent 
studies have shown that doxorubicin going into the nucleus is not only by passive 
diffusion, but also by a specific carrier. The specific carrier is the normal degradation 
protein, 26S proteasome. In cytoplasm, doxorubicin binds with 26S proteasome with 
high affinity to form a doxorubicin-proteasome complex. When this complex 
translocates into the nucleus through nuclear pores, doxorubicin dissociates from the 
proteasome and then binds with DNA with higher affinity (Kiyomiya, et al., 1998; 
Kiyomiya, et al., 2001, Minotti, et al., 2004). This mechanism has being utilized in 
preclinical and clinical studies for combinational chemotherapy of doxorubicin.  
Bortezomib is a novel proteasome inhibition anticancer drug. Inhibition of 
proteasome by bortezomib prevents the degradation of inhibitory protein IkB, thus 
inhibiting NF-kB antiapoptotic activity. Owing to the distinct binding sites of 
proteasome between bortezomib and doxorubicin, some preclinical studies showed 
synergic effects when the two drugs are used together (Minotti, et al., 2004). More 
recently, a few clinical studies have successfully demonstrated the combinational use 
of the two drugs in the treatment of patients with advanced cancer (Loconte, et al., 
2008; Lee, et al., 2008).    
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2.4 The clinical use of doxorubicin for breast cancer 
Breast cancer is the commonest cancer in Singapore women. It currently accounts for 
22.8% of all Singapore female cancers (Tan, et al., 2008). The trend of overall age 
standardized incidence rate was continually increasing from 1968 to 2002 with an 
average annual increasing rate of about 3 percent. The incidence rate in 1998-2002 
reached to 54.9 annual cases per 100,000 Singapore women (Lim, et al., 2007). The 
continuously increasing incidence rate in Singapore poses a strong demand in 
improving the public awareness in early diagnosis, prevention, as well as therapies of 
breast cancer.  
 
The therapy strategies of breast cancer are based on the stage of tumour development 
and tumour characteristics. Chemotherapy is usually recommended for breast cancer. 
Neoadjuvant chemotherapy given before surgery is to attempt to reduce the size of the 
primary tumour and to increase the likelihood of breast conservation. In contrast, 
adjuvant chemotherapy given after surgery is to destroy leftover cells that may be 
present after surgery, which will help prevent a possible cancer reoccurrence and 
improve overall survival. Metastatic breast cancer is a more advanced breast cancer 
which is almost incurable. In the metastatic stage, chemotherapy is to prolong the 
patient’s life and to palliate patient’s symptoms. Doxorubicin remains currently one of 




2.4.1 Doxorubicin as a single agent for breast cancer 
2.4.1.1 Efficacy of doxorubicin 
As a single agent used in the first-line (patients previously untreated with any 
chemotherapy regimen) or in the second-line chemotherapy (patients previously 
treated with first-line chemotherapy regimen with drugs not containing doxorubicin, 
but patients may fail to respond to the first-line chemotherapy), doxorubicin has 
demonstrated high anticancer activity for advanced breast cancer. Doxorubicin has 
been reported to give 40-85% overall response rate (ORR: complete response (CR) 
and partial response (PR)) as a single agent in the first-line chemotherapy for 
advanced breast cancer (Hoogstraten, et al., 1976; Carmo-Pereira, et al., 1987;  
Richards, et al., 1992; Paridaens, et al., 2000). While as a single agent in the second-
line chemotherapy, the ORR of doxorubicin reported is between 20% and 40% 
(Legha, et al., 1982; Paridaens, et al., 2000). 
 
The mean of ORR of doxorubicin is 43% when it was used as a single agent in the 
first-line chemotherapy for metastatic breast cancer (Sledge, 1999). It is higher than 
the mean of ORR of other cytotoxic anticancer drugs such as cyclophosphamide 
(36%), fluorouracil (28%), mitoxantrone (27%), and methotrexate (26%) as a single 
agent in the first-line chemotherapy for metastatic breast cancer (Sledge, 1999). 
Compared to doxorubicin, the two analogues, epirubicin and idarubicin, have shown 
no improvement in ORR, response duration and survival time as a single agent in the 
first-line chemotherapy to treat advanced breast cancer (Lopez, et al., 1989; Perez, et 
al., 1991). Thus, among the cytotoxic anticancer drugs presently available, 
doxorubicin is one of the most efficacious and is highly recommended for the 
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treatment of breast cancer, especially advanced breast cancer including locally 
advanced breast cancer and metastatic breast cancer. 
 
2.4.1.2 Doxorubicin dose-response relationship 
Until now, doxorubicin dosage used in clinical chemotherapy has been calculated by 
patient’s body surface area (BSA). In the clinical settings to treat advanced breast 
cancer with doxorubicin, efficacy has been proven to be related to doxorubicin dose. 
There is a steep dose-response relationship for doxorubicin. An increase of dose 
would cause a considerable increase in anticancer efficacy in patients (Carmo-Pereira, 
et al., 1987; Jones, et al., 1987; Speth, et al., 1988). Carmo-Pereira et al. found that 
compared with low dose (35mg/m2, intravenous bolus, 3-weekly for 16 courses), high 
dose (70mg/m2, intravenous bolus, 3-weekly for 8 courses) produced higher ORR and 
survival time (58% vs. 25% and 20months vs. 8 months, respectively) (Carmo-Pereira, 
et al., 1987). Jones RB et al. also showed that response rates could be as high as 85% 
for advanced breast cancer patients who received doxorubicin at high doses between 
75 and 135mg/m2 monthly (Jones, et al., 1987). These results indicated that 
moderately high dose doxorubicin with superior schedule would result in greater 
overall response rate and/or overall survival for patients. 
 
2.4.1.3 Dose limiting toxicities of doxorubicin 
Although high dose would result in better anticancer efficacy, clinical dosage of 
doxorubicin is limited by its severe adverse effects: the acute dose-limiting 




High dose of doxorubicin is associated with remarkable hematologic toxicity, 
myelosuppression, which mainly includes neutropenia and leukopenia. 
Myelosuppression is the acute dose-limiting toxicity (DLT) of doxorubicin. After 
doxorubicin administration, the time course of myelosuppression typically occurs at 
day 7 to day 10, and recovers at day 19 to day 24 (Speth, et al., 1988). The nadir 
leukocyte is known to occur approximately at day 12 to day 16 (Benjamin, et al., 
1974). Leukopenia and neutropenia are severe and occur frequently in patients after 
doxorubicin treatment. About 18-32% of advanced breast cancer patients had grade 3 
and grade 4 leukopenia when they received 60mg/m2 or 75mg/m2 intravenous bolus 
every 3 week (Hoogstraten, et al., 1976; Lopez, et al., 1989; Paridaens, et al., 2000). 
77.8% of metastatic breast cancer patients had grade 4 neutropenia, and 12% of 
patients had febrile neutropenia (patient has fever ≥38.5°C with grade 4 neutropenia) 
when they received 75mg/m2 intravenous bolus every 3 week (Chan, et al., 1999). 
When patients have prolonged severe grade 4 neutropenia which had lasted for 7 days 
or when patients have febrile neutropenia, dose reduction in the following cycle of 
doxorubicin administration is required. 
 
Unfortunately, development of severe neutropenia and leukopenia induced by 
doxorubicin is unpredictable. These toxic effects may cause hospitalization of 
patients, occasionally, even death after doxorubicin administration. Thus, they pose a 
problem for the clinical care of patients receiving doxorubicin. Clinical studies have 
focused on finding out the correlations of pharmacokinetic-pharmacodynamic (PK-
PD) and the associations of genetic factors with pharmacokinetics and 
pharmacodynamics to predict doxorubicin induced severe myelosuppression, as well 
as to optimize the therapy scheme for individual patients.  
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The potential cardiotoxicity mainly manifested as congestive heart failure (CHF) is 
another lethal toxicity caused by doxorubicin. CHF is the cumulative dose-dependent 
and generally irreversible toxicity. CHF typically occurs in the 4 to 18 weeks after the 
last doxorubicin treatment cycle (Chan, et al., 1999). The risk of developing CHF is 
as low as 0.14% at the total dose less than 400mg/m2. However, it increases to 7% 
when the total dose reaches to 550mg/m2 and 30% when the total dose reaches to 
700mg/m2 (Lefrak, et al., 1973; Chan, et al., 1999, Product Information: Doxorubicin 
Hydrochloride for Injection, 2003). Although prolonging the infusion time of 
doxorubicin is a useful way to significantly reduce the risk of CHF, the application of 
prolonged infusion increases the incidence and severity of mucositis and 
myelosuppression (Bielack, et al., 1989; Danesi, et al., 2002). The limit of total dose 
of doxorubicin was suggested to 480mg/m2 (Cresta, et al., 2004). Presently, the 
recommended regimen for advanced breast cancer is 60 to 75mg/m2 intravenous bolus 
for 3 or 4 weeks, with a repeat of the same dose for 4 to 6 cycles (Product 
Information: Doxorubicin Hydrochloride for Injection, 2003). 
 
2.4.2 Chemotherapy with doxorubicin and docetaxel for breast cancer 
Doxorubicin is commonly used for breast cancer not only as a single agent, but also in 
combination with other anticancer agents. Combination chemotherapy was introduced 
in the 1960s. The rationale of combination chemotherapy is to increase efficacy and to 
reduce toxicity. This is usually done by combining two or several drugs with different 
mechanisms of action and/or with different dose-limiting toxicities (Lyss, et al., 1984). 
Until now, it is still a good approach to treat numerous types of cancers.  
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Traditionally, doxorubicin as the key component for breast cancer could be clinically 
used in combination with other agents such as cyclophosphamide and/or fluorouracil, 
and vincristine. These first-line doxorubicin containing combinational chemotherapies 
could enhance the mean of overall response rate from 43% to 51% for metastatic 
breast cancer patients (Sledge, 1999). Furthermore, the efficacy of the doxorubicin-
containing combinational chemotherapy is slightly higher than that of non-
doxorubicin containing combinational chemotherapy (ORR: 51% vs. 45%, 
doxorubicin-containing vs. non-doxorubicin containing combinational chemotherapy) 
(Sledge, 1999). These finding indicates that doxorubicin is important in combinational 
chemotherapy. 
 
More recently, the combination of docetaxel and doxorubicin has been studied. 
Docetaxel is a semisynthetic analogue of paclitaxel. The mechanism of action of 
docetaxel is to block tubulin de-polymerization and thereby disrupt mitosis (Pazdur, et 
al., 1992; Itoh, et al., 2002). Since the 1990s, clinical studies of docetaxel for breast 
cancer treatment have grown considerably (Itoh, et al., 2002). Docetaxel has been 
reported to have good benefit as a single agent in the first-line chemotherapy for 
metastatic breast cancer patients (ORR: 38%) (Piccart-Gebhart, et al., 2008). The 
recommended dose for locally advanced breast cancer and metastatic breast cancer is 
60 to 100mg/m2 through intravenous infusion over 1 hour with a repeat in every 3 
weeks (Product Information: TAXOTERE(R) intravenous solution, 2006).  
 
The important clinical finding for doxorubicin and docetaxel combination is that 
docetaxel achieved very high efficacy (ORR was as high as 55%) in the patients with 
anthracycline-resistant advanced breast cancer (Ravdin, et al., 1995; Valero, et al., 
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1995). These findings indicate that these two most active anticancer drugs for breast 
cancer are absent of complete clinical cross-resistance. In addition, doxorubicin and 
docetaxel have different mechanisms of action and different non-hematologic 
toxicities. Thus, combination of doxorubicin and docetaxel for breast cancer would be 
a reasonable treatment approach to be studied. 
 
The maximum tolerated dose (MTD) in the first-line chemotherapy of patients with 
metastatic breast cancer has been found at the dose level combining 50mg/m2 of 
doxorubicin and 85mg/m2 of docetaxel with the dose limiting toxicity (DLT) of 
neutropenia (Misset, et al., 1999). Two doses recommended in combinational use are 
doxorubicin 60mg/m2 with docetaxel 60mg/m2 every 3 weeks, and doxorubicin 
50mg/m2 with docetaxel 75mg/m2 every 3 weeks (Misset, et al., 1999). The efficacy 
of the combination of doxorubicin and docetaxel for breast cancer is impressive. The 
ORR has been reported to be about 63-67% including 15-17% of complete remissions 
(CR) for metastatic breast cancer patients who received combinational therapy with 
doxorubicin 60mg/m2 and docetaxel 60mg/m2 (Misset, et al., 1999; Cresta, et al., 
2004). Moreover, the higher ORR and CR have been measured for stage II and stage 
III breast cancer patients who received combinational therapies with doxorubicin 50 
or 56mg/m2 and docetaxel 75mg/m2 (87%-93% of ORR including 20%-33% of CR) 
(Miller, et al., 1999; von Minckwitz, et al., 1999).  
 
Besides the combinational schedule where the two drugs are given together in each 
treatment cycle, there are two other schedules used clinically. They are alternating 
schedule where doxorubicin and docetaxel are given on a cycle by cycle, and 
sequential schedule where docetaxel is given in the first four cycles followed by 
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doxorubicin for another four cycles. Cresta S et al. compared the three schedules for 
metastatic breast cancers. (See Table 1) (Cresta, et al., 2004). They found that there 
was no significant difference in anticancer efficacy among the three schedules (CR: 
15%, 14%, and 11%; ORR: 63%, 52%, and 61%; time of progression: 36weeks, 34 
weeks and 33 weeks for combination, alternating and sequential schedule 
respectively). However, more frequency of febrile neutropenia occurred in 
combinational schedule (22% vs. 7% for combination schedule vs. alternating 
schedule and 22% vs. 0% for combination schedule vs. sequential schedule), and the 
congestion heart failure only came out in combinational schedule (10% for 
combination schedule vs. 0% for alternating schedule and 0% for sequential 
schedule). More cardiac toxicities that happened in combinational schedule might be 
due to the higher total dose of doxorubicin used in the combination schedule 
(cumulative dose: 460 mg/m2 for combinational schedule; 294 mg/m2 for alternating 
schedule and 297 mg/m2 for sequential schedule) (Cresta, et al., 2004).  These 
findings suggest that the alternating and sequential schedule could be safer for the 
patients with metastatic breast cancer than the combinational schedule. Therefore, the 
alternating and sequential schedule could be the preferred schedules for patients with 
breast cancer, at least for patients with metastatic breast cancer. 
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Table 2.1 Comparison of treatment dose, efficacy and toxicities among three 
schedules of combination, alternating and sequential with doxorubicin (A) and 
docetaxel (T). 1  
 




No. of patients 41 42 38 
Dose A: 60 mg/m2 
T: 60 mg/m2 
A: 75 mg/m2 
T: 100 mg/m2 
A: 75 mg/m2 
T: 100 mg/m2 
Median of cumulative dose of 
A 
460 mg/m2 294 mg/m2 297 mg/m2 
Median of cumulative dose of 
T 
468 mg/m2 392 mg/m2 388 mg/m2 
Anticancer effects    
CR (%) 15 14 11 
ORR (%) 63 52 61 
Time to progression (weeks) 36 34 33 
Severe toxicities    
Grade 4 neutropenia (%) 88 83 71 
Febrile neutropenia (%) 22 7 0 
CHF (%) 10 0 0 
Notes: 
 1 All data were from Cresta, et al.’s publication, 2004 
 2 Combination: patients receiving doxorubicin and docetaxel with 1 hour interval. 






2.5 Clinical pharmacokinetics of doxorubicin 
2.5.1 Distribution  
Doxorubicin hydrochloride is available as red-orange powder for clinical use. It is 
soluble in aqueous and stable at pH value ranging from 3 to 7 (Prod Info Doxorubicin 
Hydrochloride for Injection, 2003). Previous publications demonstrated that after 
intravenous bolus administration, doxorubicin is rapidly and extensively distributed 
into most tissues (Speth, et al., 1988). In plasma, 50-85% of doxorubicin is bound to 
plasma proteins (Speth, et al., 1988). Concentrations of doxorubicin measured within 
1.5-5 hours after 30mg/m2 intravenous bolus administration in liver, lymph nodes, 
nucleated blood cells, colon and breast tumour tissues are always significantly higher 
by 5 to 30 times than those in plasma (Lee, et al., 1980). Figure 2.3 shows that 
doxorubicin remained at high concentrations for a few days in nucleated blood cells 
of patients, especially in circulating white blood cells (Speth, et al., 1988). Similar 
findings have been further demonstrated by Andersen, et al. (Andersen, et al., 1999). 
They found that after lymphoma patients were treated with doxorubicin at 50mg/m2, 
the concentrations of doxorubicin in mononuclear blood cells could be up to 5.5μM at 
24 hr, about 350 times higher than those in plasma. The concentrations of doxorubicin 
in patients’ lymphoma cells were similar to those in mononuclear blood cells 
(Andersen, et al., 1999). 70% to 90% of β-lymphocyte intracellular doxorubicin has 
been detected in the cell nucleus (Dessypris, et al., 1988). In the nucleus, doxorubicin 
has high affinity to DNA and slow reversible binding to DNA (Cummings, et al., 
1986). The sequestration into tumour tissues and nucleated blood cells and the 
binding to DNA would explain its anticancer efficacy and acute hematological 






Figure 2.3 Concentration-time curves of doxorubicin (●) and doxorubicinol (□) 
in plasma, and doxorubicin (○) in nucleated blood cells in 9 patients 
administrated at 1 minute bolus injection of doxorubicin of 30mg/m2. (This 
figure was published in Speth, et al., paper, 1988).  
 
* Noted: No doxorubicin main metabolite, doxorubicinol, was detected in 













2.5.2 Metabolism  
2.5.2.1 Metabolic pathway of doxorubicin  
Marc G. Sturgill et al. demonstrated the metabolic pathway of doxorubicin as shown 
in Figure 2.4 (Sturgill, et al., 2000). The pathway of doxorubicin disposition is 
complex. It initially involves a dominant phase I reduction reaction to hydrophilic 
metabolite doxorubicinol at the C13 position catalyzed primarily by cytoplasmatic 
nicotinamide adenine dinucleotide phosphate reduced form (NADPH) dependent 
carbonyl reductases (CBR1 and CBR3), with minor contributions from aldoketo-
reductases, (AKR1A1, AKR1B10 and AKR1C3) (Cusack, et al., 1988;  Ohara, et al., 
1995; Behnia, et al., 1999; Forrest, et al., 2000 (a); Olson, et al., 2003; Kaiserová, et 
al., 2005; Choi, et al., 2006; Blanco, et al., 2008; Kassner, et al., 2008). The amino 
sugar on doxorubicinol is removed by the microsomal NADPH cytochrome c 
reductase enzymes to form inactive 7-deoxydoxorubicinol aglycone (Sturgill, et al., 
2000). At the same time, a minor pathway is that the microsomal NADPH cytochrome 
c reductase enzymes remove the amino sugar from doxorubicin to form 7-
deoxydoxorubicin aglycone, followed by a further reduction catalysed by 
cytoplasmatic NADPH dependent carbonyl reductases and aldoketo-reductases to 
form 7-deoxydoxorubicinol aglycone (Sturgill, et al., 2000). Two major doxorubicin 
metabolites, doxorubicinol and 7-deoxydoxorubicinol aglycone, could been detected 
in patient’s plasma (Andersen, et al., 1999). 7-deoxydoxorubicinol aglycone is further 
oxidized to form demethyldeoxydoxorubicinol aglycone by cytochrome P450 
enzymes. Finally, doxorubicin and its metabolites undergo the phase II 
biotransformation through conjuction reactions to form glucuronide or sulfate 





















Figure 2.4 Metabolic pathway of doxorubicin. The bold arrows indicate the 
major pathway and the normal arrows indicate the minor pathway. (This 





















































































2.5.2.2 Major metabolite of doxorubicinol 
In the metabolic pathway of doxorubicin, the reduction of carbonyl group at C-13 in 
doxorubicin to form hydroxyl group at C-13 in doxorubicinol is rapid. This reduction 
occurs in all normal cells and cancer cells, especially in liver, kidney and red blood 
cells (Speth, et al., 1988).  
 
In vitro studies show that doxorubicinol is an active metabolite, but less cytotoxic 
than the parent drug of doxorubicin. The early study showed that doxorubicinol was 
the only metabolite with cytotoxicity to human marrow erythroid and myeloid 
progenitors (Dessypris, et al., 1986). However, it is 10-fold less toxic than 
doxorubicin to human marrow erythroid and myeloid progenitors (the half maximal 
inhibitory concentration (IC50): 4.6±0.63μM for doxorubicinol vs. 0.39±0.099μM for 
doxorubicin) (Dessypris, et al., 1986). Additionally, the anticancer effect of 
doxorubicinol is less potent than doxorubicin. Uptake and retention of doxorubicinol 
in the B-lymphocytes is 4-fold less than that of doxorubicin. Doxorubicinol is the only 
metabolite found cytotoxic to B-lymphocytes. Its toxicity is 16-fold less than that of 
doxorubicin (IC50: 3.7±0.73μM for doxorubicinol vs. 0.23±0.08μM for doxorubicin) 
(Dessypris, et al., 1988). Doxorubicinol is 1.5-fold less potent in growth inhibition of 
ovarian tumour cell lines than doxorubicin (Ozols, et al., 1980). 
 
In vivo, anticancer efficacy and haematological toxicity caused by the metabolite 
doxorubicinol may be not significant in patients. Doxorubicinol is more hydrophilic 
than doxorubicin. Unlike doxorubicin which remains high in normal tissues, some 
types of tumour tissues and white blood cells, the total amount of doxorubicinol 
detected is less than 1% of that of doxorubicin in most tissues of patients (Speth, et al., 
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1988). Several studies have reported that doxorubicinol was undetectable in patient’s 
tumour tissues; especially in breast tumour tissues (Cummings, et al., 1986, Stallard, 
et al., 1990). These findings meant that the clinical significance of anticancer efficacy 
of doxorubicinol could be minimal.  
 
In vitro studies have shown that doxorubicinol induced hematologic toxicity was 10% 
that of doxorubicin, and the uptake and retention of doxorubicinol in B-lymphocytes 
was about 5 times lower than that of doxorubicin (Dessypris, et al., 1988). However, 
no doxorubicinol could be detected in nucleated blood cells in patients (refer to Figure 
2.3) (Speth, et al., 1987; Speth, et al., 1988; Andersen, et al., 1999). Thus, 
hematologic toxicity induced by doxorubicinol in patients may be very limited.  
 
Although doxorubicinol may not have an important role in chemotherapeutic efficacy 
and hematologic toxicity, it is considered as the major contributor to cardiotoxicity. 
Many studies have shown that doxorubicinol had been associated with increased 
cardiac toxicity in mice (Forrest, et al., 2000; Olson, et al., 2003; Minotti, et al., 
2004). 
 
Doxorubicinol does not penetrate into tissue well. However, as a main metabolite, it is 
present in patients’ plasma (Speth, et al., 1988). Plasma levels of doxorubicinol 
relative to doxorubicin directly indicate the catalytic conversion of doxorubicin to 
doxorubicinol in patients.  In patients, doxorubicin is the most important therapeutic 
component providing anticancer efficacy and also hematologic toxicity. Thus, the 
catalytic conversion of doxorubicin to less cytotoxicity doxorubicinol is supposed to 
influence doxorubicin induced acute hematologic toxicities and anticancer efficacy in 
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patients. Higher catalytic conversion could reduce the amount of doxorubicin in 
patient’s tumour tissues and nucleated blood cells. These could probably account for 
the lower anticancer efficacy and lower hematologic toxicity. Therefore, the plasma 
levels of doxorubicinol relative to doxorubicin are expected to correlate better with 
the hematologic toxicity than plasma doxorubicin levels alone.  
 
Wide range of metabolic AUC ratios of doxorubicinol to doxorubicin in patient 
plasmas has been reported in many studies (Speth, et al., 1988, Ackland, et al., 1989; 
Piscitelli, et al., 1993; Twelves, et al., 1998). It varied from 0.15 to 3.8 in patients 
with advanced cancer (Ackland, et al., 1989), and 0.2 to 2.0 in cancer patients with 
abnormal liver biochemistry tests (Twelves, et al., 1998). These findings indicate that 
there are obvious inter-patient variations in the catalytic conversion. 
 
2.5.3 Elimination  
According to the metabolic pathway of doxorubicin, the primary elimination of 
doxorubicin and its metabolites is through biliary excretion. About 25-45% of overall 
drug has been found in cumulative faecal excretion, whereas only about 5% of overall 
drug has been detected in urine (Speth, et al., 1988).  
 
Clinical pharmacokinetics of doxorubicin has been described in many clinical studies. 
Its pharmacokinetics was demonstrated by two-compartmental or three-
compartmental models depending on the length of intravenous infusion, the sampling 
timing and the sampling numbers. The mean total plasma clearance of doxorubicin 
was reported to range from 30 to 40 l/h/m2. A distribution half life of 1.1 hr and 
elimination half life of 16.7 hr have been characterised by a two-compartmental 
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model (Robert, et al., 1982); while, mean half life of 4.2 min, 31.2 min and 13.1 hr 
has been described by a 3-compartmental model in patients after 3 min intravenous 
infusion (Eksborg, et al., 1985). 
 
2.6 Inter-patient variations in the PK and PD of doxorubicin 
In the clinical setting, the dose of doxorubicin is calculated according to the body 
surface area (BSA). Even though patients have received standard BSA-based dosage 
of doxorubicin, wide inter-patient variations in PK and PD (toxicities and efficacy) of 
doxorubicin have been observed in many studies.  
 
2.6.1 Inter-patient variations in PK  
In PK, 5-fold inter-patient variations in the doxorubicin plasma AUC after dose 
normalization have been noticed (Eksborg, et al., 1985). Piscitelli SC et al. found the 
same magnitude of the inter-patient variations in AUC of doxorubicin as that already 
presented, and furthermore they found the inter-patient variations in AUC of 
doxorubicin were not associated with doxorubicin BSA-based dosage (r=0.23, 
p>0.05) (Piscitelli, et al., 1993).  
 
The inter-patient variations in the metabolic AUC ratios of doxorubicinol to 
doxorubicin seem to be more obvious than those observed for doxorubicin plasma 
AUC. One previous study has reported up to 25-fold inter-patient variations of 
metabolic conversion of doxorubicinol to doxorubicin in patients with the infusion of 




2.6.2 Inter-patient variations in PD  
Significant inter-patient variations in doxorubicin-induced toxicities and efficacy have 
also been found. In doxorubicin-induced hematologic toxicities, up to 19-fold inter-
patient variations of white blood cell counts at nadir and 26-fold variations of platelet 
counts at nadir have been reported in advanced breast cancer patients who had 
received the same dosage of doxorubicin (60mg/m2) (Neidhart, et al., 1983). Up to 8-
fold inter-patient variations in the doxorubicin effect on the short-term tumoural 
regression have been observed in the breast cancer patients who had received a 
combinational therapy with 50mg/m2 of doxorubicin on day 1, 1mg/m2 of vincristine 
on day 2 and 6mg/m2 of methotrexate on days 3, 4, 5 (Robert, et al., 1983).   
 
However, no report showed that the inter-patient variations in the PD of doxorubicin 
were associated with patient’s BSA. Furthermore, the chemotherapy doses in the 
obese women were suggested to be smaller rather than greater. This was because the 
clearances of doxorubicin in the obese women were negatively correlated with their 
weights. These findings indicate that prediction of toxicities based on body surface 
area is largely imprecise (Grochow, et al., 1990).  
 
Nowadays, to precisely identify the risk of doxorubicin-induced severe 
myelosuppression and the tumour resistance to doxorubicin becomes an essential 
issue for the clinical use of doxorubicin. Establishing the PK-PD correlations of 
doxorubicin is one of the useful ways in improving the prediction of doxorubicin-




2.7 Reported PK-PD correlations 
Although BSA has failed to be associated with the PD of doxorubicin, the PK of 
doxorubicin has been reported to have good correlations with the PD of doxorubicin 
in the early clinical publications. 
 
For doxorubicin efficacy, the peak plasma concentrations of doxorubicin (Cmax) have 
been found to highly correlate with concentrations of doxorubicin in breast tumours 
after administration at 1 hour (r=0.76) (Stallard, et al., 1990).  The doxorubicin 
pharmacokinetic parameter A (the macro-rate constant of the compartmental PK 
analysis) was significantly related to the short-term tumour reduction (r=0.82) in the 
patients who were treated with doxorubicin in combination with vincristine and 
methotrexate (Robert, et al., 1982). These results suggest that the efficacy of 
doxorubicin may be associated with the distribution of doxorubicin into the tissue.  
 
For doxorubicin-induced hematologic toxicity, a correlation between the white blood 
cell counts at nadir and the steady-state doxorubicin concentration (Css) has been 
established in patients who were given continuous-infusions of doxorubicin with 
median duration of 12 weeks and mean maximum infusion rate of 3.92mg/m2/day (r=-
0.53) (Ackland, et al., 1989). When patients with small cell lung cancer were treated 
with doxorubicin in combination with cyclophosphamide and vincristine, a correlation 
between the surviving factor of white blood cells (nadir value/ baseline value) and the 
AUC of doxorubicin has been found (r=0.57) (Piscitelli, et al., 1993). These 
relationships imply that doxorubicin-induced hematologic toxicity may be related to 
the doxorubicin exposure in patient’s plasma.  
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However, these findings of the PK-PD correlations were not further validated. To the 
best of our knowledge, there are no clinical results to correlate the doxorubicin 
exposure with the severe hematologic toxicity in breast cancer patients treated with 
doxorubicin as a single agent by intravenous bolus administration. 
 
Through the above review, the relationships between the clinical PK parameters and 
the PD (drug efficacy and drug toxicity) of doxorubicin were limited, especially for 
the Singaporean breast cancer population. Thus, we would like to extensively 
investigate the relationship between the PK and the PD outcomes of doxorubicin in 
the breast cancer patients who will receive doxorubicin as a single agent in one 
treatment cycle.  
 
2.8 Inter-ethnic variations in the PD of doxorubicin 
The obvious inter-ethnic variations in doxorubicin-induced hematologic toxicity have 
been presented (Beith, et al., 2002; Ma, et al., 2002). A previous study carried out at 
the National University Hospital, Singapore, has shown significant inter-ethnic 
variations in myelotoxicity with standard adjuvant combination of doxorubicin 
(60mg/m2) and cyclophosphamide (600 mg/m2) regimen in breast cancer patients. 
There was higher frequency of grade 3 and 4 neutropenia in Chinese breast cancer 
patients (63.8%) compared to Caucasian patients (40%) when they received the same 
combinational chemotherapy (Beith, et al., 2002). Chinese breast cancer patients 
experienced more profound neutropenia compared to Caucasians patients. Similar 
results have been reported when comparing Hong Kong Chinese breast cancer 
patients with Caucasian patients treated with the same regimens (77% of patients with 
grade 3 and 4 neutropenia vs. 3.7% patients with grade 3 and 4 neutropenia, 
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respectively) (Ma, et al., 2002). The reason that causes the reported inter-ethnic 
variations in hematologic toxicity in patients treated with doxorubicin and 
cyclophosphamide combination is unclear. The authors of Ma, et al., suggested that 
the PK variations of doxorubicin, some genetic variants, different lifestyles, Chinese 
patients administrated with traditional Chinese medicine, and various body fat mass 
could account for this inter-ethnic variation (Ma, et al., 2002).  
 
Singapore is a multiethnic country in Southeast Asia. The three distinct Asian ethnic 
groups in Singapore are the Chinese (77%), Malays (14%) and Indians (8%) (Lee, et 
al., 2005). The inter-ethnic variations of doxorubicin induced hematologic toxicity 
among the three distinct Asian ethnic groups have not been explored, which 
motivated this investigation. 
 
2.9 Pharmacogenetics of doxorubicin 
2.9.1 The early studies on the pharmacogenetics of doxorubicin 
As discussed in the introduction, non-genetic factors and genetic factors would result 
in inter-patient variations on the PD and PK of cytotoxic anticancer drugs. Many 
inherited genetic variants on the genes, which encode drug metabolizing enzymes, 
drug transports and drug targets, have been revealed to be associated with the PK and 
PD in individual patient. Evaluating the effect of genetic variants on the metabolic 
pathway helps to elucidate the wide inter-patient variations encountered in clinical 
chemotherapeutic outcome of doxorubicin.  
 
One study has found that the genetic variants in the doxorubicin ATP-binding cassette 
transporters are associated with the marked inter-patient variations in doxorubicin 
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exposure (Lal, et al., 2008). The haplotype of ABCB1 c1236-2677-3435 CC-GG-CC 
variants has been found to be associated with higher ABCB1 expression in vitro. 
Breast cancer patients with this haplotype of CC-GG-CC variants, compared to the 
patients with CG-GC-CG or GG-CC-GG variants, had lower doxorubicin exposure 
levels. The other genetic variant of ABCG2 c.421C>A was related to the ABCG2 
expression in vitro, but was not related to the exposure level of doxorubicin in breast 
cancer patients (Lal, et al., 2008). Currently, it is unclear whether genetic variants in 
doxorubicin metabolizing enzymes can affect doxorubicin inter-patient variations on 
the PK of doxorubicin.  
 
Furthermore, using genetic variants to predict the doxorubicin induced clinical 
pharmacodynamics outcomes has not yet been fully revealed. The association of 
doxorubicin-induced tumour reduction with the genetic variant in doxorubicin related 
genes has not been reported. It is still unclear whether genetic variations in 
doxorubicin metabolizing enzymes would explain the inter-patient variations on the 
PD of doxorubicin. Therefore, it is necessary to investigate the association of the 
genetic variants in main doxorubicin metabolizing enzymes with doxorubicin-induced 
hematologic toxicities and anticancer efficacy in the patients treated with doxorubicin.  
 
2.9.2 Metabolism of doxorubicin to doxorubicinol 
The metabolism pathway of doxorubicin is clear and discussed in section 2.1.3.2. In 
cytoplasm, doxorubicin undergoes carbonyl reduction to form doxorubicinol, a less 
cytotoxic metabolite, by carbonyl-reducing enzymes: the NADPH dependent-human 
carbonyl reductases (CBR1 and CBR3) and aldo-keto reductases (AKR1A1, 
AKR1B10 and AKR1C3) (Cusack, et al., 1988;  Ohara, et al., 1995; Behnia, et al., 
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1999; Forrest, et al., 2000 (a); Olson, et al., 2003; Kaiserová, et al., 2005; Choi, et al., 
2006; Blanco, et al., 2008; Kassner, et al., 2008).  
 
Carbonyl reductases (CBRs) belong to the short chain dehydrogenase/reductase 
(SDR) family. Compared to the aldo-keto reductases, human carbonyl reductases 
would be the most efficient metabolizing enzyme in the conversion of doxorubicin to 
doxorubicinol. This was supported by in vitro findings that carbonyl reductases 
mainly reduced daunorubicin, an analogue of doxorubicin, to form daunorubicinol at 
optimal pH 6.0 in human liver and physiological pH 7.4 in rabbit liver cytosolic 
fraction (Ohara, et al., 1995; Kaiserová, et al., 2005). In addition, one latest in vitro 
significant finding showed that human CBR1, rather than AKR1C3, AKR1A1 and 
AKR1B10, was the predominant hepatic reductase to convert doxorubicin to 
doxorubicinol in liver (Kassner, et al., 2008). Furthermore, human CBR1 has shown 
to catalyze the reduction of doxorubicin to doxorubicinol by an in vivo study. In 
transgenic mice with over-expressed human CBR1 in the heart, 82% of doxorubicin 
was converted to doxorubicinol within 0.5 hr whereas in non-expressers only 5% of 
doxorubicin was converted to doxorubicinol in the same period of time (Forrest, et al., 
2000). This study indicated that human CBR1 had high catalytic efficiency in this 
reaction and the higher the human CBR1 expression the higher the doxorubicin 
conversion rate. 
 
Human CBR3 is the second human CBR gene found. It was identified in 1998 
(Watanabe, et al., 1998). CBR3 is located at 62 kilobases downstream from CBR1 on 
chromosome 21. In human, both CBR1 and CBR3 comprise 277 amino acids each 
and are the two main monomeric, cytosolic, and NADPH-dependent enzymes. The 
  39
amino acid sequence of human CBR3 has 72% identity with human CBR1, and 79% 
sequence homology to human CBR1.( Miura, et al., 2008) (Figure 2.5).  Based on the 
sequence similarity and similar catalytic properties for typical substrates like 
menadione in the presence of NADPH, human CBR3 had been presumed to 
contribute to doxorubicin metabolism (Lakhman, et al., 2005; Hoffmann, et al., 2007). 
In addition, an orthologue, the Chinese hamster carbonyl reductase 3 (CHCR3), which 
shares 86% sequence similarity with human CBR3, exhibits strong reductase activity 
towards daunorubicin (Terada, et al., 2003). One recent report has further confirmed 
this assumption that human CBR3 is another carbonyl reductase to convert its 
substrate doxorubicin to doxorubicinol in vitro (Blanco, et al., 2008).   
 
Apart from CBR1 and CBR3, CBR2 and CBR4 also belong to the short chain 
dehydrogenase/reductase (SDR) family. However, CBR2 and CBR4 may not be 
involved in doxorubicin phase I transformation in human (Oppermann, 2007). CBR2 
gene is not in the human genome; therefore CBR2 is not present in human tissues. But 
CBR2s are highly expressed in mitochondria of lung epithelial cells of mouse, guinea 
pig, and pig (Oppermann, 2007). CBR2s are homotetramers. And their sequences are 
of low similarities to that of monomeric human CBR1 and CBR3 (<30%) 
(Oppermann, 2007). CBR2 enzymes catalyze the reduction of various aliphatic, 
alicyclic and aromatic carbonyl compounds, and their function is postulated in the 
detoxication of xenobiotic carbonyl compounds and carbonyl compounds derived 
from lipid peroxidation. (Matsunaga, et al., 2006; Oppermann, 2007). CBR4 is located 
on human chromosome 4 (Hoffmann, et al., 2007). The sequences of CBR1 and 
CBR4 show low similarity (23% identity). Until now, the function and tissue 
distribution of CBR4 remain unclear.  
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hCBR1(a.a.)1      MSSGIHVALVTGGNKGIGLAIVRDLCRLFSGDVVLTARDVTRGQAAVQQLQAEGLSPRFH    60
hCBR3(a.a.)1      MSSCSRVALVTGANRGIGLAIARELCRQFSGDVVLTARDVARGQAAVQQLQAEGLSPRFH    60
hCBR1(a.a.) 61 QLDI DDLQSIRALRDFLRKEYGGLDVLVNNAGI AFKVADPT PFHIQAEVTMKTNFFGTRD    120
hCBR3(a.a.) 61 QLDI DDLQSIRALRDFLRKEYGGLNVLVNNAAVAFKSDDPMPFDIKAEMTLKTNFFATRN 120
hCBR1(a.a.) 121 VCTELLPLI  KPQGRVVNVSSIMSVRALKSCSPELQQKFRSETI TEE ELVGLMNKFVEDTK 180
hCBR3(a.a.) 121 MCNELLPIMKPHGRVVNI SSLQCLRAFENCSEDLQERFHSETLTEGDLVDLMKKFVEDTK  180
hCBR1(a.a.) 181 KGVHQKEGWPSSAYGVTKIGVTVLSRIHARKLSEQRKGDKILLNACCPGWVRTDMAGPKA 240
hCBR3(a.a.) 181 NEVHE REGWPNSPYGVSKLGVTVLSRILARRLDEKRKADRILVNACCPGPVKTDMDGKDS 240
hCBR1(a.a.) 241 TKSPEEGAETPVYLALLPPDAEGPHGQFVSEKRVE QW  277








































Figure 2.5 Comparison of amino acid sequences of human CBR1 and CBR3.  
Tubes and arrows indicate a-helix and b-sheet structures, respectively. 
Rossmann fold with the conserved GlyXXXGlyXGly(G***G*G) sequence region 
is the nucleotide binding region (cofactor binding region), whereas a catalytical 
triad with conserved Ser (S), Tyr (Y) and Lys (K) residues is an important active 
site in human CBR1 and human CBR3.  








2.9.3 Human CBR1 substrates and CBR1 expression 
Human CBR1 is the well-studied member of carbonyl reductases in the SDR family. 
It was isolated from the human brain in 1973 by Ris, M.M. and von Warburg, J.P. 
(Ris, et al., 1973). It is a monomeric and cytosolic NADPH-dependent enzyme that 
reduces a wide variety of biological and pharmacological carbonyl compounds 
(Forrest, et al., 2000 (b)). The endogenous substrates are prostaglandins 
(prostaglandins E1 and prostaglandins E2), steroids and lipid aldehydes, while the 
xenobiotic substrates include aromatic aldehydes, ketones and quinones (Forrest, et 
al., 2000 (b); Oppermann, 2007). Drugs including daunorubicin, doxorubicin, 
haloperidol, bromperidol, metyrapone, loxoprofen, timiperone, wortmannin and 
dolasetron can be metabolized by human CBR1 (Ohara, et al., 1995; Rosemond, et 
al., 2004). Flavonoids such as quercetin and rutin, indomethacin, furosemide, 
ethacrynic acid, flufenamic acid and dicoumarol are CBR1 inhibitors and can inhibit 
the activity of human CBR1 (Hoffmann, et al., 2007).  
 
Menadione (Vitamin K3) is an excellent quinone substrate and is often used as a 
model of quinone substrate. Doxorubicin and daunorubicin are reduced at the 
carbonyl side chain forming C13 hydroxyl metabolites by carbonyl reductases, but 
their quinone rings are not reduced by them (Forrest, et al., 2000 (b)).  
 
The CBR1 enzyme is widely distributed in human normal tissues (Forrest, et al., 2000 
(b)). High CBR1 mRNA expression has been detected in human liver, kidney, 
intestine, pancreas, ovary, lung and white blood cells (Figure 2.6) (Miura, et al., 2008). 
Furthermore, wide inter-individual variations in protein expression level of CBR1 (up 
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to 70-fold differences) and the activity of doxorubicin reduction in cytosol of human 
liver samples (up to 22-fold differences) have been observed.  
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Figure 2.6 hCBR1 mRNAs in various tissues were analyzed by semi-quantitative 
PCR with 35 cycles. (1, brain; 2, thymus; 3, heart; 4, lung; 5, liver; 6, spleen; 7, 
pancreas; 8, intestine; 9, colon; 10,kidney; 11, prostate; 12, testis; 13, ovary; 14, 
leukocyte; 15, placenta;16, plasmid ).  
This figure was copied from Takeshi Miura, et al.’s publication, 2008. 
                                                                             
 
2.9.4 Human CBR3 substrates and CBR3 expression  
Human CBR3 gene was identified in 1998 by Watanabe et al (Watanabe, et al., 1998). 
Limited knowledge about the CBR3 catalytic properties and expression is known. 
Human CBR3 is also a monomeric and cytosolic NADPH-dependent enzyme (Forrest, 
et al., 2000 (b); Hoffmann, et al., 2007). Due to high similarity to CBR1 in nucleotide 
and amino acid sequences, and identical function regions (Rossmann fold of 
G***G*G region as a cofactor binding region and a catalytic triad of S-Y-K residues 
as an active site as shown in Fig. 2.5), the molecular characteristics of human CBR3 
have been presumed similar to that of human CBR1 (Miura, et al., 2008). Human 
CBR3 activity is pH-dependent. The optimum pH value is between 5.5 and 7.0 (Miura, 
et al., 2008). Furthermore, some recent studies have demonstrated that the best CBR1 
substrates, menadione and doxorubicin, were also the CBR3 substrates (Lakhman, et 
al., 2005; Blanco, et al., 2008). 
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Human CBR3 expression has been detected in various human tissues ( 
http://www.ncbi.nlm.nih.gov/UniGene/). The high mRNA levels of human CBR3 
have been found in liver, lung, intestine, ovary, spleen, and pancreas (Figure 2.7) 
(Miura, et al., 2008). The mRNA expression of human CBR3 was also found in the 
white blood cells (Figure 2.7) (Miura, et al., 2008). The sex-specific hCBR3 
expression was noticed by the authors, where lower expression appears in prostate 
and testis than that in ovary (Miura, et al., 2008).  
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Figure 2.7 hCBR3 mRNAs in various tissues were analyzed by semi-quantitative 
PCR with 35 cycles. (1, brain; 2, thymus; 3, heart; 4, lung; 5, liver; 6, spleen; 7, 
pancreas; 8, intestine; 9, colon; 10,kidney; 11, prostate; 12, testis; 13, ovary; 14, 
leukocyte; 15, placenta;16, plasmid ).  
This figure was copied from Takeshi Miura, et al.’s publication, 2008. 
 
 
2.9.5 Functional alleles in human CBR1 and CBR3  
Recently, some researchers have investigated the genetic variants in CBR1 and CBR3. 
Most of genetic variants in CBR1 and CBR3 with their own frequency in different 
ethnic groups have been identified and reported to National Centre for Biotechnology 
Information organized Single Nucleotide Polymorphism Database 
(http://www.ncbi.nlm.nih.gov.libproxy1.nus.edu.sg/SNP/).  Table 2.2 lists all reported 
non-synonymous coding region genetic variants in human CBR1 and CBR3.    
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Among these identified genetic variants, two functional nonsynomous coding region 
genetic variants, CBR1 V88I and CBR3 V244M, have been characterized by Blanco’s 
group (Lakhman, et al., 2005; Gonzalez-Covarrubias, et al., 2007). They focused on 
the various distributions of the two genetic variants in different ethnic groups and the 
functional study with different catalytic properties in an in vitro system, E coli (DE3) 
BL21-competent cells. They found that CBR1 I88 isoform only represented in 
African American with low frequency (q=0.014) and showed lower CBR1 activity to 
produce less daunorubicinol (Gonzalez-Covarrubias, et al., 2007). They also 
demonstrated that CBR3 V244M variants presented with a wide range of genetic 
variant frequencies in different ethnic groups. The CBR3 M244 isoform exhibited 
higher CBR3 activity for the quinone substrate, menadione (Lakhman, et al., 2005). 
The results elucidated the impacts of the rare CBR1 V88I variant and common CBR3 
V244M variant on the CBR1 and CBR3 activities through in vitro cell culture. 
 
As the results from in vitro cell culture may be different from those obtained through 
in vivo clinical study in patients, in vivo functional study on the two genetic variants 
becomes imperative. As doxorubicin is a suitable substrate of CBR1 and CBR3, and 
is frequently used in breast cancer treatment in Southeast Asia, it is essential to 
investigate whether the two functional genetic variants are present in different 
Singaporean ethnic groups and whether they would affect doxorubicin 
pharmacokinetics and pharmacodynamics. In addition, it would be interesting to 
investigate other genetic variants in CBR1 and CBR3 affecting the pharmacokinetics 




Table 2.2 List of non-synonymous genetic variants in the coding region of human 






In vitro functional study 
CBR1 exon 1, 262G>A,  
 rs1143663  
V88I 
CBR1 I88 isoform was only detected in 
African American with low frequency 
(q=0.014).  
CBR1 I88 isoform had lower Vmax resulting 
in lower reductase activity to reduce less 
daunorubicin to daunorubinol. (Gonzalez-
Covarrubias, et al., 2007). 
CBR1 exon 2, 391C>T, 
rs41557318  P131S  
CBR3 exon 1, 11G>A, 
rs8133052  C4Y  
CBR3 exon 1, 277G>A, 
rs2835285  V93I  
CBR3 exon 2, 391C>T, 
rs16993929   
P131S  
CBR3 exon 3, 703C>T, 
rs4987121  
M235L  
CBR3 exon 3, 716C>T, 
rs11701643  
D239V  
CBR3 exon 3, 730C>T, 
rs1056892  
V244M 
CBR3 M244 isoform had wide variations of 
the frequencies among ten human ethnic 
groups (the range of allele frequency (q) from 
0.07 to 0.67), and the whites had the lower 
frequency of the allele (q=0.31) than the 
blacks (q=0.51).  
CBR3 M244 isoform had higher Vmax 
resulting in higher reductase activity to reduce 
more menadione. (Lakhman, et al., 2005) 
Note: 
 1 The information of the non-synonymous genetic variants in CBR1 and CBR3 are 
summarized from National Centre for Biotechnology Information organized Single 
Nucleotide Polymorphism Database  
(http://www.ncbi.nlm.nih.gov.libproxy1.nus.edu.sg/SNP/) 
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2.9.6 Inter-ethnic variations of functional genetic variants on CBR1 and CBR3 
It is well known that many functional genetic alleles in the drug related genes, 
especially in the drug metabolizing enzyme genes, have apparent frequency 
differences among the different ethnic groups. The genetic frequency differences may 
give an explanation for inter-ethnic variations in drug response, including drug 
clinical pharmacodynamics outcomes (Tate, et al., 2004). A good example from the 
three distinct Southeast Asian ethnic groups, Chinese, Malay and Indian is the genetic 
frequency differences in the warfarin target enzyme, vitamin K epoxide reductase 
complex 1 (VKORC1) (Lee, et al., 2006). In clinical setting, Chinese and Malay 
patients require less maintenance of warfarin dose than Indian patients (Zhao, et al., 
2004). VKORC1 H1 haplotype is clinically associated with the low warfarin dose 
requirements, higher frequencies in Chinese (87%) and Malays (65%) but lower 
frequency in Indians (12%); whereas VKORC1 H7, H8 and H9 haplotype is clinically 
associated with high warfarin dose requirements, lowest frequency in Chinese (9%) 
compared to Malays (30%) and Indians (82%). The inter-ethnic differences in 
VKORC1 genotype would give reason for the difference of warfarin dose 
requirements among the Chinese, Malays and Indians (Lee, et al., 2006). 
 
Blanco’s et al. reported that the two functional alleles of CBR1 V88I and CBR3 
V244M had different allele distributions in different ethnic groups (Lakhman, et al., 
2005; Gonzalez-Covarrubias, et al., 2007). CBR1 I88 isoform could be detected only 
in African American, but not in Caucasian and Asian population (Gonzalez-
Covarrubias, et al., 2007). CBR3 M244 isoform has wide variations of the frequencies 
among ten human ethnic groups (the range of allele frequency (q) from 0.07 to 0.67) 
(Lakhman, et al., 2005). A significant difference in CBR3 V244M genotype 
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distribution between the whites and the blacks has been determined, where the whites 
has lower CBR3 M244 isoform (q=0.31), the blacks has higher CBR3 M244 isoform 
(q=0.51). (Chi square test, p=0.003) (Lakhman, et al., 2005). 
 
As discussed in section 2.6, the inter-ethnic variations of hematologic toxicity 
between the Chinese patients and the Caucasian patients existed when they received 
combinational therapy of doxorubicin and cyclophosphamide. Genetic variants may 
account for these inter-ethnic variations in the PD of the related drug. Therefore, a 
hypothesis that arises is whether any inter-ethnic difference on the doxorubicin- 
induced hematologic toxicity exists among the three distinct Singaporean patient 
ethnic groups, and whether any inter-ethnic difference in some functional genetic 
variants in human CBR1 and CBR3 could account for the inter-ethnic differences of 
doxorubicin pharmacokinetics and pharmacodynamics. This hypothesis will be 
examined in this study. 
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2.10 Research objectives 
The main aims of this study are: 
1. To evaluate the doxorubicin induced anticancer efficacy and the main adverse 
effects after the first cycle of doxorubicin treatment in Singaporean breast cancer 
patients; 
2. To describe the pharmacokinetics of doxorubicin and its metabolite, 
doxorubicinol, in Singaporean breast cancer patients; 
3. To correlate the pharmacokinetic parameters of doxorubicin with the doxorubicin 
induced anticancer efficacy and hematologic toxicities; 
4. To investigate all coding region genetic variants in CBR1 and CBR3 in the 
Singaporean breast cancer patients; 
5. To associate all detected genetic variants with the pharmacokinetic parameters of 
doxorubicin, the doxorubicin-induced hematologic toxicities and the short-term 
anticancer efficacy in Singaporean breast cancer population; 
6. To analyze the inter-ethnic differences in the PK and PD of doxorubicin in the 
Singaporean breast cancer patients; 
7. To explore the inter-ethnic differences in the identification of functional genetic 
variants.  
   
The whole study will be conducted in a clinical trial. Results from this clinical 
research study would help clinical researchers to have a better understanding of the 
pharmacokinetics and pharmacodynamics of doxorubicin in Singaporean breast 
cancer population. Results of genetic variants in CBR1 and CBR3 could be important 
in explaining the inter-individual difference in the pharmacokinetics and 
pharmacodynamics of doxorubicin. Moreover, results of the influential genetic 
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variants may be of value for individual treatment of breast cancer patients with 
doxorubicin in the future. 
 
Reliable results from a clinical research depend on appropriate design of the clinical 
trial, valid analytical methods and correct statistical analysis. Chapter 3 will describe 
the details of clinical trial design, analytical methods of the doxorubicin 














MATERIALS AND METHODS 
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3.1 Clinical trial design and the patient recruitment 
The clinical trial studied in this thesis was mainly designed by Dr Lee Soo Chin 
(Protocol No.: HOB17/02). The clinical trial protocol is attached in the appendix in 
the thesis.  
 
The study population comprised of female chemo-naïve patients with histologically or 
cytologically confirmed stage II-IV breast cancer (30% of patients with metastatic 
breast cancer). All patients received neoadjuvant first-line chemotherapy (patients 
previously untreated with any chemotherapy regimen), and most of them had 
undergone surgery.   
 
All patients fulfilled the following inclusion criteria: 
 Female, age ≥18 years;  
 histologically or cytologically confirmed palpable primary breast tumours 
measuring ≥2cm;  
 no prior chemotherapy, immunotherapy or hormonal therapy for the treatment of 
breast cancer;  
 Karnofsky performance score (KPS) ≥80;  
 life expectancy of at least 12 weeks;  
 adequate bone marrow function:  
o total white blood cell (WBC) count ≥3.5×109/L, 
o absolute neutrophil (ANC) count ≥1.5×109/L,  
o platelet count ≥100×109/L  
o haemoglobin level ≥9g/dL; 
 adequate hepatic function: 
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o total bilirubin level ≤1.5 times upper limit of normal (ULN),  
o aspartate aminotransferase ≤2.5 times ULN, 
o alanine aminotransferase levels ≤2.5 times ULN, 
o alkaline phosphatase ≤2.5 times ULN); 
 adequate renal function (creatinine ≤1.5 times ULN) 
 adequate cardiac function 
 Patients with reproductive potential must use an approved contraceptive method if 
appropriate (e.g., intrauterine device, birth control pills, or barrier device) during 
and for three months after the study. Females with childbearing potential must 
have a negative serum pregnancy test within 7 days prior to study enrollment. 
 
Patients were ineligible if they had any of the following: prior treatment for the 
locally advanced or metastatic breast cancer; concurrent administration of any other 
tumour therapy; serious infection diseases or concomitant disorders to compromise 
the patient’s ability to complete the study; pregnancy; breast feeding; poorly 
controlled diabetes; clinically detected second primary malignancy; active brain 
metastases; history of significant neurological or mental disorder and peripheral 
neuropathy of ≥ CTC grade 2.  
 
Written informed consent was obtained from all patients in accordance with the 
institutional and governmental guidelines. The patient was considered Chinese, Malay 
or Indian if the patient, her parents and paternal and maternal grandparents belonged 




According to the clinical trial protocol, the primary objective of the clinical study was 
to collect pre- and post-treatment tumour biopsies for gene expression analysis. The 
aim of the clinical trial study was to collect at least 50 pairs of matched pre- and post-
treatment tumour biopsies. We expected about 70% of tumour biopsy at each time 
point had sufficient quality or quantity RNA for gene expression analysis. As such, to 
obtain 50 pairs of analyzable matched pre- and post-treatment biopsies, the target 
number of patients to be recruited had been set to be 100 (0.7x0.7x100=49). 
 
In the clinical trial, total 101 patients were planned to be enrolled. 51 slips for 'Arm A' 
and 51 slips for 'Arm B' were prepared and were placed in sealed envelopes. Before 
randomization, there was stratification by metastatic or non-metastatic disease (30% 
vs. 70%). As such, 68 envelopes were placed under 'non-metastatic and 34 envelopes 
were placed under 'metastatic'. When a new patient was enrolled, the study co-
ordinator would draw an envelope from the 'metastatic' or 'non-metastatic' pile 
according to patient’s metastatic status. The patient was assigned to Arm A or Arm B 
based on the slip written in the envelope. 
 
Fifty eligible patients in Arm A were received alternating doxorubicin (A) and 
docetaxel (T) chemotherapy starting with doxorubicin (A) (Arm A: 
A→T→A→T→A→T; whereas fifty-one eligible patients in Arm B were received the 
alternating chemotherapy starting with docetaxel (T) (Arm B: T→A→T→A→T→A). 




Doxorubicin was supplied by Pfizer (Perth, Bentley, Australia), and administered at a 
dose of 75mg/m2 by slow intravenous bolus over 5 minutes.  
 
Standard prophylactic anti-emetic therapy comprising of steroids and a selective 5-
hydroxytryptamine-3 antagonist was administered. To avoid potential interactions 
with doxorubicin treatment, concomitant intake of traditional herbs or known 
interacting drugs such as p-glycoprotein substrates were not allowed. Routine use of 
prophylactic granulocyte colony stimulating factors was not permitted.  
 
As discussed in Section of 2.4.2, alternating schedule compared to combinational 
schedule, resulted in similar anticancer efficacy but lower toxicities in breast cancer 
patients. This clinical trial design using alternating schedule allowed us to investigate 
not only the long-term overall tumour response, survival time and toxicities of the 
alternating treatment using doxorubicin and docetaxel, but also the PK, PD and PG 
correlations of doxorubicin and docetaxel, separately. The secondary objective of the 
clinical study included the correlation of doxorubicin pharmacokinetics with the 
toxicity and tumor response, as well as genetic polymorphisms of relevant genes. 
Therefore, we only focus on the relationships among the PK, PD and PG of 
doxorubicin in this thesis.  
 
3.2 Efficacy and toxicity assessment 
Bidimensional tumour measurements of all clinically palpable tumours, including 
primary breast tumour and axillary lymph nodes, were performed using a calliper 
around 10 days before and around 2 weeks after the first cycle of doxorubicin 
treatment. Patients were classified to have intrinsically sensitive tumours or 
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intrinsically resistant tumours to the doxorubicin that they received in the first cycle 
of doxorubicin if they achieved ≥25% or <25% reduction in tumour dimensions after 
the first chemotherapy cycle.  
 
Toxicity assessments were conducted according to the Common Terminology Criteria 
for Adverse Events v3.0 (CTCAE version 3.0). Table 3.1 is the summary of the 
criteria used for grades of hematological toxicities. Febrile neutropenia is defined as 
that the patient’s absolute neutrophil count is less than 1.0×109/L and the patient has 
a fever (body temperature 38.5˚C). 
 
Complete blood counts, hepatic and renal functions and treatment-related toxicities 
were evaluated weekly during the first cycle of doxorubicin. In the event that the 
patient was hospitalized for febrile neutropenia, complete blood counts were tested 
daily until recovery to grade 2 or less. Nadir leukocytes, neutrophils, platelets and 
haemoglobin were defined as the lowest count documented within 21 days of 
doxorubicin administration. In this thesis, all dates of patient demographics, clinical 
chemistry, hematologic toxicities, unhematologic toxicities and tumor reduction were 
collected from case record forms (CRFs).  
 
Figure 3.1 shows the data collection for the PD of doxorubicin, the sample collection 
for the PK, PG of doxorubicin and the core biopsies for tumour tissue transcription 
analysis in this study. 
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Table 3.1 Criteria for grades of hematologic toxicities  
 
Grade Neutropenia Leukopenia Thrombocytopenia Anaemia 
 ANC (109/L) WBC (109/L) platelet count (109/L) 
haemoglobin 
(g/dL) 
1 ≥1.5 to <2.0 ≥3.0 to <3.5 ≥75 to <100 ≥10.0 to <11.5 
2 ≥1.0 to <1.5 ≥3.0 to <2.0 ≥50 to <75 ≥10.0 to <8.0 
3 ≥0.5 to <1.0 ≥2.0 to <1.0 ≥25 to <50 ≥8.0 to <6.5 
4 <0.5 <1.0 <25 <6.5 




Figure 3.1 Data and sample collections of doxorubicin 
 (A: Doxorubicin and T: docetaxel) 
 
 
Arm A:   A 
(n=50)  
– T  – A  – T  – A – T
Arm B:    T 
(n=51)  
– A – T – A – T – A  
Core biopsies for tumour tissue transcription analysis 
Blood samples for genetic variant analysis
Plasma samples for doxorubicin PK analysis





3.3 Chromatographic analysis of doxorubicin and doxorubicinol  
3.3.1 Reagents and standards 
Analytical grade doxorubicin hydrochloride was purchased from Woo Shin Medics 
Co. (Korea) and doxorubicinol was purchased from Toronto Research Chemicals Inc. 
(Canada). The internal standard, daunorubicin hydrochloride solution, was provided 
by the pharmacy, National University of Hospital (NUH), Singapore.   
 
All other chemicals were purchased from Merck (Germany). Sodium formate and zinc 
sulfate heptahydrate were GR grade (Guaranteed Reagent). Methanol, acetonitrile, 
acetone and isopropanol were high performance liquid chromatography (HPLC) grade 
for analysis. Milli Q water was used for mobile phase preparation. 
 
3.3.2 Standard solutions, calibration and quality control samples  
Stock solutions of doxorubicin (1.0mg/ml) and doxorubicinol (1.0mg/ml) were 
prepared by dissolving the appropriate amount of drugs in the mixture of methanol: 
water (1:10 v/v), aliquot (20μl) in polypropylene eppendorf tubes and stored at -80°C. 
Mixed working solutions containing 20, 10, 5, 2, 1, 0.5, 0.2μg/ml of doxorubicin and 
10, 5, 2, 1, 0.5, 0.2, 0.1μg/ml of doxorubicinol were prepared by serial dilution from 
the aliquot stock solutions with 50% of methanol in water. These solutions were 
directly used for the preparations of plasma calibrators and quality control samples. 
For the standard calibration curves, the final concentrations of doxorubicin was 2, 5, 
10, 20, 50, 100, 200ng/ml and the final concentrations of doxorubicinol was 1, 2, 5, 
10, 20, 50, 100ng/ml. For the quality control (QC) samples, the concentrations of 
doxorubicin and doxorubicinol in control plasma samples were 2.5, 30, 60, 120ng/ml 
of doxorubicin and 2.5, 15, 30, 60ng/ml of doxorubicinol. All prepared control plasma 
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calibrators and quality control samples were aliquoted (200μl) in polypropylene 
eppendorf tubes and stored at -80°C prior to use.  
 
An intermediate internal standard working stock (100µg/ml of daunorubicin) was 
diluted by adding 53.5µl of 20mg/10ml daunorubicin hydrochloride solution into 
946.5µl of 50% methanol in water, and stored at -80°C. The final spiking internal 
standard stock solution (4µg/ml) was freshly prepared on each analysis day by 
diluting with 50% methanol solution.   
 
3.3.3 Sample collections and sample preparations 
8ml whole blood was collected from the contralateral arm for analyses of doxorubicin 
and doxorubicinol levels at 0, 1, 2, 4, 7, and 24 hours after the first doxorubicin 
administration. The blood was drawn into heparinised silicon treated glass tube and 
was centrifuged for 15 minutes at approximately 1,200 ×g at room temperature. The 
patient’s plasma was transferred into a clean plastic tube and kept at -80°C prior to 
analyses. 
 
The procedure of sample preparations for bio-analysis of doxorubicin and 
doxorubicinol was modified from the method described by Anders A et al. (Anders, et 
al., 1993). It was a single step of protein precipitation. Briefly, to each 200µl of 
patient plasma sample or calibrator sample was added 10μl of 4µg/ml daunorubicin 
(internal standard) solution and was immediately vortex-mixed for 1 min. 20µl of 
40% zinc sulfate solution, 100µl of methanol and 100µl of acetonitrile were added to 
precipitate proteins and centrifuged at 15,000xg for 5 minutes. 200 µl of supernatant 
was transferred into a polypropylene eppendorf tube and concentrated under nitrogen 
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for 10 min. Finally, 60µl of concentrated supernatant was transferred to a 
polypropylene insert and kept in auto sampler for HPLC analysis. 
 
3.3.4 Chromatographic separation (HPLC) 
Chromatographic analyses were performed on a reverse-phase HPLC system 
(Shimadzu, Japan) with a fluorescence detector (Shimadzu RF-10A xl). 
Chromatographic separations were conducted using a Supelcosil LC 18 column 
(4.6×150mm, particle size 3µm) (Supelco, USA) at 40ºC. The excitation wavelength 
was set at 500nm, and the emission wavelength was set at 580nm. The gain of 
fluorescence detector was set at ×4, together with a sensitivity of ×4 and a response of 
×3. The mobile phase consisted of 0.28M sodium formate buffer (pH 3.55), acetone 
and isopropanol (72.5:25:2.5, v/v/v). Flow rate of the mobile phase was kept constant 
at 1.2ml/min.  
 
3.3.5 Method validation 
This bioanalytical method for quantification of doxorubicin and doxorubicinol were 
validated according to FDA guidance (http://www.fda.gov/CDER/GUIDANCE/).  
 
3.3.5.1 Chromatography  
Representative chromatograms of control plasma, patient blank plasma and patient 
plasma sample 2hour after doxorubicin administrated at 75 mg/m2 from one patient 
are presented in Figure 3.2. No endogenous interfering with drug peaks is observed in 
both chromatograms of control blank plasma and patient blank plasma. Doxorubicin 
and doxorubicinol are well separated by the HPLC condition and they are determined 
in all patient samples. The retention times of doxorubicin and doxorubicinol are 6.1 
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and 4.2 min., respectively, and the retention time of daunorubicin is 13.9 min (Figure 
3.2).  Complete HPLC run of each sample took about 20 min.  
Minutes
















































Figure 3.2 Chromatograms of control plasma (a), patient blank plasma (b) and 
patient plasma (c) obtained 2 hours after doxorubicin administration at 75 
mg/m2 (I.V bolus over 5min).  
Peak 1: doxorubicin (62.2ng/ml); 
Peak 2: doxorubicinol (37.0ng/ml); 







3.3.5.2 Linearity  
In total, seven different calibration curves of doxorubicin and doxorubicinol were 
prepared for this method validation. In each calibration curve of doxorubicin and 
doxorubicinol, a control blank sample (control plasma without internal standards) and 
seven plasma calibrators (the concentrations of doxorubicin: 2, 5, 10, 20, 50, 100, 
200ng/ml and the concentrations of doxorubicinol: 1, 2, 5, 10, 20, 50, 100ng/ml) were 
prepared and injected into HPLC. The calibrators were weighted according to 1/x 
(x=concentration) for least-squares regression. The calibration curves were drawn 
using linear regression of the peak area ratios of doxorubicin or doxorubicinol against 
internal standard obtained as a function of the theoretical concentration. 
 
The calibration curves are linear over a concentration range from 2 to 200ng/ml for 
doxorubicin with a coefficient of determination (r2) of 0.9995-0.9998 and 1-100ng/ml 
for doxorubicinol with r2 of 0.9993-0.9999 (Figure 3.3 a, b). This method is sensitive 
enough to measure both two analytes. 
 
There were two differences between Anders’s method and ours. Firstly, we used 
100µl of methanol and 100µl of acetonitrile instead of 200µl of methanol, which 
provides better chromatogram of plasma baseline. Secondly, we concentrated the 
supernatant before injection into HPLC. This modification enhanced the peak areas of 
doxorubicin and doxorubicinol at the limit of quantifications (LOQs: 2ng/ml for 
















0 50 100 150 200 250






























0 20 40 60 80 100 120






















Figure 3.3 Representative calibration curves for doxorubicin (a) and 






3.3.5.3 Precision and accuracy 
To determine intra-day and inter-day precision and accuracy for doxorubicin and 
doxorubicinol, the method presented here was validated by analyzing four QC 
samples prepared at nominal concentrations (2.5, 30, 60, 120ng/ml for doxorubicin 
and 2.5, 15, 30, 60ng/ml for doxorubicinol). Intra-day variability was tested on five 
different human plasma QC samples using the same calibration curve. Inter-day 
variability was tested on duplicated human plasma QC samples using seven 
calibration curves prepared daily. The precision of the method at each QC 
concentration was expressed as a coefficient of variation (CV) by calculating the 
standard deviation as a percentage of the mean calculated concentration: 
Precision (%) = (standard deviation/mean of measured)×100%. 
 
The accuracy of the assay was determined by expressing the percentage of the mean 
with reference to the true value: 
Accuracy (%) = (1-((mean of measured-the true value)/the true value)) ×100% 
 
Table 3.2 summarizes the intra-day and inter-day reproducibility of the HPLC 
determination of doxorubicin and doxorubicinol in human plasma. The intra-day and 
inter-day precision coefficients of variation ranged from 1.1% to 14% for doxorubicin 
and from 2.1% to 13.6% for doxorubicinol. The accuracy was from 100.6 to 109.6% 
for doxorubicin and from 92.2% to 105.1% for doxorubicinol.  
 
Furthermore, the inter-day precision and accuracy of limit of quantification (LOQ) 
were also validated. They were tested on seven different calibration curves. The inter-
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day precision and accuracy of LOQ were 13.8% and 105.0% for doxorubicin, and 
8.7% and 106.6% for doxorubicinol.  
 
3.3.5.4 Recovery 
The recoveries at four different plasma concentrations of doxorubicin (2.5, 30, 60, 
120ng/ml) and doxorubicinol (2.5, 15, 30, 60ng/ml) in triplicate were determined by 
comparing the peak areas of doxorubicin or doxorubicinol of the samples against 
standards. The peak areas of doxorubicin or doxorubicinol of plasma samples were 
obtained through complete extraction procedure; while the peak areas of doxorubicin 
or doxorubicinol of standard were obtained from direct injection of the same amount 
of compounds dissolved in 50% of methanol. The recovery was evaluated according 
to the following formula:  
Recovery (%) = (Peak Area in control plasma/ Peak Area of standard in 50% of 
methanol)×100. 
 
The recovery range of doxorubicin was from 79.8% to 85.0%; whereas the recovery 
range of doxorubicinol was from 80.1% to 85.9%.  
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Table 3.2 Intra-day and inter-day reproducibility using HPLC to determine the concentrations of doxorubicin and doxorubicinol in 
human plasma 
 




















2.5 2.5±0.3 14.0 100.6 2.5 2.7±0.2 8.1 109.6 
30 30.4±1.2 3.9 101.4 30 30.9±0.9 2.8 103.1 
60 62.0±3.4 5.6 103.3 60 63.8±1.1 1.7 106.4 
Doxorubicin 
120 124.8±4.7 3.8 104.0 120 122.9±1.3 1.1 102.4 
2.5 2.4±0.3 13.6 97.1 2.5 2.1±0.1 5.3 92.2 
15 15.7±0.7 4.6 104.5 15 14.7±0.4 2.5 97.8 
30 31.1±1.9 6.2 103.6 30 29.6±0.6 2.1 98.8 
Doxorubicinol 
60 62.3±2.7 4.3 103.8 60 61.5±1.9 3.0 102.6 
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3.3.5.4 Stability  
Stability of doxorubicin and doxorubicinol in citrated plasma has been assessed by 
Anders A et al. (Anders, et al., 1993). They found that the amount of doxorubicin in 
citrated plasma declined significantly after incubation at 37ºC for 2 days (up to 85% 
decline for doxorubicin). However, doxorubicin and doxorubicinol were stable in 
citrated plasma at 4ºC for 2 days, and in deproteinized samples kept in the dark at 
room temperature for one day. Because of the instability of doxorubicin in citrated 
plasma at 37ºC, evaluation of stability of doxorubicin and doxorubicinol in the 
heparinised plasma samples under our experimental conditions is necessary.  
 
The experiments of sample stability of doxorubicin and doxorubicinol were carried 
out on the QC heparinised plasma samples (n=3). Storage stability at -80ºC, freeze-
thaw stability, bench stability (26ºC), and autosampler stability were assessed.  
 
The two analytes, doxorubicin and doxorubicinol, stored at -80ºC were stable up to 31 
months. More than 95% of the initial amounts remained in the heparinised plasma.  
 
The small variations of doxorubicin and doxorubicinol (1.1% and 0.2%, respectively) 
in heparinised plasma were found after three freeze-thaw cycles. This suggests that 
the method used for the two analytes in heparinised plasma samples in this study were 
reproducible after three cycles of thaw-refreezing at -80ºC. 
 
Seven time points (0, 0.5, 1, 2, 3, 4, and 5hrs) and room temperature (26ºC) were 
selected for bench stability assay. Figure 3.4 shows the concentration-time curves for 
doxorubicin and doxorubicinol in plasma samples. Both doxorubicin and 
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doxorubicinol in heparinised plasmas for the four concentrations of quality control 
samples are stable at 26ºC only within the first 0.5 hr. The maximum reductions 
against the initial amounts are 1.4% for doxorubicin and 0.8% for doxorubicinol, 
respectively. They noticeably decline to 75% and 85% of their initial amounts at 5 hr. 
The instability at 26ºC requires a fast pretreatment procedure for the doxorubicin 
heparinised plasma samples. The deproteinisation method used is simple and can 
satisfy this requirement.  
 
There was no indication of instability for the two analytes autosampler after 
deproteinization for at least 24 hr. (doxorubicin: 94.6±4.8% of the initial amounts, and 
doxorubicinol:  98.9±2.2% of the initial amounts).  Hence HPLC analyses using the 
autosampler for up to 24 hrs is applicable.  
 
In summary, this validated HPLC method is simple, sensitive and reliable for the 
analyses of doxorubicin and doxorubicinol in human heparinised plasma samples. 
This precise, accurate and reproducible method has been used in the study of 













































































Figure 3.4 Stability of doxorubicin and doxorubicinol in heparinised plasmas at 
26ºC.  






3.4 Pharmacokinetic analysis  
Based on the smallest Akaike and Schwartz values, the sampling numbers and the 
sampling timing, the pharmacokinetics of individual patient doxorubicin was best 
described by a two-compartment model in this study. Figure 3.5 illustrates the 




Figure 3.5 Two-compartmental pharmacokinetic model parameterized with 
micro constants (this figure was modified from William D. Figg and Howard L. 
McLeod’s handbook of anticancer pharmacokinetics and pharmacodynamics.) 
 
 
During the two-compartmental analysis, plasma disposition curves were fit by the 
following integrate equation:  
C(t) = A*exp(-ALPHA*T) + B*exp(-BETA*T) 
Where C(t) is the concentration at the sampling time, A and B are macro-rate 














The Kinetica software, Version 4.4 (Thermo Fisher Scientific, Inc. USA), was used 
for this pharmacokinetic analysis. When selecting the Micro constant analysis in 
Kinetica, the pharmacokinetics of individual patient doxorubicin was first computed 
by using macro constants and was then converted to micro constants. A weighing 
function of 1/(predicted y)2 was applied. Equations used for determinations of 
parameters were: (The user manual of Kinetica Version 4.4)  
 
      Apparent volume of the central compartment: Vc=Dose/(A+B) 
Area under the concentration-time curve:        AUC=A/ALPHA+B/BETA 
      Clearance:                                                             Cl = Dose/AUC0- 
      Half-life:                                                                t1/2alpha =ln2/ALPHA 
 
                                                              t1/2 beta =ln2/BETA 
 
The calculated concentration at the time zero C0, the micro rate constants of kel (rate 
constant of elimination), k12 (rate constant of central compartment to peripheral 
compartment), and k21 (rate constant of peripheral compartment to central 
compartment) were generated based on the following equations: 
                                           C0 =A+B 
                                           Kel= (ALPHA* BETA)/K21 
 





In addition, non-compartmental pharmacokinetic analysis was conducted by use of 
area under the concentration-time curves (AUC) of doxorubicin and doxorubicinol. 
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The apparent terminal elimination rate constant (k) was estimated by log-linear 
regression analysis of the terminal phase of the plasma doxorubicin and doxorubicinol 
concentration-time curves. The AUC was estimated by the linear trapezoidal method 
with extrapolation of terminal concentrations to infinity. Metabolite ratio (MR) was 
calculated as: AUC0-doxorubicinol/AUC0-doxorubicin.  
 
 
3.5 Genetic variants on CBR1 and CBR3 
3.5.1 Genomic DNA isolation  
Ten millilitre of whole blood was collected from each patient before chemotherapy. 
The genomic DNA was extracted from peripheral mononuclear cells using the Gentra 
DNA purification Kit (Gentra System, Inc., USA) and stored at -20˚C.  
 
3.5.2 PCR amplification and purification  
All coding regions of CBR1 and CBR3, including the splice-site junctions with 20-400 
bases upstream and downstream, were amplified with polymerase chain reaction 
(PCR) using intronic primers. All designed primers used for PCR as well as annealing 
temperatures are shown in Table 3.3. The designed primers were checked by Basic 
Local Alignment Search Tool (BLAST) search to ensure specificity and then were 
synthesized by Sigma Aldrich (USA). Each PCR reaction was carried out using 125ng 
genomic DNA, 10pmol of forward and reverse primers and 12.5µl of PCR master mix 
(Promega, USA). The PCR master mix contains 50 units/ml of Taq DNA polymerase 
supplied in a proprietary reaction buffer (pH 8.5), 400μM of each dNTP and 3mM of 
MgCl2. PCR conditions consisted of an initial denaturation at 94˚C for 5 min., 
followed by 35 cycles of amplification at 94˚C for 30s, annealing at 47-61˚C for 30s, 
and elongation at 72˚C for 1 minute, and then followed by a final extension at 72˚C 
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for 5 minutes. All PCR reactions were conducted in a PCR thermal cycler (BioRAD 
laboratories, USA).  
 
Following each PCR reaction, 8μl of each PCR product was mixed with 6×loading 
dye (Promega, USA) for electrophoresis on the 1% agarose gels with ethidium 
bromide at 100v for 40 min. For confirmation, the PCR products band on the gel was 
evaluated under ultraviolet light (Gel Doc XR) (BioRAD laboratories, USA) by 
comparison with 100 bp DNA ladder (Biolabs, New England). The positive PCR 
products were stored at -20˚C prior to sequencing. 
 
Purification of PCR products was needed before sequencing. Briefly, 2μl of Shrimp 
Alkaline Phosphatase (USB, USA) and 1μl of Exonuclease I (USB, USA) were added 
to 1 μl of each PCR product. The mixture was incubated at 37˚C for 30 min., and then 
at 80˚C for 15 min. in a PCR thermal cycler (BioRAD laboratories, USA). The 
Shrimp Alkaline Phosphatase removes the dNTPs, and the Exonuclease I removes 
residual primers.  The purified samples were stored at -20˚C prior to use.  
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Table 3.3 Primer sequences and annealing temperatures for the analysis of the 
CBR1 and CBR3 genes  
 
Region  Primer Sequence  Annealing Temperature 
Forward primer 5’-tctaggcacatggccactaggaat-3’ 
CBR1 
Exon 1 
Reverse primer  5’-ttctccaaggtttctgcactccct-3’ 
57°C 
Forward primer 5’-actttaggcagagggcactaagtt-3’ 
CBR1 
Exon 2 
Reverse primer  5’- agtaaagcctccaccagcctgaat-3’ 
61°C 
Forward primer 5’-atgtgtggcttcgagttgggtact-3’ 
Reverse primer  5’-agccagctatgctcacaggcttacat-3’ 
59°C 
Forward primer-11 5’-tctcacgggattgttgcacacct-3’ 
Reverse primer-11  5’-agctcaccactgttcaactctctt-3' 
Forward primer-21 5’-acaagatcctcctgaatgcctgct-3’ 
CBR1 
Exon 3 
Reverse primer-21 5’-agttgtactgtcccttcccttgac-3’ 
- 
Forward primer 5’-actgacccatcaaggtccgatttg-3’ 
CBR3 
Exon 1 
Reverse primer  5’-ctcagcgaatcacggaaagcgaaa-3’ 
58°C 
Forward primer 5’-ccgacctcgttcttaaaaattg-3’ 
CBR3 
Exon 2 
Reverse primer  5’-atgttggagtgagaagccaaac-3’ 
47°C 
Forward primer 5’-accagtggttgtacctctgtgata-3’ 
CBR3 
Exon 3 
Reverse primer  5’- cagaaataatcaaaccacagcatc-3’ 
47°C 
Note: 1 an internal primer for DNA sequencing 
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3.5.3 DNA sequencing  
Each purified PCR product as a template was amplified for sequencing. The BigDye 
Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems Inc., Canada) was 
applied in the reaction. The 20μl of reaction solution for PCR amplification comprised 
of 4μl of purified PCR product, 1μl of 0.8μM forward or reverse PCR primer or an 
internal primer, 1μl of BigDye, 3.5μl of BigDye buffer and 10.5μl of water. The 
amplification was carried out on a PCR thermal cycler (BioRAD laboratories, USA) 
and performed for 25 cycles of 10 sec at 96˚C, 5 sec at 50˚C, and 4 min at 60˚C.  
 
CBR1 exon 3 has 719bp. It was too long to complete the sequencing of this exon at 
one time under our experimental condition. As such, two pairs of internal primers for 
CBR1 exon 3 were designed (Table 3.3). They were used for separate sequencing of 
this exon.  
 
Before sequencing, the amplified DNA was precipitated with a mixture of 68μl of 
95% of ethanol, 2μl of 3M sodium acetate (pH 4.6) and 1μl of glycogen. After 
cooling at -80˚C for 1hr, the reaction mixture was centrifuged at 6000 rpm for 30 min. 
The supernatant was carefully removed and the DNA pellets were then rinsed with 
150μl solution of 70% of ethanol in water. After removing the supernatant, the clean 
amplified DNA pellets were dried at 90˚C for 1min. Highly deionized formamide (Hi-
DiTM) (Applied Biosystems Inc., Canada) was used to re-suspend the DNA pellets 
before injecting into the ABI 3100 automated sequence analyzer (Applied Biosystems 
Inc., Canada)  
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Generated sequences were compared with the reference for CBR1 and CBR3 
(Genbank reference EF141836 and EF462915) by BLAST. Each variant identified 
was confirmed by sequencing both the sense and antisense strand, and by duplicating 
the experiment at least once. 
 
3.6 Cancer-free Asian subject population assay 
168 unrelated cancer-free Asian subjects comprising of 75 Chinese, 46 Malays and 47 
Indians were analyzed for each functional genetic variant on CBR1 and/or CBR3 
identified in the breast cancer patients to establish the population frequencies of these 
variants. Some cancer-free samples were from blood donors, and the others were from 
the subjects who participated in other pharmacogenetics studies. Written informed 
consents were obtained from all of them. The cancer-free subject was considered 
Chinese, Malay or Indian if the subject, his or her parents and paternal and maternal 
grandparents belonged to the same ethnic group. 
 
3.7 Tumour tissue transcription analyses on CBR1 and CBR3 
Before chemotherapy, core biopsies (25mg on average) were taken from each 
subject’s primary breast tumour for gene expression analysis as part of the clinical 
protocol. Tumour cores were snap frozen in liquid nitrogen and stored at -80˚C prior 
to further analyses.  
 
Total RNA was extracted from the tumour using RNeasy mini kit (Qiagen, The 
Netherlands) and assessed for quality with an Agilent 2100 Bioanalyzer (Agilent, 
USA). Total RNA was labelled by biotin and hybridized on the Affymetrix U133+2 
microarray chip comprising of 54,674 probe sets, according to the manufacturer’s 
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instructions (Santa Clara, USA). Scans were performed with an Affymetrix GeneChip 
scanner, and the expression value for each gene was calculated using the Affymetrix 
Microarray Analysis suite (v5.0), computing the expression intensities in arbitrary 
‘signal’ units defined by the software. Scaling factors were determined for each 
hybridization based on an arbitrary target intensity of 500. Scans were rejected if the 
scaling factor exceeded a factor of 30. Expression was calculated using the robust 
multi-array average (RMA) algorithm implemented in the Bioconductor 
(http://www.bioconductor.org) extensions to the R statistical programming 
environment. RMA generates log-2 scaled measures of expression using a linear 
model robustly fit to background-corrected and quantile-normalized probe-level 
expression data. The expression data for CBR1 (probe set 209213_at) and CBR3 
(probe set 1559917_a_at) were extracted and analyzed.  
 
3.8 Statistical analysis  
All statistical analyses were preformed using the SPSS Version 15.0. (SPSS, Inc, 
Chicago IL).  
 
Patient characteristics before the first cycle of doxorubicin treatment, the 
pharmacokinetic data, doxorubicin-induced hematologic toxicities, short-time tumour 
reduction and tumour tissue CBR1 and CBR3 expressions were presented as mean ± 
standard deviation in this thesis.  
 
Prior to statistical comparison of data and parameters between the two treatment arms, 
normality of distribution of data was analyzed. If Kolmogorov-Smirnov test and 
Shapiro-Wilk test were significant (p value ≤0.05), the non-normality of distribution 
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was assigned. Otherwise, normality of distribution had to be confirmed by Skewness 
and Kurtosis. If Skewness value was between -1 and 1 as well as Kurtosis value was 
between -1 and 1, the normality of distribution was assigned (Chan, 2003). The 
student’s t-test was used for the normally distributed parameters. When the 
parameters in two treatment arms were non-normality, the comparisons between two 
treatment arms were performed by use of the Mann-Whitney U test which is more 
appropriate. Moreover, since small sample size (n=48-50 in each treatment arm) may 
cause the parameters to be skew, the student’s t-test was also used for comparison of 
the parameters in two treatment arms even though the parameters were non-normality 
distribution. The p values from the student’s t-test and the Mann-Whitney U test were 
present in the thesis. Chi-square test was used to compare nominal variables of patient 
characteristics between the two treatment arms. 
 
The pharmacokinetic parameters were correlated with the nadir hematologic toxicities 
and short-time tumour reduction either by using Pearson test for normally distributed 
parameters or by using Spearman test for non-normal parameters, as well as the 
nominal variable of the percentage of patients with ≥25% tumour reductions.  
 
Since this thesis focuses on evaluating the effect of genetic variants on CBR1 and 
CBR3 responsible for the CBR1 and CBR3 action of converting doxorubicin to 
doxorubicinol, the pharmacokinetic parameters of interest included AUC 0-∞ of 
doxorubicin and doxorubicinol, and the metabolic AUC ratio (MR). The different 
genetic variants were associated with these pharmacokinetic parameters, nadir 
hematologic toxicities, short-time tumour reduction and tumour tissue CBR 
expressions. Because of the non-Gaussian distribution of most parameters such as 
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metabolic AUC ratio, AUC of doxorubicinol and hematologic toxicities, the non-
parametric Mann-Whitney test was applied for two-group comparisons, and the 
Kruskal-Wallis test was applied for multiple comparisons with Bonferroni correction 
where a corrected p-value of less than 0.017 was considered significant (Dawson, et 
al., 2004). The Bonferroni correction is a multiple-comparison correction used when 
several dependent or independent statistical tests on asset of data are being performed 
simultaneously. In order to avoid statistical significance on the same data falsely, the 
p value needs to be lowered to account for the number of comparisons (N) being 
performed. The p value is corrected by 0.05/(N(N − 1)/2) (Dawson, et al., 2004).  
The non-parametric Jonckheere-Terpstra test (JT trend test) is for the situations in 
which treatments are ordered in some way (Bewick, et al., 2004). The JT trend test 
was used to determine the significance of the trends between the subgroups classified 
by genotype and ethnic groups. Dummy variables were created to code for genotypes. 
A generalized linear model was used to analyze the effect of each genotype on 
leukocyte suppression at nadir. Stepwise multiple linear regression model was used to 
select the independent genetic and non-genetic covariables of percentage change in 
leukocyte count at nadir that contributed to improvement of the model, excluding 
covariables with p>0.1. 
Due to marked difference in sample sizes (unequal variances) in the three ethic groups 
in our patients, the pharmacokinetic parameters, nadir hematologic toxicities and 
short-time tumour reduction among the three groups were compared by use of non-
parametric Mann-Whitney test for two ethnic group comparisons, by use of Kruskal-
Wallis test with Bonferroni correction (p<0.017) for all three groups and JT test for 
trends. Fisher exact test and Chi-square test with Bonferroni correction (p<0.017)   
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were used to compare the frequencies of nominal variables between different 
genotype groups and ethnic groups. 
 
The Lewontin’s D’ was used to determine linkage disequilibrium (LD) and r2 was 
used to measure the correlation between the two genetic variants. D’ and r2 were 
calculated using the software PowerMarker (Version 3.25, 














CHAPTER FOUR  












4.1 Characteristics of patients 
4.1.1 Characteristics of patients before the first cycle of doxorubicin treatment  
Total one hundred and one (101) Singaporean female breast cancer patients were 
enrolled. Two Chinese patients assigned to Arm B withdrew after the first cycle of 
docetaxel treatment, leaving ninety-nine patients assessable for the study of 
doxorubicin pharmacokinetics, toxicities and tumour reduction, and genetic 
correlations.  
 
Evaluable baseline characteristics of patients before the first cycle of doxorubicin 
treatment are summarized in Table 4.1. Their mean age of the study cohort was 49 
years (range 26-68) and their mean body surface area was 1.55m2 (range 1.2-1.97 m2). 
The three distinct Asian ethnic groups, Chinese, Malays and Indians in Singapore, 
were involved in this study. The ethnic distribution in the study (65% Chinese, 26% 
Malay, 7% Indian) closely reflected the demographics of the Singapore population: 
77% Chinese, 14% Malay, and 8% Indian. 
 
Two third of patients were having non-metastatic locally advanced breast cancer, 
whereas the rest one third of patients were having metastatic breast cancer. The main 
metastatic sites were liver, lung and bone. All patients’ KPSs (Karnofsky 
Performance Score) were ≥80%. According to KPS scale definition rating (%) 
criteria, all patients with ≥80% are able to carry on normal activities, and no special 
care is needed. Thus, patients before the treatment had good performance status. 
 
In addition, all patients had adequate hepatic, renal functions before the first cycle 
treatment with doxorubicin. The maximum alanine aminotransferase (ALT), aspartate 
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aminotransferase (AST) and alkaline phosphatase (ALP) levels in patients were 
89U/L, 96U/L, and 247U/L respectively, which were less than 2.5 times upper limit 
of normal (ULN) (the reference range of ALT: 15-70U/L, the reference range of AST: 
10-50U/L and the reference range of ALP: 40-130U/L). For renal function, the 
maximum creatinine level was 118µmol/L which was less than 1.5 times ULN (the 
reference range; 45-90 µmol/L for women). 
 
Patients had adequate baseline bone marrow function prior to receiving doxorubicin 
treatment. Only one patient in Arm B had slightly lower absolute neutrophil count 
(1.4×109/L), and the total white blood cell count (WBC) of another patient was 
3.2×109/L. The WBC counts of all other patients were more than 3.5×109/L. The 
absolute neutrophil counts were more than 1.5×109/L and the platelet counts were 
more than 100×109/L.  
 
Before the first cycle of doxorubicin treatment, the mean value of patients’ tumour 
sizes was large (mean value of bidimensional product: 163cm2) with a wide inter-
patient difference (range: 2-813cm2).  
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Age, years (mean ± SD) (range)               49±10  (26-68) 
Body surface area (mean ± SD) (range)   1.55±0.16m2  (1.20-1.97 m2) 
Race 
   Chinese  (C)                                   
   Malay (M) 
   Indian (I) 
   Others (O) 2                                   






   Non-metastatic disease 
   Metastatic disease 
Metastatic sites 
   Liver and/or lung and/or bone 
   Others 





                                13 
Karnofsky Performance Score (KPS) 
   90-100%  




Liver functions  
  ALT (mean ± SD)  (range) 1               
  AST (mean ± SD) (range) 1             
  ALP (mean ± SD) (range) 1             
 
29±16U/L  (9-89U/L) 
27±16U/L  (10-96U/L) 
83±30U/L  (18-247U/L) 
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Renal function  
   Creatinine (mean ± SD) (range)             
 
65±14µmol/L  (40-118 µmol/L) 
Hematological Parameters:  
  WBC (mean ± SD) (range) 1              
  ANC  (mean ± SD) (range) 1              
  Platelets (mean ± SD) (range)               
  Hemoglobin (mean ± SD) (range)          
 
7.8±2.4×109/L  (3.2-17.8×109/L) 
5.1±1.9×109/L  (1.4-12.5×109/L) 
316±81×109/L  (178-578×109/L) 
12.1±2.8 g/dL (8.2-35.6 g/dL) 
Mean tumour size (mean ± SD) (range)   163±163cm2  (2-813 cm2) 
 
Notes:  
1 ALT: alanine aminotransferase; AST: aspartate aminotransferase; ALP: alkaline 
phosphatise; WBC: white blood cell count; ANC: absolute neutrophil count.  




4.1.2 Comparison of patient characteristics between two the treatment arms  
In this clinical trial, as half of patients in treatment Arm B (n=49) received one cycle 
of docetaxel before the first cycle of doxorubicin treatment, a comparison of the 
patient characteristics before the first cycle of doxorubicin treatment between the two 
treatment arms was necessary.  
 
The comparison data are shown in Table 4.2. Patients in the two treatment arms were 
balanced for demographics including the number of patients, the age, the BSA, the 
race, the metastasis status and the KPSs. We noticed that the difference in the p values 
at the aspartate aminotransferase (AST) level between the two treatment arms of our 
patients before the first cycle of doxorubicin treatment were different (p=0.076 for 
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Mann-Whitney U test, and p=0.010 for student’s t-test). The normality of the 
parameter in treatment arms was carefully evaluated by statistical tests (Arm A: 
p=0.000 for Shapiro-Wilk test, Arm B: p=0.000 for Shapiro-Wilk test). The 
parameters in both treatment arms were non-normality. Therefore, the comparison 
between two treatment arms performed by use of the Mann-Whitney U test was more 
appropriate. The liver and kidney functions between the two treatment arms were 
similar. As discussed in section 4.1.1, all patients had adequate hepatic, renal 
functions before the first cycle treatment with doxorubicin.  
 
However, patients in Arm B who were treated one cycle of docetaxel before they 
received the first cycle of doxorubicin had better baseline of hematological 
parameters than those in Arm A.  The absolute neutrophil counts of patients in Arm B 
were higher than those in Arm A (Arm B: 5.5±2.0109/L vs. Arm A: 4.8±1.7109/L, 
p=0.030 for Mann-Whitney U test; p=0.048 for student’s t-test). The white blood cell 
and platelet counts in Arm B seemed be slightly higher than those in Arm A, but not 
reaching statistical significance (Arm B vs. Arm A: WBC: 8.2±2.6109/L vs. 
7.4±2.1109/L, p=0.113 for Mann-Whitney U test; p=0.125 for student’s t-test; 
platelets: 330±82109/L vs. 302±79109/L, p=0.128 for Mann-Whitney U test; 
p=0.087 for student’s t-test). It was noticed that there was no difference in the 
hematological parameters between the two arms when they were included in the 
clinical study before receiving any treatment (Arm B vs. Arm A, WBC: 
7.1±2.1109/L vs. 7.4±2.1109/L, ANC: 4.7±1.8109/L vs. 4.8±1.7109/L, platelets: 
307±86109/L vs. 302±79109/L, and hemoglobin: 12.2±1.7g/dL vs.12.5±3.7g/dL; all 
p values >0.05). Patients in Arm B showed better hematologic parameters before they 
  86
received the first cycle treatment of doxorubicin. This could be resulted from the 
better care after the first cycle of docetaxel treatment.  
 
Additionally, before the first cycle of doxorubicin treatment,  the mean value of the 
tumour sizes of the Arm B patients was smaller than that of the Arm A patients, but 
difference was not significant (Arm B vs. Arm A: 135.9±138.9cm2 vs. 
190.8±179.8cm2, p=0.078 for Mann-Whitney U test; p=0.098 for student’s t-test). 
This would be the result of docetaxel initial dose efficacy in the Arm B patients. The 
difference could have some effects on the doxorubicin pharmacodynamics outcome.  
 
We were aware of the differences of hematologic parameters and tumour sizes 
between the two arm patients before they were administrated the first cycle of 
doxorubicin. These differences in hematologic parameters and tumor sizes should be 
related to the first cycle of docetaxel treatment to Arm B patients. Doxorubicin 
induced tumour reductions in actual size (tumour reduction = (pre-treatment 
measurement - end of the first cycle of doxorubicin treatment measurement) and in 
percentages between the two treatment arms (tumour reduction %= (pre-treatment 
measurement - end of the first cycle of doxorubicin treatment measurement)/pre-
treatment measurement ×100%), as well as the hematologic toxicities at nadir values 
and in percentages (decreases in nadir hematologic toxicities% = (baseline counts – 
nadir counts)/baseline counts ×100%) were present in the thesis. In order to accurately, 
reliably and quantitatively evaluate the correlations of doxorubicin induced 
hematologic toxicities and anticancer efficacy with the doxorubicin PK and genetic 
variances, the percentage decreases at nadir hematologic toxicities and the percentage 
of tumour reduction as the main PD parameters were used in this thesis. The 
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hematologic baseline counts and the pre-treatment measurements of tumour size for 
Arm B patients were collected after the first cycle of docetaxel treatment and just 
before the first cycle of doxorubicin treatment. 
 
Table 4.2 Comparison of patient characteristics between the two treatment arms 
before the first cycle of doxorubicin treatment  








Number of patients  50 49 - - 
Age (yrs) (Mean± SD) 49.0±10.3 49.5±9.3 - 0.812 
BSA (m2) (Mean± SD) 1.56±0.15 1.54±0.17 - 0.607 
Race: C: M: I: O 34: 12: 3: 1 30: 14: 4: 1 0.9113 - 









KPS:   
80%:90%:100% 
 
2: 10: 38 
 





Liver Function:  
   ALT (Mean± SD) 
   AST (Mean± SD) 



























Hematological Parameters:  
  WBC (109/L) 
  ANC (109/L)   
  Platelets (109/L) 
























Tumour Size (baseline) (cm2) 190±180 136±139 0.078 0.098 
Notes: 1Arm A: A→T→A→T→A→T; 2Arm B: T→A→T→A→T→A (A: 
doxorubicin and T: docetaxel). 3The p values from Chi-square test.  
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4.2 Efficacy 
4.2.1 Anticancer efficacy  
According to the clinical design, the long-term responses of patients, such as ORR, 
CR, PR and survival time, were related to not only the doxorubicin treatment, but also 
the docetaxel treatment and the surgery. Thus, we could not evaluate the long-term 
responses for the doxorubicin efficacy in this thesis. However, from the clinical trial, 
we could obtain reliable doxorubicin-induced short-term tumour response which was 
measured after the first cycle of doxorubicin treatment. Hence, in this thesis, the 
doxorubicin efficacy was focused on short-term tumour response, where the tumour 
reduction in actual size, the percentage of tumour reduction and the percentage of 
patients with ≥25% tumour reductions after the first cycle of doxorubicin treatment 
were used as the efficacy parameters.  
 
After the first cycle of doxorubicin treatment, the tumour reduction in actual size in 
the ninety nine patients achieved to 40.6±53.9cm2 and the tumour reduction in 
percentage was 28.5%±20.2% (Table 4.3). The doxorubicin-induced tumour reduction 
in actual size ranged from -69cm2 to 322cm2 and percentage of tumour reduction 
ranged from -29% to 100%, indicating the large inter-patient variations of the 
doxorubicin-induced anticancer efficacy.  
 
In addition, a tumour reduction of ≥25% after the first cycle of doxorubicin treatment 
was empirically assigned as intrinsic sensitive to doxorubicin. Therefore, more than 
half of the patients (58%) in our study had tumours intrinsically sensitive to the 





Table 4.3 Antitumor efficacy of doxorubicin (n=99)  
 
Antitumor efficacy  
Tumour reduction after 1 cycle of doxorubicin (cm2): Mean±SD     40.6±53.9cm2 
Tumour reduction after 1 cycle of doxorubicin (%): Mean±SD        28.5±20.2  
Percentage of patients with ≥25% tumour reductions after the first 




4.2.2 Comparison of anticancer efficacies between the two treatment arms 
We also compared the three efficacy parameters of doxorubicin between the two arms 
of patients. Table 4.4 shows that the two arms of patients have similar doxorubicin-
induced tumour reduction and percentage of patients with intrinsically sensitive 
tumours.  
 
Table 4.4 Comparison of antitumor efficacy of doxorubicin between the two 
treatment arms  
 











Tumour reduction after 1 cycle of 









Tumour reduction after 1 cycle of 









Percentage of patients with ≥25% 
tumour reductions after the first 










1Arm A: A→T→A→T→A→T;  
2Arm B: T→A→T→A→T→A (A: doxorubicin and T: docetaxel). 




In this study, doxorubicin, as a first-line single agent, demonstrated high anticancer 
efficacy in Singaporean breast cancer patients with up to 58% of them showing 
greater than or equal to 25% of tumour reduction. 
 
Wide inter-patient variations in doxorubicin-induced short-term tumour reduction had 
been observed. The range in doxorubicin-induced tumour reduction in actual size (-
69cm2 to 322cm2) and in percentages (-29% to 100%) in our patients receiving the 
first cycle of doxorubicin treatment was large. This range was larger than the reported 
from 10 to 80%, where the breast cancer patients had received the first-line 
chemotherapy at the dose level of combining 50mg/m2 of doxorubicin on day 1, 
1mg/m2 of vincristine on day 2 and 6mg/m2 of methotrexate on day 3, 4, and 5 
(Robert, et al., 1982). The larger variation in tumour reduction in our patients may be 
resulted from the larger patient number (n=99) in our study than that in the reported 
group (n=12). Insights into the determinants of doxorubicin anticancer efficacies 
would help to potentially reduce this variability and improve the effective use of 
doxorubicin.  
 
As discussed in section 4.1.2, before the first cycle of doxorubicin treatment, the 
mean value of tumour sizes in Arm B patients was smaller than that of in Arm A 
patients (Arm B vs. Arm A: 135.9±138.9cm2 vs.190.8±179.8cm2, p=0.078 for Mann-
Whitney U test; p=0.098 for student’s t-test). After the first cycle of doxorubicin 
treatment, the doxorubicin induced tumour reductions in actual size and in 
percentages, as well as the percentage of patients with ≥25% tumour reductions 
between the two treatment arms were similar (Table 4.4). This finding suggests that 
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the effect of baseline difference of tumour sizes is unlikely to be significant. This 
evidence provides a background that the efficacy data of the two arms of patients 
could be combined together for further correlation analysis.  
 
4.3 Toxicities  
4.3.1 Hematologic toxicities 
4.3.1.1 All patients’ hematologic toxicities 
Table 4.5 demonstrates that patients who were treated with doxorubicin at a dose of 
75mg/m2 by slow intravenous bolus over 5 minutes had acute hematologic toxicities. 
85% of patients experienced grade 3 or 4 neutropenia, and 46% of patients had grade 
3 and 4 leukopenia. The mean values of percentage of decrease in absolute neutrophil 
at nadir and in white blood cells at nadir were 89%, and 71%, respectively (Table 4.5). 
Of 99 patients, 16 patients had neutropenia fever. They were hospitalized for 2 to 11 
days until neutropenia recovered to grade 2 or less.  
 
Severe thrombocytopenia and anemia in our patients were rare. Only one patient 
experienced grade 3 thrombocytopenia. Grade 4 anemia occurred in two patients and 
grade 3 in four patients. The mean values of percentage of decrease in platelets at 
nadir and in haemoglobin at nadir were 33% and 12%, respectively.  
 
The wide inter-individual differences in myelosuppressions were obviously observed, 
with up to 368-fold variations in absolute neutrophil cell suppression (ANC nadir 
range from 0.01×109/L to 3.68×109/L), 15-fold variations in white blood cell 
suppression (WBC nadir range from 0.39×109/L to 5.76×109/L) and 10-fold variations 
in platelets suppression (platelets nadir range from 48×109/L - 496×109/L).  
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Table 4.5 Summary of doxorubicin associated hematologic toxicities in the first 











(Mean±SD)    
nadir range 
 
  Neutropenia 14 85 ANC:  
89±11 
ANC:  
0.01×109/L - 3.68×109/L  
  Leukopenia 40 46 WBC: 
 71±14 
WBC:  
0.39×109/L  - 5.76×109/L  
  
Thrombocytopenia 
4 1 Platelets:  
33±22 
Platelets:  
48×109/L - 496×109/L   
  Anaemia  59 6 Haemoglobin: 
 12±11 
Haemoglobin:  
4 g/dL - 14 g/dL 
  Febrile 
neutropenia  
- 16 - - 
 
 
4.3.1.2 Comparison of hematologic toxicities between the two treatment arms 
The hematologic toxicities between the two treatment arms are shown in Table 4.6. 
There was no significant difference observed among the hematologic toxicities at 
nadir values, the percentage of decrease at nadir in hematologic toxicities and the 
incidences of febrile neutropenia between the two arms of patients (all p values>0.05) . 
Therefore, the results of hematologic toxicities from the two arms of patients were 
merged for further investigation into the PK-PD correlations and the PG-PD 
associations.  
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Table 4.6 Comparison of doxorubicin associated hematologic toxicities between 
















ANC at nadir (×109/L)  0.50±0.49 0.55±0.62 0.632 0.654 
WBC at nadir (×109/L)   2.23±1.11 2.19±1.11 0.771 0.873 
platelet at nadir(×109/L)   208±86 211±72 0.576 0.832 
haemoglobin at nadir g/dL  10.6±1.8 10.4±1.5 0.313 0.563 
% decrease in ANC at nadir 89±10 89±12 0.828 0.969 
% decrease in WBC at nadir 70±14 72±14 0.273 0.440 
% decrease in platelet at nadir 30±25 36±17 0.737 0.242 
% decrease in haemoglobin  at 
nadir 13±13 10±8 0.219 
0.158 
Febrile neutropenia 11 5 0.1713 - 
Notes:  
1Arm A: A→T→A→T→A→T;  
2Arm B: T→A→T→A→T→A (A: doxorubicin and T: docetaxel). 
3The p values were evaluated by use of Chi-square test for nominal variables. 
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4.3.2. Non-hematological toxicities 
The incidences of doxorubicin-induced non-hematological toxicities are listed in 
Table 4.7. The most common non-hematological toxicities were fatigue, alopecia, 
nausea and anorexia, with an occurrence of more than 40%. No grade 4 non-
hematological toxicity was observed. Grade 3 of these toxicities was infrequent, and 
only one patient experienced grade 3 toxicities of nausea, anorexia and vomiting. 
 
 The Arm B patients had received one cycle of docetaxel treatment before the first 
cycle of doxorubicin treatment. Some patients in Arm B started the non-hematological 
toxicities with the first cycle of docetaxel treatment.  
 
We noticed that no patient presented with the lethal cardiotoxicity, manifested as the 
congestive heart failure (CHF), within the three weeks after the first cycle of 
doxorubicin treatment. 
 
Table 4.7 Non-hematological toxicities in the first cycle of doxorubicin treatment  
 
 All patients 
(n=99) 
Number of patients started adverse 
effects with the first cycle of docetaxel 
treatment 
Fatigue (Grade1/2) 70/1 7/1 
Nausea (Grade 1/2/3) 46/8/1  
Anorexia (Grade 1/2/3) 43/1/1 3/0/0 
Alopecia (Grade 1/2) 19/41 1/10 
Vomit (Grade 1/2/3) 25/8/1  
Dysgeusia (grade 1) 29 5 
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Cont’d    
 All patients 
(n=99) 
Number of patients started adverse 
effects with the first cycle of docetaxel 
treatment  
Diarrhea (Grade 1/2) 7/3  
Mucositis (Grade 1/2) 8/7 5 
Myalgia (Grade 1/2) 7/2 3 
Nail change (Grade 1) 8  
Chills (Grade 1)  5  
Weight loss (Grade 1/2) 2/3  
Giddiness (Grade 1) 2  
Arthralgia (Grade 1) 2  
Mouth ulcer (Grade 1) 1  




Neutropenia and leukopenia, as anticipated, were clinically the most significant 
hematologic toxicities observed (Table 4.5). They equally occurred in high 
frequencies in both two treatmnent arms in our patients after treatment with 
doxorubicin, as a first-line single agent (Table 4.6). Furthermore, the inter-patient 
variabilities observed in doxorubicin-induced absolute neutrophil cell suppression and 
in white blood cell suppression were wide (Table 4.5). Thus, to identify the 
relationship between the pharmacokinetics and these hematologic toxicities, as well as 
to determine the contributors of genetic variants to these hematologic toxicities could 
be useful in doxorubicin dosage optimization.  
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Previous reports showed that only about 18% to 32% of advanced breast cancer 
patients experienced grade 3 and 4 leukopenia when they received 75mg/m2 
doxorubicin by IV bolus every 3 weeks (Richards, et al., 1992; Lopez, et al., 1989). 
Compared to these reported findings, our breast cancer patients seemed to experience 
more profound leukopenia (46%) after being treated with doxorubicin at the same 
dosage.  
 
Severe thrombocytopenia and anemia in our patients were not common. Only 1% of 
our patients had grade 3 thrombocytopenia and 6% of our patients had grade 3 or 
grade 4 anemia (Table 4.5). These results were similar to previous findings that no 
grade 4 thrombocytopenia was reported, less than 8% of patients had grade 3 
thrombocytopenia, and 5% of our patients had grade 3 or grade 4 anemia. (Richards, 
et al., 1992; Lopez, et al., 1989). As well, the mean values of percentage of decrease 
in platelets at nadir and in haemoglobin at nadir were low, indicating that platelets and 
haemoglobin suppression at nadir were tolerable (Table 4.5).  
 
Non-hematologic toxicities were quite common in our patients treated with 
doxorubicin, but less degree of severity. Therefore, the associations of the non-
hematological toxicities with the PK and the PG of doxorubicin were not studied in 
this work.  
 
It was noticed that no patient presented with the lethal cardiotoxicity manifested as 
the congestive heart failure (CHF) within the three weeks after the first cycle of 
doxorubicin treatment. As discussed in Section 2.4.1.3, the CHF typically occurs in 
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the 4 to 18 weeks after the last cycle of doxorubicin treatment with a cumulative dose 
more than 480 mg/m2 (Chan, et al., 1999). The risk of developing CHF is as low as 
0.14% when the total dose is less than 400mg/m2 (Chan, et al., 1999; Product 
Information: Doxorubicin Hydrochloride for Injection, 2003).  In our clinical study, 
the dosage of doxorubicin in the first cycle was set to the recommended dosage, 
75mg/m2 (Product Information: Doxorubicin Hydrochloride for Injection, 2003). The 
cumulative dose of doxorubicin was not more than 225mg/m2. This clinical design 
was expected to reduce the risk for patients to develop CHF.  
 
In summary, the current results provided evidence that leukopenia and neutropenia 
were the most clinically significant hematologic toxicities. The inter-patient variations 
in these hematologic toxicities were obvious. Due to no difference in hematologic 
toxicities between the two arms (A and B) of our patients received the first cycle of 
doxorubicin treatment, the hematologic toxicities from the two arms of patients were 




4.4 Clinical pharmacokinetics of doxorubicin 
4.4.1 Comparison of pharmacokinetic parameters between the two treatment 
arms 
Concentrations of doxorubicin and doxorubicinol in plasmas were determined in 99 
patients. The pharmacokinetic profiles of doxorubicin at mean concentrations in all 
ninety-nine patients as well as in treatment arms A patients and in treatment Arm B 
patients are shown in Figure 4.1. The two mean concentration curves of doxorubicin 
from the patients in different treatment arms are very close to the mean concentration 
curves of doxorubicin form the all patients.  
 


























Doxorubicin (all patients, n=99)
Doxorubicin (patients in Arm A, n=50)
Doxorubicin (patients in Arm B, n=49)
 
Figure 4.1 The pharmacokinetic profiles of doxorubicin in plasma 
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Furthermore, non-compartmental analysis and two-compartmental analysis were used 
to derive the main individual patient pharmacokinetic parameters of doxorubicin and 
doxorubicinol by using Kinetica 4.4. The two-compartmental model best described 
the change of the concentration of doxorubicin in plasma against time in 98 patients, 
but failed to fit the concentration-time curve to get the two-compartmental PK 
parameters for one patient. Therefore, the two-compartmental PK parameters of 
doxorubicin shown in Table 4.8 and Table 4.9 are based on 98 patients.  
 
Similar to the PD parameters, the pharmacokinetic parameters of doxorubicin 
between the two treatment arms have also been compared by use of the Mann-
Whitney U test and the student’s t-test (Table 4.8). We noticed that the difference in p 
values at the terminal phase elimination half-life (T ½ ) between the two treatment 
arms of our patients were different (p=0.149 for Mann-Whitney U test and p=0.037 
for student’s t-test). The normality of the parameter in treatment arms was carefully 
evaluated by statistical tests (Arm A: p=0.028 for Shapiro-Wilk test; Arm B: p=0.000 
for Shapiro-Wilk test). The parameters in both treatment arms were non-normality. 
Therefore, the comparison between the two treatment arms performed by use of the 
Mann-Whitney U test was more appropriate.   
 
The two arms showed similar doxorubicin pharmacokinetic parameters. Thus, the PK 









Table 4.8 Comparisons of pharmacokinetic parameters of doxorubicin and 
doxorubicinol between the two arms of patients 
 












AUC (0-∞) (mg/l*h) 
T ½ (α) (h) 
T ½ (β) (h) 









































AUCdoxorubicin  (mg/l*h) 1.19±0.35 1.15±0.30 0.883 0.560 
AUCdoxorubicinol (mg/l*h) 1.73±0.64 2.13±1.99 0.961 0.178 
AUC ratio doxorubicinol/doxorubicin 1.53±0.66 1.84±1.46 0.619 0.178 
Notes:  
1Arm A: A→T→A→T→A→T;  
2Arm B: T→A→T→A→T→A (A: doxorubicin and T: docetaxel). 
 
 
4.4.2 Clinical pharmacokinetics of doxorubicin  
The pharmacokinetic profile of doxorubicin at mean concentrations in our patients has 
been shown in Figure 4.1. The main pharmacokinetic parameters of doxorubicin and 
doxorubicinol in local patients with breast cancer are summarized in Table 4.9.  
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Table 4.9 Main pharmacokinetic parameters of doxorubicin and doxorubicinol 
in local patients with breast cancer.  
 
Parameters Mean±SD    
Dose (mg) (n=99) 115.1±11.4 
Doxorubicin (n=98) 
AUC (0-∞) (mg/l*h) 
T ½ (α) (h) 
T ½ (β) (h) 










0.27±0.13   
0.31±0.39  
518±336  
89.7±29.9   
AUCdoxorubicin  (mg/l*h) (n=99) 1.17±0.33 
AUCdoxorubicinol (mg/l*h) (n=99) 1.93±1.48 
AUC ratio doxorubicinol/doxorubicin (n=99) 1.68±1.13 
 
The mean value of clearance is 89.7l/h. The mean values of distribution half-life of 
doxorubicin (T ½ α) and a terminal phase elimination half-life (T ½ ) are 0.72 hr and 
15.7 hr, respectively.  
 
The non-compartmental analysis was also used to estimate the AUC of doxorubicin 
and doxorubicinol. It was applied for all 99 patients. The metabolic AUC ratios (MR: 
AUC0-doxorubicinol/AUC0-doxorubicin) were calculated by using the non-compartmental 
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AUC values. The mean±SD value of the metabolic AUC ratio was 1.68±1.13. A 13-
fold range in the metabolic AUC ratios (MR) was observed (range from 0.66 to 8.63). 
The AUC of doxorubicinol showed higher inter-patient variations than that of 
doxorubicin (15-fold with range from 0.83 to 12.08mg/l*h for doxorubicinol vs. 7-
fold with range from 0.30 to 2.09mg/l*h for doxorubicin).  
 
Wide inter-patient variations in the AUC of doxorubicin, the AUC of doxorubicinol 
and the metabolic AUC ratio were observed in our patients. The age of patients, 
baseline body surface area, KPS, actual dose of doxorubicin and hepatic and renal 
function were correlated with the three PK parameters.  The AUC of doxorubicin was 
not associated with the actual dose of doxorubicin or the patient’s BSA in our patients 
(r=-0.006, p=0.951 and r=0.023, p=0.824, respectively). But, the AUC of doxorubicin 
was associated with patient’s liver function in our patients (correlation with alkaline 
phosphatase, ALP: r=0.267 and p=0.008; correlation with alkaline phosphatase, AST: 
r=0.187 and p=0.064, for the Pearson test). No correlation of the AUC of 
doxorubicinol and the metabolic AUC ratios with the demographic parameters and the 
BSA-based dosage was found in this study. 
 
4.4.3 Discussion 
In this study, after receiving 75mg/m2 of doxorubicin at a single dose, the mean 
clearance, the mean distribution half-life of doxorubicin (T ½ α) and a terminal phase 
elimination half-life (T ½ ), were consistent with the earlier literature reports 
(Benjamin, et al., 1973, Robert, et al., 1982, Eksborg, et al., 1985). The mean±SD 
value of the metabolic AUC ratio was 1.68±1.13, which was consistent with a value 
of 1.6±1.3 reported by Ackland SP et al (Ackland, et al., 1989). 
  103
 
We observed significant interindividual variabilities in plasmas doxorubicin AUC, 
doxorubicinol AUC and metabolic AUC ratios of doxorubicin pharmacokinetics, and 
correlated them with patient’s demographic parameters and the BSA-based dosage of 
doxorubicin. Similar to the finding by Piscitelli SC et al., the AUC of doxorubicin 
was not associated with the actual dose of doxorubicin or the patient’s BSA in our 
patients (Piscitelli, et al., 1993). The AUC of doxorubicin was associated with 
patient’s alkaline phosphatase (ALP) in our patients. These findings suggested that 
marked inter-patient variations in doxorubicin exposure may be related to the liver 
function, but not the BSA or the BSA-based dosage. No correlation of the AUC of 
doxorubicinol and the metabolic AUC ratios with the demographic parameters and the 
BSA-based dosage was found in this study, indicating that these non-genetic factors 
may not affect the conversion of doxorubicin to doxorubicinol and the formation of 
doxorubicinol in our patients.  The next step would be to look for genetic factors in 
the genes which encode the doxorubicin metabolizing enzymes and transporters that 
may explain the wide inter-patient variations in the AUC of doxorubicinol and the 




4.5 Pharmacokinetic-pharmacodynamic relationships 
4.5.1 Relationship of doxorubicin efficacy with PK 
We analyzed the clinical pharmacologic parameters of patients for their potential 
contribution to the doxorubicin-induced tumour reduction. For these analyses, 
patient’s physiologic parameters and the PK parameters were included. The 
physiologic parameters were:  
 Age,  
 Body surface area,  
 KPS,  
 Actual dose of doxorubicin,  
 Serum albumin at baseline,  
 Alkaline phosphatase level at baseline,  
 Aspartate aminotransferase level at baseline,  
 Alanine aminotransferase level at baseline,  
 Bilirubin level at baseline,  
 Total protein in serum at baseline.  
The parameters of liver function and kidney function were measured just before the 
first cycle of doxorubicin treatment.  
 
The pharmacokinetic parameters calculated were: 
 AUC of doxorubicin  
 AUC doxorubicinol,  
 Metabolic AUC ratios of doxorubicinol versus doxorubicin,  
 Clearance,  
 Distribution half-life of doxorubicin,  
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 Terminal phase elimination half life,  
 Rate constant of elimination,  
 Rate constant of central compartment to peripheral compartment, K12,  
 Rate constant of peripheral compartment to central compartment, K21,  
 The ratio of K21 to K12, 
 Macro-rate constants of A, 
 Macro-rate constants of B, 
 Macro–elimination rate constants of alpha, 
 Macro–elimination rate constants of beta, 
 Concentrations of doxorubicin,  
 Concentrations of doxorubicinol,  
 Concentration ratios of doxorubicinol to doxorubicin at different sampling 
time.  
These pharmacokinetic parameters were also involved in this correlation analysis.   
 
All these parameters were separately correlated with the percentage of tumour 
reduction and the percentage of ≥25% tumour reduction after the first cycle of 
doxorubicin treatment.  
 
Non-normality of distribution at the percentage of tumour reduction (p=0.004 for 
Kolmogorov-Smirnov test and p=0.002 for Shapiro-Wilk test) was found. The 
percentage of patients with ≥25% tumour reductions was a nominal variable. 
Therefore, Spearman’s Rho correlation test was applied for both correlation analyses.   
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The correlation between the percentage of tumour reduction and k21 (the rate constant 
of peripheral compartment to central compartment) and the correlation between the 
percentage of patients with ≥25% tumour reduction and k21, are shown in Figure 4.2. 
The calculated PK parameter, k21, is clearly negatively correlated with the percentage 
of tumour reduction (r=-0.261, p=0.01) and the percentage of patients with ≥25% 
tumour reduction (r=-0.309, p=0.002).  
 
According to the two-compartmental pharmacokinetic model, the concentration of 
doxorubicin in the peripheral tissue compartment versus the concentration 
doxorubicin in central circulation compartment depends on the distribution rate from 
the tissue to the circulation (K21) as well as depends on the distribution rate from the 
circulation to the tissue (K12) (Figure 3.5). Therefore, the ratio of K21 to K12 could be 
another interesting parameter to indicate the distribution of doxorubicin into the 
peripheral compartment. However, in this study, the ratio of K21 to K12 was not 
significantly correlated with the percentage of tumour reduction (r=-0.037, p=0.714) 
and the percentage of patients with ≥25% tumour reduction (r=0.017, p=0.871).  
 
No other correlation was found between the tumour reduction and patient’s baseline 
physiologic parameters or the doxorubicin pharmacokinetic parameters (all p 
value>0.05). The BSA values of patients may not affect the short-term doxorubicin 
efficacy (r=-0.019, p=0.851 for correlation between percentage of tumour reduction 
and BSA, and r=0.087, p=0.392 for correlation between percentage of patients with 
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Figure 4.2 Correlations between the doxorubicin pharmacokinetic parameter of 
K21 and patient percentage of tumour reduction after the first cycle of 








4.5.2 Relationship of hematologic toxicities with PK  
Since neutropenia and leukopenia were the most severe doxorubicin-induced 
toxicities that occurred in our patients, we analyzed the correlations of a variety of 
clinical pharmacologic parameters with the percentage of decrease in absolute 
neutrophil at nadir and the percentage of decrease in white blood cells at nadir. The 
independent co-variables used in this analysis were the same as those used in the 
correlation analysis of doxorubicin efficacy. Due to non-normality of distribution at 
the percentage of decrease in absolute neutrophil at nadir and the percentage of 
decrease in white blood cells at nadir, Spearman’s Rho correlation test was used in 
this investigation. 
 
The significant correlations of the percentage of decrease in white blood cells at nadir 
and the percentage of decrease in absolute neutrophil at nadir were the concentration 
ratios of doxorubicinol to doxorubicin at 1 hr after the administration of intravenous 
infusion of 75mg/m2 of doxorubicin (Table 4.10 and Figure 4.3). The concentration 
ratios at 2 hr were also associated with the percentage decrease in white blood cells at 
nadir (Table 4.10 and Figure 4.3). The patient’s concentration ratios at 1 hr are widely 
distributed in the range from 0.09 to 1.12 as shown in Figure 4.3. As discussed in 
Section 2.5.2.2, these results support our speculation that: (1) the patient’s catalytic 
conversion rate of doxorubicin to doxorubicinol affects the doxorubicin-induced 
hematologic toxicity; (2) the plasma levels of doxorubicinol relative to doxorubicin at 
1 hr, instead of plasma levels of doxorubicin alone, could be associated with 




No correlations were found between the clinical baseline physiological parameters 
and the other pharmacokinetic parameters of doxorubicin, and the two hematologic 
suppression values. The BSA of a patient was not related to either the doxorubicin-
induced absolute neutrophil suppression at nadir or the white blood cells suppression 
at nadir. Correlation between the BSA and the percentage of decrease in absolute 
neutrophil at nadir was 0.026, (p=0.801); and correlation between the BSA and the 
percentage of decrease in white blood cells at nadir was 0.006 (p=0.956).  
 
 
Table 4.10 Significant correlations with the percentage of decrease in white blood 
cells at nadir and the percentage of decrease in absolute neutrophil cells at nadir 
(n=99) 
 
Percentage decrease in 
white blood cells at nadir 
Percentage decrease in absolute 








doxorubicinol/doxorubicin at 1h 
-0.236 0.019 -0.214 0.034 
Concentration ratios 
doxorubicinol/doxorubicin at 2h 
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Figure 4.3 Correlations the percentage of decrease in white blood cells at nadir 
with the concentration ratios at 1 hour (a) and with the concentration ratios at 2 
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In this study, a pharmacokinetic-pharmacodynamic (PK-PD) correlation of 
doxorubicin-induced tumour reduction has been found, where the doxorubicin transfer 
rate from peripheral tissue compartment to central blood compartment could be 
related to doxorubicin-induced tumour reduction. It is known that patient’s breast 
tumour tissue is one of key tissues for the uptake and accumulation of doxorubicin. 
The early studies showed that about 1-5 hr after intravenous bolus administration of 
doxorubicin, the highest concentrations of doxorubicin have been detected in patient’s 
normal liver (2.7μg/g), normal lymph node (2.6μg/g) and tumour tissues including 
breast tumour tissues (1.93μg/g). Other tissues such as muscle, fat and skin had lower 
doxorubicin concentrations (the median range from 0.04 to 0.4μg/g) (Lee, et al., 
1980). The concentrations of doxorubicin in breast tumour tissues were 400 times 
higher than that in patient’s plasma (Cummings, et al., 1986). Moreover, in patient’s 
breast tumour, up to 72% of doxorubicin was bound to intracellular components 
(Cummings, et al., 1986). This binding fraction was higher than that detected in liver 
tissue (43%) (p value<0.01), suggesting more doxorubicin accumulation in patient’s 
breast tumours (Cummings, et al., 1986). 
  
K21 is the rate constant of peripheral tissue compartment to central blood 
compartment. We observed that it was negatively correlated with doxorubicin-
induced tumour reduction. This suggests that the lower transfer rate from patient’s 
tissues, including breast tumour tissues, to patient’s blood could result in more 
doxorubicin uptake and retention in patient’s tissues, especially in the breast tumour 
tissue, which would cause greater tumour reduction. 
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The previously reported finding of significant correlation between the doxorubicin 
pharmacokinetic parameter A (macro-rate constant) and the percentage of tumour 
reduction hasn’t been found in our patients (r=0.05, p=0.625 from our data) (Robert, 
et al., 1982). One of the possible reasons is that the parameter A of our patients was 
calculated from the two-compartmental modelling, whereas the published data were 
from the three-compartmental model. The integral equations for the two-
compartmental fitting model and the three-compartmental fitting model are different. 
This will affect the values of parameter A calculated. The other possible reason is the 
additional use of other agents, vincristine and methotrexate, in the previous published 
study; tumour reduction was not only caused by doxorubicin but also induced by 
other two anticancer drugs, vincristine and methotrexate. The breast cancer patients 
described in the publication received a combination therapy with doxorubicin on day 
1, vincristine on day 2 and methotrexate on days 3, 4, 5 (Robert, et al., 1982).   
 
In this study, the plasma concentration ratios of doxorubicinol to doxorubicin at 1 hr 
were correlated with the two severe doxorubicin-induced hematologic toxicities, the 
absolute neutrophil suppression at nadir and the white blood cell suppression at nadir. 
A previous report showed that doxorubicin exposure (AUC) was associated with the 
surviving factor of white blood cells (defined by nadir value/baseline value) (Piscitelli, 
et al., 1993). The correlation between doxorubicin AUC and the natural log of 
surviving factor of white blood cells was 0.57 (p=0.0025, n=26). As we known, a 
correlation between doxorubicin exposure and toxicity and qualifying by saying that 
toxicity is a complex parameter influenced by multiple factors. In our patients, the 
previously reported findings of were not substantiated that AUC of doxorubicin was 
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not related to the percentage of decrease in white blood cells at nadir (r=-0.046, 
p=0.654, n=99).   
 
In conclusion, the pharmacokinetic parameter, the doxorubicin transfer rate from 
peripheral tissue compartment to central blood compartment, could be associated with 
doxorubicin-induced tumour reduction. The plasma concentration ratios of 
doxorubicinol to doxorubicin at 1 hour and 2 hour could be correlated with the 
doxorubicin-induced the white blood cell suppression at nadir. BSA and BSA-based 
dosage were not associated with the wide hematologic toxicities and tumour 
reduction. Dose calculated by patient’s BSA would be imprecise to predict the 
doxorubicin-induced hematologic toxicities and efficacy. The further studies on 
genetic factors may improve our understanding on the wide inter-patient variations in 
doxorubicin efficacy and hematologic toxicities in patients with breast cancer.  
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4.6 Doxorubicin pharmacogenetics on human CBR1 and CBR3 
In the following part of this chapter, we will describe the influence of genetic variants 
on the main metabolizing enzymes of doxorubicin, human CBR1 and CBR3, on the 
pharmacokinetics and pharmacodynamics of doxorubicin in our Singaporean patients.  
 
4.6.1 Human CBR1 and CBR3 genetic variants in Singaporean breast cancer 
patients  
4.6.1.1 Identified genetic variants on CBR1 and CBR3 
All coding regions of CBR1 and CBR3 including the splice-site junctions with 20-400 
bases upstream and downstream were amplified and the generated sequences were 
compared with the reference sequence for CBR1 and CBR3 (Genbank reference 
EF141836 and EF462915) by BLAST. Figure 4.3 shows the chromatograms of each 
genetic variant on CBR3 and CBR1. The genetic variants were determined by 
sequence analysis. Homozygous is defined as containing two copies of the same allele, 
whereas heterozygous is defined as containing two different alleles of the same gene. 
The naming of the intronic genetic variants was based on the distance of a mutated 
intronic nucleotide to the closest exonic nucleotide.  For intronic genetic variants 
located at the beginning of the introns and 3’-untranslated region, they were expressed 
as the number of the last nucleotide of the preceding exon, a plus sign and the position 
in the intron with the mutations. In this study, they were CBR1 397+125G>T, CBR1 
397+210C>G, CBR1 834+133G>A and CBR1 834+346G>C.  For intronic genetic 
variants located at the end of the introns and 5’-untranslated region, they were 
expressed as the number of the first nucleotide of the following exon, a minus sign 
and the position upstream in the intron with the mutations. They were CBR3398-
12G>A, CBR1 exon 1,-48G>A and CBR1 398-48C>T.   
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A total of six genetic variants on CBR3 and twelve genetic variants on CBR1 have 
been identified in our Singaporean breast cancer patients. Five of the six CBR3 
variants and six of the twelve CBR1 variants are coding region variants. Five novel 
genetic variants are CBR3 370G>A (E124K), CBR1 221G>T (R74L), CBR1 223G>A 
(D75N), CBR1 249C>T (G83G), and CBR1 601G>A (V201I).  
 




CBR3 exon 1, 11G>A (C4Y) (shown as sense strand) 
   
CBR3 exon 1, 255T>C (N85N) (shown as sense strand) 
   
CBR3 exon 1, 279C>T (V93V) (shown as sense strand) 
   
CBR3 exon 2, 370G>A  (E124K)* (shown as antisense strand) 
  
 
CBR3 exon 3, 730G>A  (V244M) (shown as sense strand) 
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CBR3398-12G>A   (shown as antisense strand) 
   
CBR1 exon 1,219G>C (L73L)  (shown as sense strand) 
   
CBR1 exon 1,221G>T (R74L)*  (shown as sense strand) 
  
 
CBR1 exon 1,223G>A (D75N)*  (shown as sense strand) 
  
 
CBR1 exon 1,249C>T (G83G)*  (shown as sense strand) 
  
 
CBR1 exon 1,-48G>A  (shown as sense strand) 
  
 
CBR1 exon 3,601G>A  (V201I) * (shown as antisense strand) 
  
 
CBR1 exon 3,627C>T  (A209A) (shown as antisense strand) 
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CBR1 397+125G>T (shown as antisense strand) 
   
CBR1 397+210C>G (shown as antisense strand) 
   
CBR1 398-48C>T (shown as antisense strand) 
   
CBR1 834+133G>A (shown as sense strand) 
   
CBR1 834+346G>C (shown as sense strand) 
   
 
Figure 4.4 The chromatograms of CBR3 and CBR1 genetic variants.  
The black peak was for G genotype, the green peak for A genotype, the red peak 
for T genotype and the blue peak for C genotype.  
Note: * Novel variant. 
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4.6.1.2 Allelic frequencies of CBR1 and CBR3 genetic variants  
CBR1 and CBR3 genetic variants and their allelic frequencies are listed in Table 4.11. 
Of the five CBR3 coding region variants identified, three were non-synonymous: 
11G>A, 370G>A and 730G>A. Two of these, 11G>A and 730G>A, were common 
(the common variants with a minor allele frequency >0.05) in our population with 
overall variant allele frequencies of 0.48 and 0.42 respectively. The 11G>A 
polymorphism results in a cysteine-to-tyrosine (Cys-Tyr) amino acid change, whereas 
the 730G>A polymorphism results in a valine-to-methionine (Val-Met) amino acid 
change. 370G>A was novel, occurring only in one Malay patient who was 
heterozygous for the variant. It results in a glutamic acid-to-lysine (Glu- Lys) amino 
acid change.  The other four reported non-synonymous genetic variants in the coding 
regions of human CBR3, 277G>A, 391C>T, 703C>T, and 716C>T, were not found 
in our Singaporean breast cancer population. (Refer to Table 2.2)   
 
Four novel CBR1 coding region variants were detected. Three non-synonymous 
variants, 221G>T, 223G>A, and 601G>A, occurred only once in three different 
Malay patients who were heterozygous. And a synonymous variant, 249C>T, was 
found in a Chinese patient who was heterozygous. The three 221G>T, 223G>A and 
601G>A polymorphisms result in arginine–to-leucine (Arg-Leu), aspartic acid-to-
asparagine (Asp-Asn), and valine-to-leucine (Val-Leu) amino acid change, 
respectively. The two previously reported synonymous coding region variants, 
627C>T and 219G>C, were identified with similar allele frequencies in our 
population (allele frequencies 20% and 16%, respectively) compared to those reported 
in Caucasians (allele frequencies 15% and 15%, respectively) (Gonzalez-Covarrubias, 
et al., 2007). We did not detect the reported functional CBR1 V88I variant in 
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Singaporean breast cancer patients. The CBR1 I88 isoform was reported to cause a 
lower Vmax and the CBR1 V88I was only identified in African Americans at low 
frequency (allele frequency 1.4%) (Gonzalez-Covarrubias, et al., 2007). Our results 
confirm that the CBR1 V88I variant is rare and it may not occur in our patient 
population consisting of the three distinct Singaporean ethnic groups: Chinese, Malay 
and Indian.  
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Table 4.11 Summary of CBR1 and CBR3 genetic variants (n=101)  







CBR3 exon 1, 11G>A (C4Y)  (rs8133052)  GG:GA:AA=37:30:33 0.48 
CBR3 exon 1, 255T>C (N85N)  (rs881711)  TT:TC:CC=75:23:2 0.13 
CBR3 exon 1, 279C>T (V93V) (rs881712) CC:CT:TT=40:30:30 0.45 
CBR3 exon 2, 370G>A*(E124K)  GG:GA=99:1 0.005 
CBR3 exon 3, 730G>A (V244M)(rs1056892) GG:GA:AA=40:36:24 0.42 
CBR3 398-12G>A (rs2835286) GG:GA:AA=71:26:3 0.16 
 
CBR1 exon 1, 221G>T* (R74L) GG:GT=99:1 0.005 
CBR1 exon 1, 223G>A* (D75N) GG:GA=99:1 0.005 
CBR1 exon 1, 219G>C (L73L) (rs25678) GG:GC:CC=69:30:1 0.16 
CBR1 exon 1, 249C>T* (G83G) CC:CT =99:1 0.005 
CBR1 exon 3, 601G>A* (V201I)  GG:GA=99:1 0.005 
CBR1 exon 3, 627C>T (A209A) (rs20572) CC:CT:TT=62:36:2 0.20 
CBR1 exon 1, -48G>A (rs11542168) GG:GA=96:4 0.02 
CBR1 397+125G>T (rs1005696) GG:GT:TT=14:48:38 0.62 
CBR1 397+210C>G  (rs1005695) CC:CG:GG=14:46:40 0.63 
CBR1 398-48C>T (rs2835265) CC:CT:TT=62:36:2 0.20 
CBR1 834+133G>A (rs9024) GG:GA:AA=62:36:2 0.20 
CBR1 834+346G>C (rs998384) GG:GC:CC=46:40:14 0.34 





4.6.1.3 Linkage disequilibrium  
Linkage disequilibrium among the CBR1 and CBR3 genetic variants identified has 
been determined. No linkage disequilibrium was detected between any of the CBR1 
genetic variants and the CBR3 genetic variants (D’ values <0.5 and r2 values <0.2).  
 
A strong linkage was found between the CBR3 synonymous genetic variants, 255T>C, 
and one intronic variants CBR3 398-12G>A (D’=0.9612, r2=0.7366). The other was a 
weak linkage between the two CBR3 non-synonymous genetic variants, 11G>A and 
730G>A (D’=0.5226, r2=0.1435).  
 
Complete linkage was observed between CBR1 627C>T and the two CBR1 intronic 
variants, 398-48C>T and 834+133G>A (D’=1 and r2=1). In addition, strong linkage 
was observed among three other CBR1 intronic variants, 397+125G>T, 




4.6.2 Influence of common CBR3 variants on the PK, PD of doxorubicin and the 
tumour tissue CBR3 expression  
4.6.2.1 CBR3 C4Y (11G>A) variant  
Each common CBR3 variant was correlated with the PK and PD parameters of 
doxorubicin. The C4Y (11G>A) variant seems to be particularly important in 
influencing not only the PK of doxorubicin, but also the doxorubicin-induced 
hematologic toxicities and anticancer efficacy, and intra-tumoral CBR3 expression as 
well. 
 
The correlations between the CBR3 C4Y (11G>A) variant and the pharmacokinetics 
of doxorubicin, the hematologic toxicities, the anticancer efficacy and the CBR3 
expression in tumour tissue are summarized in Table 4.12 and shown in Figure 4.5.  
 
4.6.2.1.1 PK correlations 
Compared with patients who were homozygous for the variant allele (A allele), 
patients with wild-type allele (G allele) had significantly higher AUC of 
doxorubicinol (2.181.37mg/l*h, 2.042.11mg/l*h, 1.540.61mg/l*h for GG, GA and 
AA, p=0.012, for overall; p=0.004 for GG vs. AA; and p=0.003 for JT trend test) and 
metabolic AUC ratios of doxorubicinol to doxorubicin (1.861.26, 1.721.34 and 
1.450.67 for GG, GA and AA, p=0.016, for overall; p=0.009 for GG vs. AA; and 
p=0.004 for JT trend test, respectively).  
 
4.6.2.1.2 Hematologic toxicity correlations 
In concordance, patients with the G allele experienced less leukocyte and platelet 
suppressions at nadir, and there were two trends of progressively greater leukocyte 
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and platelet suppression at nadir with increasing copies of the A allele (leukocyte 
suppression at nadir: 66%15%, 72%15% and 75%11% for GG, GA and AA; 
p=0.019 for JT trend test and platelet suppression at nadir: 29%21%, 33%21% and 
36%24% for GG, GA and AA; p=0.020 for JT trend test, respectively). Grade 3 and 
4 nadir neutropenia was least frequent in patients with homozygous for the G allele, 
although the difference did not reach statistical significance (p=0.082).  
 
4.6.2.1.3 Efficacy correlation 
Additionally, patients carrying at least one copy of the G allele also had less tumour 
response compared to patients who were homozygous for the A allele (percentage of 
patients with ≥25% tumour reductions after the first cycle of doxorubicin treatment:  
47% vs. 76% for GG vs. AA, p=0.015 and overall p=0.034).  
 
4.6.2.1.4 Tumour tissue CBR3 expression   
Higher tumour tissue transcriptional expression of CBR3 was found in patients with 
the CBR3 11G allele, with a trend to higher CBR3 transcription with increasing copies 
of the G allele (1348772, 888903 and 651476 for GG, GA and AA; p=0.005 for 
overall, p=0.001 GG vs. AA, and p=0.003 for JT trend test).  
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Table 4.12 Correlation between CBR3 C4Y (11G>A) variant and doxorubicin pharmacokinetic parameters, toxicities, tumour reductions 
and intra-tumoral CBR3 expression (n=99)  
 




















        
  AUCdoxorubicin  (mg/l*h)                             1.200.30 1.180.33 1.140.35 0.520 0.414 0.815 0.678 0.385 
  AUCdoxorubicinol (mg/l*h)                           2.181.37 2.042.11 1.540.61 0.050 0.004 0.364 0.012 0.003 
  AUC ratios doxorubicinol/doxorubicin                          1.861.26 1.721.34 1.450.67 0.037 0.009 0.356 0.016 0.004 
Hematologic toxicities (meanSD)         
  % decrease in white blood cell at nadir 6615 7215 7511 0.097 0.019 0.591 0.052 0.019 
  % decrease in absolute neutrophil at 
nadir 
8712 9014 917 0.463 0.464 0.858 0.687 0.500 
  % decrease in platelet at nadir 2921 3321 3624 0.285 0.023 0.302 0.080 0.020 
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  % patients with grade 3+4 nadir 
neutropenia 
75 90 91 0.116 0.082 0.902 - - 
  % patients with  febrile neutropenia   14 17 18 0.754 0.627 0.874 - - 
Antitumour efficacy         
  Tumour reduction (%) 25.421.4 24.616.7 35.620.7 0.867 0.094 0.090 0.148 - 
 % of patients with  ≥25% tumour 
reductions after first cycle of 
doxorubicin treatment  
47 50 76 0.822 0.015 0.034 0.034 - 
Tumour tissue CBR3 expression1 n=27 n=19 n=20      
 1348772 888903 651476 0.033 0.001 0.866 0.005 0.003 
 
Notes: 
1Baseline intra-tumoral CBR3 expression levels were available only on 66 patients with sufficient quantity of good quality RNA for gene 
expression microarray analysis. 
2After Bonferroni correction, the value of p0.017 was considered statistically significant for multiple comparisons of the pharmacokinetic 
parameters, the percentage decreases in hematologic toxicities and tumour tissue CBR3 expression. 
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Figure 4.5 Box plots of the relationships between the CBR3 C4Y (11G>A) alleles 
and  
(a) Metabolic AUC ratios of doxorubicinol to doxorubicin;  
(b)Doxorubicin induced leukocyte suppression; (Percentage decreases in 
leukocytes were calculated by (baseline counts – nadir counts)/baseline counts 
×100%) 
(c) Breast tumour tissue CBR3 expression (Baseline intra-tumoral CBR3 
expression levels were available only on 66 patients with sufficient quantity of 
good quality RNA for gene expression microarray analysis). 
Note:  
(1) p0.017 was considered statistically significant for multiple comparisons between 
groups after Bonferroni correction; and p0.05 was considered significant for overall 
and trend test comparisons.  
(2) The box indicates the 25th and 75th percentiles, the line within the box is the 
median, error bars are above and below the 90th and 10th percentiles respectively, and 































































4.6.2.2 CBR3 730G>A (V244M) variant 
The CBR3 730G>A (V244M) genotype was correlated with doxorubicin 
pharmacokinetics (Table 4.13). Patients with the A allele had 1.5-fold higher 
doxorubicinol AUC than those with the G allele, suggesting higher catalytic activity 
of CBR3 (1.560.60mg/l*h, 2.081.95mg/l*h, 2.291.60mg/l*h for GG, GA and AA; 
p=0.034 overall by Kruskall Wallis test, p=0.009 for GG vs. AA, p=0.011 for JT trend 
test). CBR3 730G>A genotype did not correlate with the metabolic AUC ratios of 
doxorubicinol to doxorubicin, the hematologic toxicities of patients or the tumour 
reduction. Patients with the A allele also had significantly higher intra-tumoral CBR3 
expression than those with the G allele (549527, 1240868, 1221713 for GG, GA 
and AA; p=0.001 for overall, p=0.002, GG vs. GA; p=0.001, GG vs. AA).  
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Table 4.13 Associations of CBR3 V244M (730G>A) variant with pharmacokinetic parameters, toxicities, tumour reductions and intra- 
tumoral CBR3 expression (n=99). (MeanSD) 
 
 















Pharmacokinetic  parameters        
  AUCdoxorubicin  (mg/l*h)                                 1.100.35 1.210.28 1.240.34 0.084 0.062 0.487 0.092 
  AUCdoxorubicinol (mg/l*h)                            1.560.60 2.081.95 2.291.60 0.203 0.009 0.174 0.034 
  AUC ratios doxorubicinol/doxorubicin                           1.540.73 1.681.21 1.901.50 0.975 0.098 0.103 0.185 
Hematologic toxicities  
  % decrease in white blood cell at nadir 7213 7116 6913 0.962 0.282 0.365 0.538 
  % decrease in absolute neutrophil at nadir 8913 919 8811 0.390 0.799 0.350 0.567 
  % decrease in platelet at nadir 3715 3126 3023 0.335 0.130 0.566 0.305 
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  % decrease in hemoglobin at nadir 1313 1211 98 0.567 0.466 0.301 0.540 
  % patients with grade 3+4 nadir neutropenia  85 89 79 0.738 0.735 0.462 - 
  % patients with  febrile neutropenia   13 22 13 0.283 1.00 0.500 - 
Antitumour efficacy        
 Tumour reduction (%) 25.822.2 31.117.8 20.128.0 0.358 0.904 0.326 0.494 
 % of patients with  ≥25% tumour reductions 
after first cycle of doxorubicin treatment 
64 58 46 0.608 0.155 0.342 0.360 
Intra tumoral CBR3 expression1 n=22 n=27 n=17     
 549527 1240868 1221713 0.002 0.001 0.952 0.001 
Notes: 
1Baseline intra-tumoral CBR3 expression levels were available only on 66 patients with sufficient quantity of good quality RNA for gene 
expression microarray analysis. 
2After Bonferroni correction, the value of p0.017 was considered statistically significant for multiple comparisons of the pharmacokinetic 
parameters, the percentage decreases in hematologic toxicities and tumour tissue CBR3 expression. 
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4.6.3 Influence of common CBR1 variants on the PK of doxorubicin 
For CBR1 genetic correlation analysis, we firstly performed an exploratory analysis 
on the three novel CBR1 non-synonymous coding region variants and the novel CBR3 
E124K variant by ranking all the PK parameters, hematologic toxicities and tumour 
reductions for each patient carrying the variant in the entire patient cohort. We did not 
find any of these patients to demonstrate extreme PK parameters or hematologic 
toxicities or the percentage of tumour reduction. The reported functional CBR1 V88I 
variant was not found in Singaporean breast cancer patients. Therefore, we couldn’t 
investigate the influence of the in vitro functional genetic variant on the 
pharmacokinetics and pharmacodynamics of doxorubicin in patients.  
 
We then correlated each common CBR1 genetic variant with PK parameters, 
hematologic toxicities, tumour reductions and intra-tumoral CBR1 expressions. Only 
the group having three strong linkage intronic variants, 397+125G>T, 397+210C>G 
and 834+346G>C, showed correlation with the pharmacokinetics of doxorubicin.  As 
evidenced in Figure 4.6, patients carrying the G allele at 397+125G>T have higher 
doxorubicinol AUC (2.56±1.98, 2.03±1.74, 1.54±0.52 for GG, GT, TT, and p=0.041 
for overall; p=0.014 for GG vs. TT and p=0.008 for the trend test).  
 
The association of the AUC of doxorubicinol was also found with the other two 
linkage intronic genetic variants, CBR1 397+210C>G (p=0.039 for overall; p=0.013 
for CC vs. GG and p=0.014 for the trend test), and CBR1 834+346G>C (p=0.062 for 














Figure 4.6 Influence of CBR1 397+125G>T on the AUC of doxorubicinol.  The 
box indicates the 25th and 75th percentiles, the line within the box is the median, 
error bars are above and below the 90th and 10th percentiles respectively, and the 
symbols illustrate all data points outside the 10th and 90th percentiles. 
 
However, CBR1 397+125G>T was not associated with the intra-tumoral CBR1 
expressions. In addition, there was no correlation between the CBR1 genetic variant 
with hematologic toxicities and the tumour reductions.  
 
4.6.4 Correlation of leukocyte toxicity  
To determine whether CBR genotypes could be a biomarker for doxorubicin-induced 
myelotoxicity, we developed a generalized linear and a stepwise multiple linear 
regression model for percentage of decrease of leukocyte count at nadir using 
covariables consisting of common CBR1 and CBR3 variants which were not in 
linkage disequilibrium, actual dose of doxorubicin, age, body surface area, serum 
albumin, alkaline phosphatase, aspartate transaminase, alanine transaminase, 
bilirubin, total protein at baseline, AUC doxorubicin, AUC doxorubicinol, and 















































significant genetic predictor of percentage of decrease in leukocyte count at nadir. 
Only CBR3 11G>A was contributory to the final multiple linear regression model 
(r=0.244, and p=0.015, n=99). It was noteworthy that the actual BSA-based dosage of 
doxorubicin again did not contribute to the model (r=0.006, p=0.956). 
 
4.6.5 Discussion  
In this study, CBR3 C4Y (11G>A) polymorphism resulting in substitution of tyrosine 
for cysteine at the fourth amino acid occurs at the surface of the CBR3 enzyme at the 
N-terminal end. The 11G>A was associated with the reduced conversion of 
doxorubicin to doxorubicinol, suggesting lower carbonyl reductase activity in patients 
with the A variant allele. As discussed in Section 2.5.2.2, AUC of doxorubicinol and 
metabolic AUC ratios of doxorubicinol to doxorubicin are two important parameters 
to indicate the metabolite rate of doxorubicin in patients. Consistent with the greater 
cytotoxicity of doxorubicin over doxorubicinol, patients with homozygous variant 
(the A variant allele) experienced significantly greater tumour reduction and more 
profound myelosuppression. CBR3 mRNA levels in tumour tissue were higher for 
patients with the wild-type 11GG compared to 11GA or 11AA genotypes, suggesting 
increased transcriptional efficiency with the wild-type allele in addition to potential 
functional effects on the protein. The acute dosage limiting toxicities of doxorubicin 
are leukopenia (white blood cell suppression) and neutropenia (absolute neutrophil 
suppression). Only CBR3 11G>A genotype contributed significantly to the model for 
leukocyte toxicity, whereas measures of body size or actual BSA-based dosage of 
doxorubicin did not. These results further support the potential use of CBR3 11G>A 
genotype for doxorubicin dosage individualisation. 
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The genetic variant of CBR3 C4Y (11G>A) may affect enzyme expression, therefore 
could be associated with the conversion of doxorubicin to doxorubicinol, 
doxorubicin-induced hematologic toxicities and efficacy. These findings in carbonyl 
reductases are not surprising. Previous studies have shown CBR1 expressions were 
associated with the metabolic AUC ratios of doxorubicin in mice and doxorubicinol-
induced cardiotoxicity. The mice with a loss of one CBR1 allele had lower 
doxorubicinol levels in plasma (1.85±0.05μg/ml vs. 3.25±0.60μg/ml for CBR1+/- 
mice vs. CBR1+/+ mice), lower metabolic AUC ratios (0.23 vs. 0.59 for CBR1+/- 
mice vs. CBR1+/+ mice) and experienced less doxorubicinol-induced cardiotoxicity 
than wild-type mice (18% in CBR1+/- mice vs. 91% in CBR1+/+ mice) (Olson, et al., 
2003). The other consistent finding on human CBR1 over-expression in transgenic 
mice hearts has been reported. Over-expression of hCBR1 caused four times higher 
doxorubicinol formation and sixteen times higher conversion rates detected in the 
mice hearts, therefore resulting in acute cardiac damage in more mice (Forrest, et al., 
2000 (a)). Additionally, a previous study showed that over-expression of CBR1 in 
tumour cells would cause higher daunorubicin inactivation and increase of 
chemoresistance (Plebuch, et al., 2007). ). In this study, we observed mRNA CBR3 
expression in breast tumour tissues with large inter-patient variations (range of 
mRNA CBR3 expression levels from 48 to 3473). The levels of mRNA CBR3 
expression in breast tumour tissues are similar to those of the mRNA CBR1 
expression levels in breast tumour tissues (mean±SD values for the levels of mRNA 
expression in breast tumour tissues: 1005±789 for CBR3 expression, and 806±518 for 
CBR1 expression, p=0.185 by Wilcoxon Signed Ranks Test). Recently, doxorubicin 
has been proven to be one of the CBR3 substrates (Blanco, et al., 2008).  The similar 
expression levels between CBR1 and CBR3 in our patient tumour tissues implies that 
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CBR3 expression may be important in the PD outcomes of doxorubicin. As discussed 
in Section 2.5.2.2, doxorubicinol, as the main metabolite, causes cardiotoxicity, but it 
may not cause hematologic toxicity and anticancer efficacy. Unlike doxorubicinol, 
doxorubicin, as the parent-drug, is the key in inducing hematologic toxicity and 
anticancer efficacy in patients. The metabolic ratio of doxorubicinol to doxorubicin in 
plasma was assumed to be an indicator of the doxorubicin-induced hematologic 
toxicities. Thus, the explanation of our results that the genetic variant of CBR3 C4Y 
(11G>A) may affect the enzyme expression, therefore resulting in different metabolic 
rates and different doxorubicin-induced hematologic toxicities and efficacy, sounds 
reasonable. In order to further clarify these issues, in vitro functional studies to 
determine the mechanistic relationship between CBR3 C4Y (11G>A) genetic variants 
and CBR3 mRNA expression levels is necessary. 
 
CBR3 730G>A (V244M) was a previously reported common polymorphism with a 
variant frequency of 0.42 in our population (Lakhman, et al., 2005). It was associated 
with a 1.5-fold increase in doxorubicinol AUC compared to the wild-type variant in 
patients, suggesting higher catalytic activity of CBR3. This finding is consistent with 
in vitro findings where the M isoform resulting from the A allele was reported to have 
2-fold higher Vmaxmenadione and 1.6-fold higher VmaxNADPH, which suggests a faster 
association-dissociation rate for NADPH/NADP per catalytic cycle (Lakhman, et al., 
2005). However, there was no significant difference on metabolic AUC ratios of 
doxorubicin among the three genotype groups of patients. Moreover, there was no 
correlation between the three genotypes and the doxorubicin-induced hematologic 
toxicities, and tumour reductions. This suggests the hematologic toxicities may be 
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associated with the metabolic AUC ratios of doxorubicinol to doxorubicin, not the 
AUC of doxorubicinol alone.  
 
Although we observed weak linkage between CBR3 11G>A and CBR3 730G>A 
(D’=0.5226, r2=0.1435), the correlative data with the PK and PD of doxorubicin were 
stronger with CBR3 11G>A than with CBR3 730G>A, suggesting that the former may 
have effects independent from the latter. The possibility at this is that the weak CBR3 
730G>A associations are a side-effect of the weak linkage with CBR3 11G>A. 
Further functional research to elucidate the roles of these two variants is needed.       
 
Our results suggest that the wild-type intronic genetic variant 397+125G>T seems to 
affect the CBR1 enzyme activity in producing more doxorubicinol, but not to change 
the CBR1 expression in the tumour. Usually, for a non-coding variant, it may break a 
consensus splicing site sequence if it is in the splicing site; it may break motifs 
involved in post-transcriptional regulation if it is at 3’-untranslated region; it may 
change the binding site if it is in the transcription factor-binding site of the gene, 
therefore affecting the gene expression. (Yuan, et al., 2006). The locations of the three 
intronic variants are shown in Figure 4.7. The CBR1 397+125G>T and CBR1 
397+210C>G are located at intron 2, but away from the exon 2 at 125bp and 210bp, 
respectively; whereas CBR1 834+346G>C is in the 3’ near gene region, not in the 3’-
untranslated region (http://www.ncbi.nlm.nih.gov.libproxy1.nus.edu.sg/SNP/). Two 
microRNA databases were used for screening the intronic sequences of CBR1 
(http://www.microrna.org/microrna/home.do; http://mirdb.org/miRDB/index.html). 
Currently, only the intronic variants located at 3’-untranslated region have been 
studied. These three intronic genetic variants are not located at 3’-untranslated region, 
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and also don’t link with the common 3′-UTR genetic variant, CBR1 834+133G>A 
(rs9024). Therefore, no information of the three intronic genetic variants could be 
found from the two microRNA databases. Additionally, no report has shown that the 
group of variants is located at any CBR1 transcription factor-binding site. (Forrest, et 
al., 2000 (b); Hoffmann, et al., 2007). Thus, they are unlikely to affect the CBR1 
splicing site function and the post-transcriptional regulation. This is a possible reason 
why the variants are not associated with CBR1 intra-tumoural expression. The reason 
for the influence of the three genetic variants on the AUC of doxorubicinol is 
unknown. A possible explanation is that the variants may be in linkage disequilibrium 
with other sequence variant, affecting the formation of doxorubicinol. This variant is 
not within the regions that we have screened. Future studies are required to validate 
the current findings, so as to understand the role of the three intronic variants in 




Intron 1 Intron 2 3'-UTR5'-UTR 3’ near gene
 
Figure 4.7 Distribution of CBR1 397+125G>T, CBR1 397+210C>G and CBR1 
834+346G>C in the CBR1 gene. (UTR: untranslated region) 
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4.7 Inter-ethnic variations on the PD of doxorubicin 
4.7.1 Inter-ethnic variations on hematologic toxicities  
The exploratory analysis of inter-ethnic variations among the three ethnic groups, 
Chinese, Malay, and Indian, was conducted with the pharmacokinetics of doxorubicin, 
the hematologic toxicities, the tumour reductions and the CBR1 and CBR3 
expressions.  
 
Although the metabolic AUC ratios of doxorubicin were not significantly, difference 
among the ethnic groups, 1.77±1.36 for Chinese, 1.54±0.46 for Malays and 1.54±0.43 
for Indians (p=0.761), significant differences in doxorubicin-induced hematologic 
toxicities were found among the three ethnic groups. Chinese patients experienced 
greater degree of doxorubicin-induced neutropenia and leukopenia than Malay and 
Indian patients. Grade 3 and 4 neutropenia were more frequent in Chinese compared 
to Malays and Indians (92%, 73% and 57% for Chinese, Malays and Indians, p=0.016 
for Chinese vs. Malays and p=0.027 for Chinese vs. Indians). A decreasing trend of 
hematologic toxicities observed in all three lineages is noted across Chinese, Malay 
and Indian patients. The percentage of decrease in leukocyte count at nadir was 74  
12%, 66  15% and 60  21% for Chinese, Malays and Indians, respectively (overall 
p=0.014 by Kruskal Wallis test and p=0.004 for JT trend test); the percentage of 
decrease in neutrophil count at nadir was 91  11%, 87  10% and 80  14% for 
Chinese, Malays and Indians, respectively (overall p=0.015 by Kruskal Wallis test 
and p=0.004 for JT trend test); and percentage of haemoglobin suppression at nadir: 
14  12%, 8  8%, and 9  5% for Chinese, Malays and Indians, respectively (overall 
p=0.024 by Kruskal Wallis test and p=0.010 for JT trend test, respectively). No 
significant difference among the three ethnic groups was found in doxorubicin-
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The inter-ethnic comparisons were exploratory due to small sample size. As there 
were markedly unequal variances in the sample sizes, and the PK and PD parameters 
in the different ethnic groups were not normally distributed, non-parametric Mann-
Whitney test with Bonferroni correction, where a corrected p-value of less than 0.017 
was considered, was applied for the inter-ethnic comparisons. A larger cohort in 




































































































Figure 4.7 Box plots of inter-ethnic differences in doxorubicin-induced 
hematologic toxicities in Asian breast cancer patients.  
(a) Differences in percentage of decrease in white blood cells at nadir;  
(b) Differences in percentage of decrease in absolute neutrophil at nadir; and  
(c) Differences in percentage of decrease in haemoglobin at nadir.  
The box indicates the 25th and 75th percentiles, the line within the box is the 
median, error bars are above and below the 90th and 10th percentiles respectively, 






4.7.2 Inter-ethnic comparisons of CBR3 genotype  
CBR3 11G>A was associated with doxorubicin-induced hematologic toxicities. And 
CBR3 730G>A has been reported to have a wide variations of the frequencies in ten 
human ethnic groups (Lakhman, et al., 2005). Thus, we determined the inter-ethnic 
differences of CBR3 11G>A and CBR3 730G>A in our patient population, and in the 
general population of cancer-free controls of the three ethnic groups. 
 
Inter-ethnic differences of CBR3 11G>A allele frequency were more obvious than 
CBR3 730G>A allele frequency (Table 4.14). Chinese patients had lower frequency 
of the CBR3 11G allele than Indians (45.5% vs. 85.7%, p=0.004), whereas Malays 
were intermediate (59.1%, p=0.030 for Malay patients vs. Indian patients). This is 
consistent with the pattern of hematologic toxicities observed in the three ethnic 
groups, with higher hematologic toxicities in Chinese patients. The frequencies of the 
CBR3 C4Y (11G>A) variants were consistent with those in a larger cancer-free 
population including 75 Chinese, 46 Malays and 47 Indians (for each ethnic group, p 
value >0.05 for patients vs. cancer-free population). Concordantly, in the larger 
cancer-free population for inter-ethnic comparisons of genotype frequencies, Chinese 
and Malays had lower frequencies of the CBR3 11G allele compared to Indians (G 
allele frequency 0.400, 0.500 and 0.681 respectively for Chinese, Malays and Indians, 
p<0.001 for Chinese vs. Indians, and p=0.012 for Malays vs. Indians).  
 
Furthermore, compared to the data reported for Caucasian and African American 
population, Chinese have a lower allelic frequency of CBR3 11G (G allele frequency 
0.426 vs. 0.639 and 0.727 respectively, p=0.010 for Chinese vs. Caucasians, and 
p<0.001 for Chinese vs. African-Americans),  while the allelic frequencies were 
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similar between the Indians and the two Western populations 
(http://www.ncbi.nlm.nih.gov/SNP/).  
 
On the other hand, the frequency distribution of other common CBR3 730G>A alleles 
was similar among the three ethnic groups of patients (all pair-wise p values>0.017). 
The frequencies of the CBR3 V244M (730G>A) variant in patients were consistent 
with those in a larger cancer-free population. There was also no significant difference 
in frequencies of the CBR3 730G allele among the three Asian races in the larger 
cancer-free population (all pair-wise p values>0.017). The only significant difference 
of the frequencies of CBR3 730G>A was between Indians and Caucasians (p=0.021). 
The variations of the A allele frequencies in our three cancer-free population, and in 
the reported Caucasians and African-Americans were rather small (the range from 
0.325 to 0.543). 
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Table 4.14 Summary of CBR3 C4Y (11G>A) and CBR3 730G>A (V244M) allele frequencies and the differences in different Asian ethnic 
breast cancer patients and in different cancer-free ethnic populations  
 
Populations N Allele frequencies Ethnic differences2 
  CBR3 C4Y (11G>A)  
  G A Cp vs. Mp Cp vs. Ip Mp vs. Ip 
Asian breast cancer patients       
  Chinese (Cp) 66 0.455 0.545 0.305 0.004 0.030 
  Malays (Mp) 26 0.538 0.462    
  Indians (Ip) 7 0.857 0.143    
Cancer-free subjects     Cs vs. Ms Cs vs. Is Ms vs. Is 
  Chinese (Cs)  75 0.400 0.600 0.128 0.001 0.012 
  Malays (Ms) 46 0.500 0.500    
  Indians (Is) 47 0.681 0.319    
    Cp vs. Cs Mp vs. Ms Ip vs. Is 
    0.355 0.657 0.223 
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    Cau vs. Cs Cau vs. Ms Cau vs. Is 
  Caucasians (Cau)1 18 0.639 0.361 0.010 0.156 0.649 
    AA vs. Cs AA vs. Ms AA vs. Is 
  African Americans (AA) 1 22 0.727 0.273 0.001 0.012 0.581 
  CBR3 V244M (730G>A)    
  G A Cp vs. Mp Cp vs. Ip Mp vs. Ip 
Asian breast cancer patients       
  Chinese (Cp) 66 0.583 0.417 0.261 0.105 0.032 
  Malays (Mp) 26 0.673 0.327    
  Indians (Ip) 7 0.357 0.643    
Cancer-free subjects     Cs vs. Ms Cs vs. Is Ms vs. Is 
  Chinese (Cs)  75 0.593 0.407 0.813 0.038 0.039 
  Malays (Ms) 46 0.609 0.391    
  Indians (Is) 47 0.457 0.543    
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    Cp vs. Cs Mp vs. Ms Ip vs. Is 
   0.865 0.442 0.481 
    Cau vs. Cs Cau vs. Ms Cau vs. Is 
  Caucasians (Cau) 1 20 0.675 0.325 0.347 0.469 0.021 
    AA vs. Cs AA vs. Ms AA vs. Is 
  African Americans (AA) 1 23 0.609 0.391 0.853 1.000 0.093 
 
Notes:  
1 Frequencies of CBR3 C4Y (11G>A) and frequencies of CBR3 V244M (730G>A) for Caucasians and African Americans were obtained from 
the NCBI SNP database (rs8133052; http://www.ncbi.nlm.nih.gov/SNP/, and rs1056892; http://www.ncbi.nlm.nih.gov/SNP/ , respectively).  
2After Bonferroni correction, the value of p0.017 was considered statistically significant for pair-wise comparisons of the allele frequencies 




4.7.3 Genotype-phenotype correlation after stratifying for ethnicity  
 As there were significant inter-ethnic differences in CBR3 11G>A genotype 
distribution in our population, we stratified by ethnicity and performed genotype-
phenotype correlation analyses for the four PK and PD parameters that were 
significant in overall comparisons, and trend test for the entire cohort (Table 4.15).   
 
In the largest Chinese subgroup (n=64), the correlations of the genotype with AUC 
doxorubicinol, metabolic AUC ratios, CBR3 expression and tumour reduction 
remained significant. The Chinese patients with GG variant had higher AUC 
doxorubicinol and metabolic AUC ratios of doxorubicinol to doxorubicin (AUC 
doxorubicinol: 2.48±1.86, 2.20±2.33, and 1.61±0.65 for GG, GA and AA, 
respectively; GG vs. AA, p=0.034, and JT trend test p=0.037; and the metabolic AUC 
ratios of doxorubicinol to doxorubicin: 2.16±1.77, 1.82±1.48, 1.43±0.71 for GG, GA 
and AA, respectively; GG vs. AA, p=0.037 and JT trend test p=0.023). The Chinese 
patients with GG variant also exhibited higher intra-tumoural CBR3 expression 
(1472±749, 977±979, and 685±490 for GG, GA and AA, respectively; GG vs. AA, 
p=0.002, overall test, p=0.019, and JT trend test, p=0.014). Chinese patients with GG 
variant showed lower anti-tumour efficacy (41%, 54% and 87% for GG, GA and AA, 
respectively; GG vs. AA, p=0.007, overall test, p=0.002). The correlations of the 
genotype with hematologic toxicities were not statistically significant in Chinese 
patients, although Chinese patients with the AA variants seemed to experience greater 
leukocyte and platelet suppression (leukocyte suppression:  73%, 73%, and 76%, for 
GG, GA and AA, respectively; platelet suppression: 32%, 33%, and 40%, for GG, GA 
and AA, respectively). Overall, the same pattern on the correlations of the genotype 
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with the doxorubicin phenotype was observed between the larger subgroup Chinese 
patients and the main cohort.  
 
In the smaller Malay subgroup (n=26), correlation was found only between CBR3 
11G>A and AUC doxorubicinol (p=0.049 for JT trend test). Although there was no 
significant difference in hematologic toxicities in Malay patients, we noticed that 
Malay patients with GG variant had the lowest mean values of leukocyte and platelet 
suppression (leukocyte suppression: 61%, and platelet suppression: 28%) compared 
with the patients with GA and AA (leukocyte suppression: 67% and 72% respectively; 
platelet suppression: 30% and 30% respectively).  
 
In the Indian subgroup, six out of seven Indian patients had CBR3 11GG and one 
patient 11AA. Although none of the other significant correlations was found in Malay 
and Indian patient subgroup because of the small sample size, the overall trend in 
genotype-phenotype correlation was consistent with the main cohort.  
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Wide inter-ethnic variations were found in doxorubicin dose limiting toxicities, 
neutropenia and leukopenia. In this study, Chinese patients experienced greater degree 
of doxorubicin-induced hematologic toxicities than Indian patients. We analyzed the 
frequency of the CBR3 C4Y (11G>A) allele in the three ethnic groups. And we found 
that the Chinese had lower frequency of the CBR3 11G allele than the Indians. As 
discussed in Section of 4.6.2.1, the CBR3 11G allele was associated with lower 
doxorubicin-induced hematologic toxicities. This finding in Chinese patients with 
lower frequency of the CBR3 11G is consistent with the pattern of hematologic 
toxicities observed in the ethnic groups, with higher hematologic toxicities in Chinese 
patients.  
 
Furthermore, compared to the data reported for Caucasian and African American 
population, Chinese have a lower allelic frequency of CBR3 11G.  Previous studies 
found Chinese breast cancer patients experienced more profound hematologic toxicity 
compared to Caucasians patients with standard adjuvant combination of doxorubicin 
(60mg/m2) and cyclophosphamide (600 mg/m2) regimen (Beith, et al., 2002;  Ma, et 
al., 2002). Since the CBR3 11G allele was associated with lower hematologic toxicity, 
we assumed that this genetic variant may account for higher hematologic toxicities 
experienced in Chinese patients. This was an exploratory assumption from our study. 
Future clinical study is needed to confirm this assumption.   
 
On the other hand, conmpared to obvious difference of the CBR3 11G>A allele 
frequencies among Chinese, Malay, Indian, Caucasian and Africa Americans, the 
CBR3 730G>A allele frequencies was not apparent. Up to 10-fold variation of the A 
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allele frequencies of CBR3 730G>A has been reported among Chinese, Indo-Pakistani, 
Japanese, Mexican, Middle Eastern, South American Andes, Southeast Asian 
(excluding Japanese and Chinese), Pacific, North African of the Sahara, and South 
African of the Sahara (Lakhman, et al., 2005). However, the variations of the CBR3 
730A allele frequencies in our three population, and the reported Caucasians and 
African-Americans were rather small. In vitro, this genetic variant has been found to 
be associated with the distinctive catalytic efficacy of CBR3 (Lakhman, et al., 2005). 
In our in vivo study, it was also related to the formation of doxorubicinol, but not to 
the doxorubicin-induced hematologic toxicities. Compared to the obvious inter-ethnic 
differences of CBR3 11G>A allele frequencies, the inter-ethnic differences CBR3 
730G>A allele frequencies were weak, suggesting that the CBR3 11G>A may be 
more important to contribute the observed inter-ethnic variations in the PD of 
doxorubicin.  
 
CBR3 11G>A allele distributions differ among Chinese, Malays and Indians (Table 
4.14). We stratified by ethnicity and then performed association analyzes in different 
ethnicities. Although most significant correlations weren’t found in Malay and Indian 
patient subgroup because of the small sample size, the same pattern on the 
correlations of the genotype with the doxorubicin phenotype was observed between 
the larger subgroup Chinese patients and the main cohort. This result suggests that the 
observed genotype-phenotype correlations were consistent because of the internal 
















Doxorubicin is an anthracycline anticancer drug with a wide spectrum of cytotoxic 
activities in solid malignancies and lymphomas. It has been in clinical use for the past 
40 years. Despite this, limited data exists to guide dosing based on pharmacokinetic-
pharmacodynamic relationships, particularly in Singaporean patients. Significant 
interethnic variability of doxorubicin toxicities suggests possible pharmacogenetic 
influences on its pharmacological effects. This is the first clinical association on the 
association of genetic variants in the genes encoding the enzymes on phase I 
metabolic pathway of doxorubicin with the PK and PD of doxorubicin. This 
dissertation covered the following research topics: (1) assessment of the PK of 
doxorubicin, doxorubicin-induced toxicities and efficacy in Singaporean breast cancer 
population; (2) establishment of the relationships of the PK of doxorubicin with the 
toxicities and efficacy; (3) exploration of the influence of genetic variants in carbonyl 
reductases on the PK and PD of doxorubicin in southeast breast cancer patients.  
 
The study was conducted in a clinical trial at the National University Hospital in 
Singapore. In the study, the total ninety-nine female breast cancer patients received 
the first cycle of doxorubicin, where half of them in treatment Arm B received one 
cycle of docetaxel treatment before the first cycle of doxorubicin treatment. All 
patients received doxorubicin as a single agent, and excluded use of other medicines 
with possible pharmacological interaction including traditional herbs, and routine use 
of colony stimulating factors which would influence interpretation of 
myelosuppressive effects of doxorubicin. The percentage decreases at nadir 
hematologic toxicities and the percentage of tumour reduction were used in the 
correlation study to minimize the effect from the first cycle of docetaxel treatment in 
Arm B patients. The hematologic baseline counts for Arm B patients were collected 
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after the first cycle of docetaxel treatment and just before the first cycle of 
doxorubicin treatment. These make our finding more reliable.   
 
Firstly, the pharmacokinetics of doxorubicin and its major metabolite, doxorubicinol, 
in the breast cancer patients was investigated. An accurate and reliable HPLC method 
for bio-analytical quantitation of doxorubicin and doxorubicinol in plasma was setup 
and validated. The results from two-compartmental modelling showed that the main 
pharmacokinetic parameters, doxorubicin clearance and half-time, from our patients 
were consistent with that in previous reports from Caucasian patients. Wide inter-
patient variations in plasma AUC of doxorubicinol and metabolic AUC ratios were 
observed. However, these variations were not correlated with patient’s BSA and 
BSA-based dosage.  
 
The reduction of doxorubicin to doxorubicinol is the main and rapid reaction in 
humans. Compared to doxorubicin induced hematologic toxicities and anticancer 
toxicities, doxorubicinol exhibits less cytotoxicity. Thus, the reduction of doxorubicin 
to doxorubicinol is a process of detoxification for blood cells and tumours. As the 
presence of doxorubicinol in patient’s plasma is high, the plasma levels of 
doxorubicinol relative to doxorubicin, which directly indicate the catalytic conversion 
of doxorubicin to doxorubicinol in patients, are expected to better correlate with 
cytotoxic effect than the plasma levels of doxorubicin. 
 
Among the doxorubicin-induced toxicities, the two common severe hematologic 
toxicities observed in our patients were neutropenia and leukopenia. Our patients 
seemed to experience greater degree of grade 3 and 4 leukopenia than the previously 
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reported Caucasian patients who were administrated with the same dose of 
doxorubicin. Leukocyte suppression was not correlated with BSA, BSA-based dosage 
and AUC of doxorubicin. However, it was negatively associated with the 
concentration ratios in plasma at 1 hr (r= -0.236, p=0.019) and at 2 hr (r=-0.214, 
p=0.033) after doxorubicin administration. These results support our presumption that 
the concentration ratios of doxorubicinol to doxorubicin, rather than the plasma levels 
of doxorubicin, could be better correlated with hematologic toxicities.  
 
 On the other hand, after the first cycle of doxorubicin treatment, the percentage of 
tumour reduction achieved in our patients was 28.5%. And 58% of patient’s tumours 
were intrinsically sensitive to doxorubicin. Large inter-patient variations of the 
percentage of tumour reduction were found to be related to the PK parameter of K21, 
the rate constant of peripheral tissue compartment to central blood compartment (r=-
0.261, p=0.010). High uptake and accumulation of doxorubicin in patient’s breast 
tumour tissues could be a possible reason to explain the relationship between the 
doxorubicin-induced tumour reduction and K21.   
 
Carbonyl reductases (CBR1 and CBR3), as phase I metabolic enzymes, are thought to 
play a significant role in the reduction of doxorubicin to doxorubicinol in most normal 
and tumour tissues. In this study, we prospectively sequenced CBR1 and CBR3 coding 
regions and spliced site junctions in patients receiving single agent doxorubicin, and 
correlated CBR1 and CBR3 genetic variants with doxorubicin pharmacokinetics, 
hematologic toxicities and antitumor efficacy in Singaporean breast cancer patients. 
Through comprehensive sequencing, two common non-synonymous coding region 
variants in CBR3, 11G>A and 730G>A, were identified. The 11G>A polymorphism, 
  157
which results in substitution of tyrosine for cysteine at the fourth amino acid at the 
amino terminal, was associated with reduced conversion of doxorubicin to 
doxorubicinol. This means that patients with the G allele would have a higher 
carbonyl reductase activity. Consistently, patients with the G allele experienced 
significantly less myelosuppression and lower tumour reduction. CBR3 mRNA levels 
in tumour tissue were higher for patients with the 11GG compared to those with 11GA 
or 11AA genotypes. The results of increased transcriptional efficacy with the wild-
type allele could be a reason to cause higher metabolic rates, and lower doxorubicin-
induced hematologic toxicities and efficacy in our patients. CBR3 730G>A (V244M), 
a previously reported functional polymorphism, was associated with 1.5-fold increase 
in doxorubicinol AUC compared to wild-type, confirming its higher catalytic activity 
in patients. This finding is consistent with in vitro findings that the M isoform was 
reported to have 2-fold higher Vmaxmenadione and 1.6-fold higher VmaxNADPH. This 
variant was also associated with higher CBR3 mRNA levels in tumour tissues, which 
means that the enhanced transcriptional efficacy may be another contributor to the 
higher catalytic activity. However, this variant was not associated with the 
hematologic toxicities and efficacy.    
 
Several rare but novel CBR1 coding region polymorphisms were found in our 
population, but they did not exert significant influence on the PK and PD of 
doxorubicin. The functional variant of CBR1 V88I, which was associated with lower 
Vmax in vitro and occurred at low frequencies only in African Americans, was not 
detected in our Southeast breast cancer patients. Among all detected genetic variants 
in CBR1, CBR1 397+125G>T, which involves in the group of three linking intronic 
variants, was the only variant to have correlation with doxorubicinol AUC. Patients 
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carrying the wide-type GG have higher doxorubicinol AUC. However, this variant 
failed to be correlated with the PD of doxorubicin and intra-tumoral CBR1 
expressions. Currently, knowledge in the influence of intronic variant is limited.  
Further validation is therefore necessary.  
 
To determine if CBR genotypes could be a biomarker for doxorubicin hematologic 
toxicity, we developed a generalized linear and a stepwise multiple linear regression 
model for percentage change of leukocyte count at nadir using covariables consisting 
of common CBR1 and CBR3 variants, and patient baseline characteristics. The results 
revealed that CBR3 11G>A was the only significant genetic predictor of percentage 
change in leukocyte count at nadir. 
 
In our previous clinical research, we had observed that Chinese breast cancer patients, 
compared to Caucasians, would experience more profound neutropenia from the 
standard adjuvant doxorubicin/cyclophosphamide regimen. In this study, we finally 
sought to describe the frequency distribution of the influential genetic variants in the 3 
main ethnic groups, Chinese, Malay and Indian. Ethnic difference in doxorubicin-
induced myelosuppression was found, with higher hematologic toxicities observed in 
Chinese than in Malays and Indians. When comparing the frequencies of common 
CBR3 variants in the three ethnic groups, we found that Chinese had significantly 
lower frequency of the CBR3 11G allele than Indians. Comparing our ethnic 
frequencies of CBR3 11G>A with reported data from Caucasians and African 
Americans, Chinese also had lower frequency of the wild-type G allele, while Indians 
had similar allelic frequencies to the two Western populations. The CBR3 11G allele 
was associated with higher conversion efficiency of doxorubicin to doxorubicinol, 
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and lower hematologic toxicity. The CBR3 11G>A genotype may therefore account 
for the greater doxorubicin-induced myelosuppression observed in Chinese. 
Furthermore, in the subgroup of Chinese patients, the correlations of this genotype-
phenotype were found to be similar to the main cohort. This result suggests that the 
observed genotype-phenotype correlations were consistent because of the internal 
















Doxorubicin is a cytotoxic anticancer drug with a wide spectrum of cytotoxic 
activities in solid tumours. Due to its high anticancer efficacy for breast cancer, it has 
been clinically used for the treatment of breast cancer patients for more than thirty 
years and is likely to remain a standard therapy for breast cancer for the next few 
decades. Therefore, it would be important to make progressive steps towards 
explaining the interindividual variability of doxorubicin pharmacodynamics to 
optimise its clinical utility. The findings in this thesis showed both the concentration 
ratios of doxorubicinol to doxorubicin in plasma  at 1 hr after administration of 
doxorubicin, and  the patients’ genetic variant of CBR3 11G>A are potential 
predictors for white blood cell toxicity. And the pharmacokinetic parameters of K21 
and this genotype were associated with breast tumour reduction. However, it is 
unknown whether the other genetic variants in the doxorubicin related genes would be 
associated with the doxorubicin pharmacodynamic outcomes. As discussed in 
Sections 2.3.1 and 2.5.2.1, doxorubicin’s mechanisms of action and the metabolic 
pathway are complicated and many other genes are involved in. Future 
pharmacogenetic studies would focus on the doxorubicin target genes (e.g. 
Topoisomerase 2A, and tumour protein p53), transporter genes (e.g. proteasome 26S 
subunit, ATPase 1), metabolizing enzymes (e.g. phase II enzymes: glutathione S-
transferase 1, glutathione S-transferase, Mu-1 and UDP-glycosyltransferase 1A1), and 
regulators of these related genes including regulators of CBR1 (Sturgill, et al., 2000; 
Minotti, et al., 2004; Choi, et al., 2006; Tan, et al., 2008). Assessing the impact of the 
genetic variants in these genes on doxorubicin-induced hematologic toxicities and 
efficacy will be useful to predict the hematologic toxicity and/or the efficacy. 
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The processes of cancer pharmacogenetics studies for identification of genetic 
markers predictive of patient’s response to or toxicity from chemotherapy have been 
elucidated in Figure 6.1 (Lee, et al., 2005). The effect of candidate genetic marker 
needs to be validated by other clinical trials and further confirmed by in vitro assay. In 
this study, we identified a candidate genetic marker, CBR3 11G>A.  Assessing the 
impact of this genetic variant of CBR3 11G>A on the PK and PD of doxorubicin will 
be conducted through processes of marker validation and in vitro functional assay. 
The marker validation will be carried out using a similar clinical methodology, but 
involving a larger sample size for the main cohort and equal patient numbers among 
the three ethnic groups, Chinese, Malay and Indian. Hopefully, this investigation will 
not only validate the influence of genetic variant on the PK and PD of doxorubicin, 
but also verify the interethnic differences in hematologic toxicities.  
 
The functional effects of these clinically relevant variants of CBR will need to be 
elucidated in vitro using E coli (DE3) BL21-competent cells, a traditional expression 
system without ubiquitin-mediated degradation pathway, which has been used in 
CBR3 730G>A functional characterization (Lakhman, et al., 2005). This future in 
vitro study will characterize the function of the genetic variant on the mRNA 
expression levels, and the functional properties of the resulting CBR3 C4 and CBR3 
Y4 enzyme isoforms. The kinetic analyses of the two enzyme isoforms with the 
CBR3 substrates, doxorubicin and other anticancer drugs (e.g.: daunorubicin and 
epirubicin), will be carried out. Additionally, the influence of the genetic variants on 
CBR3 gene expression in breast tumor will be further investigated in vitro using 




Figure 6.1 Processes of cancer pharmacogenetic studies for identification of 
genetic/molecular markers predictive of patient response to chemotherapy. 




In this thesis, we focused on the short-term toxicities and efficacy of doxorubicin. 
These short-term hematologic toxicities and efficacy are mainly due to the parent-
drug of doxorubicin. The long term efficacy of overall tumour response and survival 
time using the alternating treatment of doxorubicin and docetaxel were not considered. 
The cumulative dose-dependent cardiotoxicity, congestive heart failure, was not 
observed after the first cycle of doxorubicin treatment. It is known that cumulative 
dose-dependent cardiotoxicity normally occurs in patients treated with a total dosage 
of doxorubicin of above 480mg/m2 in 4 to 18 weeks after the last cycle of treatment. 
But, the total dosage of doxorubicin for our breast cancer patients in this study was 
not more than 225mg/m2. This is the reason why the lethal cardiotoxicity wasn’t a 
focus in this study. Early studies suggested that doxorubicin’s metabolite, 
doxorubicinol, might play a role in cardiotoxicity as it had been detected in patient’s 
heart tissues. Transgenic mice with heart-specific expression of human carbonyl 
reductase 1 showed that doxorubicin was rapidly converted to doxorubicinol in the 
mouse hearts, therefore advancing the development of doxorubicin-induced 
cardiotoxicity. Our results have shown the three genetic variants, CBR3 11G>A, 
CBR3 730G>A and CBR1 397+125G>T, are related to the doxorubicinol AUC in 
patient’s plasma. In the future clinical study with larger sample size, cardiotoxicity 
shall be considered and associated with the three genetic variants.   
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1.1. Molecular biology and cancer treatment 
Advances in the field of genomic and proteomic research has brought a new frontier to the 
understanding of molecular events relating to cancer susceptibility, cancer development,
angiogenesis and metastasis, and treatment response. The imminent completion of the Human
Genome Project will make available a blueprint to scientists for gene discovery.1 The next 
step of advancement would be to characterize the functions, forms, and regulation of these 
genes with respect to disease states and therapy. The integration of genomics with proteomics 
would elucidate crucial biological pathways.2 In the field of oncology, such studies could
uncover important molecular targets in the development and maintenance of the malignant
state, as well as elucidate mechanisms of resistance to drug and radiation therapy.3 Such
molecular knowledge can be applied clinically to refine cancer treatment. As an example, the 
genetic profiles of the tumor and the patient may be used to select the most appropriate type 
and dose of chemotherapeutic agent to achieve the best tumor efficacy while minimizing
toxicity to normal tissues. 
1.2. Tumor genetic profile as a predictor of treatment response 
Conventional chemotherapy to treat cancer lacks sophistication in its inability to accurately
predict treatment efficacy and drug toxicity for the individual patient. For decades,
morphologic features have been used to predict treatment response and prognosis. As an
example, different cancer types respond differently to chemotherapy: adriamycin is active in
breast,4 but not in colorectal cancer; all-trans retinoic acid has remarkable activity in the 
promyelocytic form of acute leukaemia, but not in other subtypes.5 More recently, the use of 
molecular markers to predict treatment response and prognosis in specific tumor types has 
been incorporated into clinical practice. In breast cancer, the presence of estrogen or
progesterone receptors is the most powerful predictor of tamoxifen response,6 while c-erb-B2
over-expressing tumors demonstrate relative resistance to conventional non-anthracycline 
containing chemotherapy, and may be more appropriately treated with dose-intense 
anthracycline-containing regimens.7 In non-small cell lung cancer, the presence of -tubulin
mutations results in tumor resistance to anti-tubulin agents such as paclitaxel.8 In gliomas,
high expression of O6-methyl guanine-DNA methyltransferase (MGMT) results in poorer
survival following carmustine treatment, while silencing of the gene by methylation leads to
better overall survival.9 Thus, treatment may potentially be modified based on the molecular
profile of the tumor to achieve more consistent and predictable responses. An excellent 
example of the application of molecular knowledge in cancer therapeutics is the recent
success of glivec, a specific inhibitor of the BCR-ABL tyrosine kinase in the treatment of 
chronic myeloid leukaemia.10, 11 
Up to recently, isolated molecular markers have been used to predict tumor response. Such a 
strategy is fraught with difficulty, since tumor response is often a function of complex
interactions of multiple genes and pathways. The simultaneous analysis of thousands of genes 
has now been made possible by micoarray technology.12 Such technology has the ability to 
identify important genes in relation to particular functions, and has the further potential to 
elucidate interactive relationships between genes.13 The ability to study mRNA arrays using 
fine needle samples has further facilitated these studies as samples can be taken safely and 
repeatedly.14, 15 
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More recently, protein expression profiles in tumors have been studied using ProteinChip
technologies with surface enhanced laser desorption / ionization – mass spectrometry 
(SELDI-MS).16, 17 These studies are complementary to gene expression studies, and together 
could yield valuable data providing insight into important genes and pathways in
tumorigensis and drug resistance. 
1.3. Patient genetic profile as a predictor of drug toxicity 
The ‘optimal’ doses of conventional chemotherapy have largely been determined from
maximally tolerable doses (MTD) derived from the study of a limited cohort of patients based
on toxicity. Unfortunately, there is significant inter-individual variability in pharmacokinetics 
resulting in a wide range of side effects including fatal toxicities, despite corrections for 
weight, height, renal and hepatic function.18-20 Even the commonly used body surface area to
individualize chemotherapy dosing has recently been reported to correlate poorly with drug
clearance.21 Inter-individual differences in drug efficacy and toxicity are in part related to
genetic polymorphisms in drug metabolizing enzymes (DMEs), transporters and receptors.22 
The study of these genetic polymorphisms in relation to drug pharmacokinetics (PK) and 
pharmacodynamics (PD) can potentially lead to more rational therapeutics that reduces risks
of severe toxicity. Several examples currently exist where subjects carrying certain alleles
suffer from a lack of efficacy or increased toxicity to drugs commonly used in different fields 
of medicine. The CYP2C9*2 and CYP2C9*3 allele have been associated with retarded
elimination of S-warfarin, lower maintenance doses and more frequent bleeding episodes.23 
Homozygotes for the C677T polymorphism in the 5,10-methylenetetrahydrofolate reductase 
(MTHFR) gene had lower MTHFR activity and experienced increased methotrexate 
toxicity,24 while genetic polymorphisms of thiopurine methyl transferase were reported to be
an important determinant of mercaptopurine toxicity.25 Individuals homozygous for the 
C3435T polymorphism of the multidrug resistance (MDR)-1 gene have significantly lower 
duodenal MDR-1 expression and experienced higher plasma digoxin levels compared to
normal homozygotes.26 A single base-pair substitution in the dihydropyrimidine 
dehydrogenase (DPD) gene resulted in complete deficiency of the DPD enzyme and
potentially lethal toxicity to 5-fluorouracil.27 The clinical application of such knowledge has 
the potential to reduce treatment related toxicity, while maintaining efficacy. 
Gene expression changes in the peripheral blood mononuclear cells could be a good surrogate 
marker to predict toxicity following chemotherapy as it is a readily accessible source of
material. The gene sets or profiles obtained could be diagnostic for certain forms of toxicity.
This principle of generating transcriptional fingerprints in relation to chemical perturbations
or chemotherapy has been demonstrated in vitro28, 29, in acute myeloid leukemia30 and in 
acute lymphocytic leukemia31, 32 among others. The feasibility of obtaining gene expression 
patterns from mononuclear cells in the peripheral blood has been demonstrated in normal
healthy volunteers33 as well as in patients undergoing chemotherapy.34 
1.4. Singapore as a major contributor to Asian genetics research  
Genetic polymorphisms demonstrate ethno-geographic differences.35 For example, the N-
acetyl-transferase-2 gene is polymorphic, with Orientals being generally “fast acetylators” 
and Caucasians “slow acetylators”.36 Similar ethnic differences in genetic polymorphisms 
37, 40, 41 UGT1A1,have also been observed for Cyp2C19,37-39 Cyp2D6, 42, 43 and the MDR-1
gene.44 While extensive genotypic data has been generated for Western patients, similar
information has been lacking in Asians. Much of the current existing information have been
based on Asian subjects in the West.43, 45, 46 These data often suffer from small sample size, 
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and may not represent information derived from a homogeneous group, since subjects from
different Asian ethnic groups are lumped together to form a heterogeneous group and called
the ‘Asian’ data.47-49 There are significant phenotypic differences between these ethnic
groups even within Asia,50 which may in turn reflect differences in genotypic make-up.38, 41 
Thus, it is important that a more homogeneous dataset is generated from within Asia. 
Singapore is ideal for such studies and could be a major contributor to Asian 
pharmacogenetics data. The presence of three major resident ethnic groups in our population,
namely Chinese, Malay and Indian, offers the added opportunity to study and compare drug
handling phenotype (PK and PD) and genotype between distinct ethnic groups in an attempt 
to address possible racial differences in drug handling and tumor response.  
1.5. Breast cancer as a model to study cancer gene expression
We plan to study the genetic profiles of tumor and patient in relation to chemotherapy with 
the ultimate goal of using the information to refine cancer treatment for each individual. We
have selected breast cancer as the model, and will specifically study stage II to IV breast
cancer patients with measurable primary breast tumor and who are receiving chemotherapy as
first-line treatment. This is an ideal model as breast cancer is common in Singapore, is
chemosensitive, and primary breast tumor is easily amenable to repeated sampling for genetic
studies. Pre-operative chemotherapy in early stage and locally advanced breast cancer is
established treatment that results in similar survival outcome as conventional post-operative
treatment, with the added advantages of improved drug delivery through better blood supply,
tumor down-sizing to facilitate breast conservation, and the opportunity to assess tumor 
chemosensitivity.51 While combination chemotherapy comprising of two or three agents is
conventionally given in such a setting because of superior response rate, it has no proven 
survival benefit over single agents administered sequentially. In this study, we adopt the 
strategy of using two of the most active agents in breast cancer, adriamycin and docetaxel,
administered as single agents in a sequential fashion. Such a strategy allows tumor gene 
expression profiles and drug pharmacokinetics to be studied without the confounding effects 
of another drug. Sequential single agents also have the potential advantages of allowing 
higher doses of each drug to be administered, resulting in maximal cell kill and avoiding
antagonistic interactions between drugs. We have designed a phase II study where patients 
could be randomized to one of two different sequences of adriamycin and docetaxel. This 
provides the opportunity to study differences in tumor response and gene expression changes 
in relation to different sequences of drugs. Pharmacokinetics and genotyping studies will be
carried out and correlated with treatment response and toxicity. Specific genes to be studied
include CYP3A5 and MDR1 that affect docetaxel clearance, and glutathione-S-transferase
(GST) that affects adriamycin metabolism.
This study would make available collaborative data that allows for multi-dimensional 
analysis to identify (1) “cluster gene patterns” that may predict good clinical response to
chemotherapy, and (2) differential gene expressions in response to different cytotoxic agents 
from which genes of drug resistance may be sieved out. Crucial genes that affect tumor
response and resistance may be further investigated comprehensively with such phenotype-
genotype linkage based on microarrays. Our study will comprehensively study the 
relationship of genotype of multiple DMEs on more than one drug in the same patient. To our
knowledge, this has not been done previously. The results of this study will be an important 
step forward in fulfilling the promise of individualized dosing based on genetic information. 
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2. Aims of Research Proposal 
2.1. Hypothesis 
We hypothesize that changes in tumor gene expression profiles vary in response to different 
sequences and types of chemotherapy, and that gene expression changes will correlate with 
tumor response. We are also looking to correlate drug pharmacokinetics and treatment 
toxicity with genotype of drug metabolizing enzymes and tranporters. 
2.2. Primary Objective 
1. Evaluate the impact of adriamycin and docetaxel on tumor gene expression profiles. 
2. Correlate overall tumor response with tumor gene expression profiles. 
2.3. Secondary objectives 
To correlate adriamycin and docetaxel pharmacokinetics with:
1. Genetic polymorphisms of MDR-1, Cyp3A and GSTs. 
2. Drug toxicity and tumor response. 
3. Peripheral mononuclear cell gene expression profiles 
3. Investigational Plan 
3. 1 Summary of study design
This is a single-centre, open-label, randomized phase II study of two different schedules of
sequential adriamycin and docetaxel in breast cancer. 
A total of one hundred patients with measurable disease will be enrolled and randomly
assigned to each of two study arms: 
Arm A: AT AT AT 
Arm B: TAT AT A 
where ‘A’ represents adriamycin 75mg/m2 q 3 weeks and ‘T’ represents docetaxel 75mg/m2 
q3 weeks 
Tumor core biopsy will be performed before treatment, following the first cycle of 
adriamycin, following the first cycle of docetaxel, and at study withdrawal or study
completion for a total of four tumor cores for gene expression studies. The final biopsy may
be obtained at surgery if the patient is scheduled for lumpectomy or mastectomy. The tumor
cores will be stored in liquid nitrogen for subsequent RNA extraction and gene expression 
studies. 
Blood sampling will be carried out for pharmacokinetic studies for adriamycin and docetaxel 
during the first cycle of each chemotherapeutic agent.  
10ml blood will be taken from each participant prior to the start of treatment for genotyping
studies. 
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3.2 Study schema 
Stage II-IV breast cancer patients with measurable primary breast tumor 
Stratification by stage (metastatic vs non-metastatic) 
Randomization to Arm A or Arm B 
 Arm A  Arm B
 AT AT AT TAT AT A 
A: Adriamycin 75mg/m2 q 3 weeks 
T: Docetaxel 75mg/m2 q 3 weeks 
Core biopsy of breast tumor before treatment, after cycle 1 of adriamycin, after cycle 
1 of docetaxel, and at study withdrawal or study completion for a total of 4 core 
biopsies
Pharmacokinetics studies during cycle 1 of each chemotherapy drug 
Blood for patient genotype
 Data analysis 
1. Comparison of acute genetic and protein expression changes in tumor in response to
the two different schedules of chemotherapy (ie Arm A versus Arm B).  
2. Correlation between clinical response (good clinical response, stable disease and 
progressive disease) and tumor gene and protein expression changes. 
3. Correlation between drug pharmacokinetics and treatment toxicity/tumor response. 
4. Correlation between patient genotype and drug pharmacokinetics. 
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3.3 Investigator Information 
The names, titles, and institutions of the investigators are listed in the Contacts for Protocol.
If investigators are added after the ethical review board and/or the local regulatory agency
have approved the study, these additions will not be considered changes to the protocol, but 
the Contacts for Protocol will be updated to provide this information. 
3.4. Study Population
3.4.1. Criteria for enrollment
3.4.1.1. Inclusion criteria
Patients may be included in the study only if they meet all of the following criteria:
 Female, age  18 years. 
 Histologic or cytologic diagnosis of breast carcinoma. 
 Stage II to IV breast cancer with measurable primary breast tumor, defined as
palpable tumor with both diameters 2.0cm or greater as measured by caliper. 
 Patients must not have received prior chemotherapy or hormonal therapy for the 
treatment of breast cancer. 
 Karnofsky performance status of 70 or higher. 
 Estimated life expectancy of at least 12 weeks. 
 Adequate organ function including the following: 
- Bone marrow: 
 White blood cells (WBC)  3.5 x 109/L 
 Absolute neutrophil (segmented and bands) count (ANC)  1.5 x 109/L 
 Platelets  100 x 109/L
 Haemoglobin  9g/dL
- Hepatic: 
 Bilirubin  1.5 x upper limit of normal (ULN), 
 ALT or AST  2.5x ULN, (or >5 X with liver metastases) 
 Alkaline phosphatase  2.5x ULN.
- Renal: 
 creatinine  1.5x ULN 
- Cardiac: 
 Adequate cardiac function 
 Signed informed consent from patient or legal representative.  
 Patients with reproductive potential must use an approved contraceptive method if 
appropriate (eg, intrauterine device, birth control pills, or barrier device) during and 
for three months after the study. Females with childbearing potential must have a 
negative serum pregnancy test within 7 days prior to study enrollment. 
3.4.1.2. Exclusion criteria 
Patients will be excluded from the study for any of the following reasons:
 Prior treatment for locally advanced or metastatic breast cancer. 
 Treatment within the last 30 days with any investigational drug. 
 Concurrent administration of any other tumor therapy, including cytotoxic
chemotherapy, hormonal therapy, and immunotherapy. 
 Active infection that in the opinion of the investigator would compromise the
patient’s ability to tolerate therapy.
 Pregnancy.
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 Breast feeding. 
 Serious concomitant disorders that would compromise the safety of the patient or 
compromise the patient’s ability to complete the study, at the discretion of the 
investigator. 
 Poorly controlled diabetes mellitus. 
 Second primary malignancy that is clinically detectable at the time of consideration
for study enrollment. 
 Symptomatic brain metastasis. 
 History of significant neurological or mental disorder, including seizures or dementia.
 Peripheral neuropathy of  CTC grade 2. 
 History of hypersensitivity to drugs formulated in Tween 80, the vehicle used for 
commercial docetaxel formulations. 
3.4.2. Patient Assignment 
Eligible patients will be stratified by stage (metastatic or non-metastatic) at a 3:7 ratio.
Accordingly, we will recruit a total of 70 non-metastatic and 30 metastatic patients, to be
randomized in equal proportion to either Arm A or Arm B. 
Patients will be entered into the trial by a telephone call to the Cancer Therapeutics Research
Group (CTRG), Singapore (+65 6772-4628) between 0830 to 1730 hours from Monday to 
Friday, and between 0830 to 1230 hours on Saturday (Singapore time), or by Fax (+65 6872-
3137) at any time, stating that the patient is to be entered into the trial. Confirmation fax will 
be sent to the investigator. 
Written informed consent for entry into the study will be obtained prior to randomisation. All 
eligibility criteria and consent form will be checked before treatment is allocated.  
3.5. Dosage and Administration
3.5.1. Material and Supplies 
Adriamycin and docetaxel will be obtained locally from the manufacturer. Storage conditions
for unopened vials, reconstitution, and storage conditions for the reconstituted solution will 
follow the manufacturer’s recommendations. Docetaxel solutions should be prepared and
stored in glass, polypropylene or polyolefin containers. Non-PVC containing and
polyethylene-lined administration sets should be used.   
3.5.2. Dosage Administration
A cycle is defined as an interval of 21 days. A delay of cycle due to holidays, weekends or 
bad weather will be permitted and not counted as a protocol violation.  
The actual doses of adriamycin and docetaxel administered to subjects will be determined by
calculating the body surface area at the beginning of the cycle. A  5% variance in the
calculated total dose will be allowed for ease of dose administration. 
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3.5.3. Treatment plan 
Arm A: AT AT AT 
Arm B: TAT AT A 




Patients receiving docetaxel should receive routine pre-medications with oral dexamethasone 
8mg twice daily for 3 days, starting 1 day prior to each docetaxel administration. Anti-
emetics are prescribed according to the investigator’s preference. 
Adriamycin
Anti-emetics are prescribed according to the investigator’s preference. 
3.6. Dose modifications 
3.6.1. Dose adjustments or delays for subsequent cycles 
Any patient who requires a dose reduction based on nadir haematological toxicity or non-
haematological toxicity will continue to receive a reduced dose for the remainder of the 
study. Any patient with a prior dose reduction who experiences a toxicity that would cause a 
third dose reduction must be discontinued from the study therapy. Treatment may be delayed
for up to 42 days from day 1 of the current cycle to allow a patient sufficient time to recover
from study drug-related toxicity. A patient who cannot start the next cycle for 42 days from
day 1 of the current cycle must be discontinued from study therapy unless the Principal 
Investigator approves continuation. 
3.6.2. Haematologic Toxicity 
Dose adjustments at the start of a subsequent course of therapy will be based on nadir platelet 
and neutrophil counts from the preceding cycle of therapy. ANC must be  1.5x 109/L prior
to the start of a new cycle. Treatment may be delayed for up to 42 days from day 1 of the 
current cycle to allow proper time for recovery. Upon recovery, if treatment is resumed, the 
dose of study drugs must be adjusted according to the guidelines in Table 1. 
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Table 1: Dose adjustments for adriamycin and docetaxel based on nadir hematology 
values for preceding cycles
Platelets (x109/L) ANC (x109/L) Percent of day 1 dose in
previous cycle 
 25  1.0 100%
 25 0.5 – 0.99 if not associated
with documented infection or 
fever 
100%
 25 <0.5 lasting for <7 days and 
not associated with 
documented infection or 
fever 
100%
25 0.5 – 0.99 if associated with 
documented infection or 
fever 
80% 
 25 <0.5 lasting for 7 days or 
associated with documented 
infection or fever 
80% 





If dose adjustment is required for non-hematological toxicity, the patient will continue to
receive the reduced dose for the remainder of the study, unless otherwise specified. 
3.6.3.1. Liver toxicity
If at the start of the next treatment cycle serum bilirubin is elevated to 1.5x ULN, or 
AST/ALT are elevated to 2.5x ULN in patients without liver metastasis, or >5.0x ULN in
patients with liver metastasis, respectively, the cycle should not begin until serum
bilirubin/ALT/AST have returned to below these levels. If the laboratory values do not return
to these limits within 42 days from day 1 of the current cycle, the patient should be
discontinued from study therapy. In the event of CTC grade 3 or 4 liver toxicity
(ALT/AST/serum bilirubin), subsequent administration of the particular chemotherapy drug
should be discontinued. Administration of the alternative chemotherapy drug is allowed
provided that levels have recovered to eligibility levels. 
3.6.3.2. Peripheral neuropathy 
In the event of CTC grade 2 peripheral neuropathy, subsequent doses of docetaxel should be
reduced by 20% in all administrations and cycles. In the event of CTC grade 3 or 4 peripheral 
neuropathy, study treatment should be discontinued.
3.6.3.3. Myalgia, Arthralgia, Asthenia, Fatigue 
In the event of CTC grade 2 mylagia, arthalgia, asthenia or fatigue lasting for more than 7
days, subsequent doses of docetaxel should be reduced by 20% in all administrations and
cycles. In the event of CTC grade 3 or 4 myalgia, arthralgia, asthenia or fatigue, study
treatment should be discontinued. 
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3.6.3.4. Hypersensitivity reaction 
If in spite of administration of proper pre-medication, a hypersensitivity reaction occurs, the 
specific treatment that is medically indicated for given symptoms should be instituted 
immediately. Continuation or discontinuation of study treatment will be at the discretion of
the investigator, and will depend on the severity of the hypersensitivity reaction, tumor
response, and the medical judgment by the investigator if it is in the best interest of the 
patient to continue or to discontinue study treatment. If study treatment will continue, the 
subsequent doses of docetaxel should not be reduced. 
Table 2: Management of hypersensitivity reactions for patients receiving docetaxel 
Mild symptoms (CTC grade 1): 
Localized cutaneous reaction such as
mild, transient pruritus, flushing or rash,
drug fever <38C 
Consider decreasing the rate of infusion until 
recovery of symptoms; stay at bedside. Upon 
resolution of symptoms, complete infusion of 
docetaxel at the initial planned rate.  
Moderate symptoms (CTC grade 2): 
Urticaria, drug fever 38C,
asymptomatic bronchospasm
Stop docetaxel infusion, give IV dexamethasone 
10mg and/or IV diphenhydramine 50mg. Resume
taxane infusion after recovery of symptoms
Severe symptoms (CTC grade 3): Stop docetaxel infusion, give IV dexamethasone 
Bronchospasm, generalized urticaria, 10mg and/or diphenhydramine 50mg and/or
drop in systolic blood pressure to epinephrine, as appropriate. 
80mmHg, angioedema DISCONTINUE DOCETAXEL THERAPY. 
Anaphylactic reaction (CTC grade 4) Stop docetaxel infusion, give IV dexamethasone 
+/- diphenhydramine 50mg +/- epinephrine +/- 
general measures for treatment of patients with
anaphylactic shock, as appropriate. 
DISCONTINUE DOCETAXEL THERAPY 
3.6.3.5. Cardiac toxicity
Adriamycin should be discontinued if LVEF drops by 20% from baseline or drops to 30%. 
3.7. Concomitant therapy 
Patients are allowed to receive full supportive therapies concomitantly during the study. No
other anti-tumor therapy (chemotherapy, immunotherapy, hormonal cancer therapy, surgery
for cancer, radiotherapy for cancer) or experimental medications will be permitted while the 
patients are receiving study therapy. Any disease progression requiring other forms of 
specific anti-tumor therapy will be cause for early discontinuation of study therapy.
3.7.1. Colony stimulating factors 
Routine use of colony stimulating factors is not permitted in this study. Patients should not 
receive prophylactic granulocyte colony stimulating factor (G-CSF) in any cycle. G-CSFs for
subsequent cycles should only be considered for patients who have ANC <0.5 x 109/L,
neutropenic fever, or documented infections while neutropenic. G-CSF must be discontinued
at least 24 hours prior to the start of the next cycle of chemotherapy. 
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3.8. Efficacy Evaluations 
3.8.1. Baseline Assessments 
Clinical Assessments: Within 2 weeks prior to enrollment, physical examination will be 
performed for measurement of palpable tumor lesions by caliper or ruler.
Radiological Assessments: Within 4 weeks prior to enrollment, baseline radiological
imaging studies for tumor assessment as appropriate will be performed on each patient. A
baseline plain chest X-ray is mandatory. All other imaging studies will be at the discretion of 
the investigator. 
3.8.2. Timing of subsequent tumor assessments
The same clinical evaluation and radiological imaging methods used at baseline must be used
consistently for subsequent tumor assessments. 
Clinical Assessment: To be repeated every 3 weeks prior to the start of every treatment
cycle.  
Radiological Assessment: To be repeated approximately every 6 weeks as appropriate, prior
to the start of every other treatment cycle.  
If the patient’s disease has responded to therapy (either using clinical or radiological 
assessment), the response should be confirmed after at least 3 weeks from the first 
documentation of response.  
3.8.3. Efficacy criteria for tumor response 
3.8.3.1. Disease status and measurability 
Measurable disease: Bi-dimensionally measurable lesions with clearly defined margins and 
two perpendicular diameters that are clearly measurable by any of the following: 
 Palpation, with both diameters 2.0cm or greater as measured by caliper.
 Inspection, with both diameters 2.0cm or greater as measured by caliper.
 Chest X-ray, with at least one diameter 1.0cm or greater. 
 Computerized tomography (CT), with both diameters greater than 1.0cm.
Evaluable disease: Uni-dimensionally measurable lesions with one clearly measurable 
diameter by any of the following:
 Chest X-ray, with one measurable diameter of 2.0cm or greater. 
 Computerized tomography (CT) with one measurable diameter of 2.0cm or greater. 
Non-evaluable disease: Ascites, pleural effusion, bone metastases, diffuse or confluent skin
metastases without clear margins, disease documented by indirect evidence only (eg, by
laboratory values). 
All documented lesions are to be followed. If an organ has multiple measurable lesions, 
choose three to be followed before the patient is entered on study. The remaining measurable
lesions in that organ will be documented and considered evaluable for the purpose of
objective status determination.  
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3.8.3.2. Objective Response Status
Objective response will be recorded at each evaluation.
Complete response (CR): Complete disappearance of all measurable and evaluable disease.
No new lesions. No disease-related symptoms. No evidence of non-evaluable disease,
including normalization of abnormal laboratory values secondary to metastatic breast cancer.  
Minimal residual disease (MRD)52, 53: Residual palpable irregularity at the site of the 
primary tumor that is too small to be measured, representing an almost CR to treatment
Partial response (PR): Defined as 50% reduction relative to baseline in the sum of 
products of perpendicular diameters of all measurable lesions. No progression of evaluable 
disease. No new lesions.
Stable disease (SD): Does not qualify for CR, PR, or progressive disease.  
Progressive disease (PD):
 25% increase in the sum of products of bi-dimensionally measurable lesions OR
 obvious worsening of any evaluable disease OR 
 reappearance of any lesion which had disappeared OR 
 appearance of any new lesion/site OR
 failure to return for evaluation due to death or deteriorating condition (unless clearly
unrelated to the cancer).  
Worsening of existing non-evaluable disease does not constitute progression.  
In patients with pre-existing bone metastases, the appearance of any new bone lesion as 
documented by bone scan or skeletal X-ray constitutes progression. 
Exception: Lesions that appear to increase in size due to the presence of necrotic tissues will
not be considered to have progressed. 
Unknown: Progression has not been documented and one or more measurable or evaluable 
sites have not been assessed. 
Best response: Two objective status determinations of CR, PR or SD before disease 
progression are required for a best response of CR, PR or SD respectively. Patients with an
objective status of PD on or before the second on-study treatment evaluation will have a best 
response of PD. Best response is unknown if the patient does not qualify for a best response 
of PD and if all objectives statuses after the first determination and before progression are 
unknown. For CR and PR, responses must be confirmed by a second assessment 3 to 4 weeks 
(minimum 21 days) after the first documentation of response, using the same method of 
measurement as at baseline.
Good clinical response53: Defined as CR, MRD or PR. This has been shown to be a valid
surrogate marker for survival.53 
3.8.3.3. Definition of Efficacy Measures 
A tumor responder is defined as any patient exhibiting a best study response of CR, MRD or 
PR (based on palpation and/or imaging). 
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Among tumor responders, the duration of tumor response is measured from the date of
randomization until the first date of documented disease progression or death due to any
cause, whichever occurs first. Duration of tumor response will be censored at the date of the 
last follow-up visit for tumor responders who are still alive and who have not progressed. 
Time to treatment failure is defined as the time from the date of randomization to the date
of the first of the following events: early discontinuation of study therapy, progressive
disease, or death due to any cause. Time to treatment failure will be censored at the date of
the last follow-up visit for patients who did not discontinue early, who are still alive, and who 
have not progressed. 
Time to documented disease progression is defined as the time from the date of 
randomization to the first date of documented disease progression. Time to documented
disease progression will be censored at the date of death for patients who have not had 
documented disease progression. For patients who are still alive at the time of analysis and 
who have not had documented disease progression, time to documented disease progression
will be censored at the date of the last follow-up visit.
3.9. Safety 
Investigators are responsible for monitoring the safety of subjects who have entered this 
study and for alerting the Principal Investigator of any event that seems unusual, even if this
event may be considered an unanticipated benefit to the subject. 
The investigator is responsible for appropriate medical care of subjects during the study.
The investigator remains responsible for following, through an appropriate health care option, 
adverse events that are serious or that caused the subject to discontinue before completing the 
study. The subject should be followed until the event resolves or is explained. Frequency of 
follow-up is left to the discretion of the investigator. 
3.9.1. Safety Measures 
Safety measures that will be used in the study include physical examinations and clinical
laboratory tests (haematology and blood chemistries). Patients will be rated for toxicity prior 
to each cycle using the NCI CTC scale.
3.9.2. Clinical Adverse Events 
A clinical trial adverse event is any untoward medical occurrence in a subject administered a
pharmaceutical product, without regard to the possibility of a causal relationship. Cases of
pregnancy should be reported for tracking purposes. Lack of drug effect is not an adverse
event.
Adverse events will be collected after the subject has been enrolled. If a subject experiences
an adverse event after the informed consent document is signed (entry) but the subject is
never assigned to treatment (enrollment), the event will NOT be reported unless the 
investigator feels that the event may have been caused by a protocol procedure. 
Prior to enrollment, the investigator will note the occurrence and nature of each subject’s 
medical condition(s). During the study, site personnel will again note any change in the 
condition(s) and the occurrence and nature of any adverse events. 
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Subjects should be closely followed for adverse events while receiving study therapy and for 
30 days after last dose of study therapy in order to detect delayed toxicity. After this period,
investigators should only report serious adverse events that are felt to be causally related to
study drug therapy or to a protocol procedure.
Events leading to the clinical outcome of death will be included as part of the safety and 
efficacy analyses for this study, and will not be recorded as adverse events unless the
investigator believes the event may have been caused by the study therapy.
3.9.3. Serious Adverse Events (SAE) 
3.9.3.1. Definition of SAE 
Any of the following would constitute a serious adverse event.  
 Death 
 Prolonged inpatient hospitalization 
 A life-threatening experience (that is, immediate risk of dying) 
 Severe or permanent disability
 Congenital anomaly
Neutropenic fever is commonly associated with docetaxel and adriamycin treatment and its 
incidence has been well characterized, therefore reporting of this event as an SAE is not 
necessary, unless it results in prolonged hospitalization or death. Neutropenic fever will 
nonetheless be reported as adverse events. 
3.9.3.2. Reporting of SAE 
The investigator must record all serious adverse events, regardless of treatment or
relationship to study drug, as soon as he/she is informed of the event. Investigators must 
report immediately to the Principal Investigator any serious adverse events. 
3.9.3.3. Follow-up of SAE 
Any serious and or unexpected adverse event should be medically well documented and the 
information made available as soon as possible. 
3.10. Discontinuations 
The criteria for enrollment must be followed explicitly. If a subject who does not meet 
enrollment criteria is inadvertently enrolled, that subject should be discontinued from the 
study and the Principal Investigator contacted.
In addition, patients will be discontinued from the study therapy in the following
circumstances: 
 Evidence of progressive disease. 
 Patient experiences unacceptable toxicity. 
 The investigator decides that the patient should be withdrawn. If this decision is 
because of a serious adverse event or a clinically significant laboratory value, the 
study drug is to be discontinued and appropriate measures taken. 
 The patient requests discontinuation.
 The patient, for any reason, requires another type of tumor treatment. In this case, 
discontinuation from the study occurs immediately upon introduction of the new 
treatment. 
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 The patient becomes pregnant or fails to use adequate birth control (for those patients
who are able to conceive). 
 The patient is non-compliant with study procedures. 
 The investigator, for any reason, stops the study or stops the patient’s participation in
the study. 
Patients who discontinue study therapy early will have post-study follow-up procedures 
performed as described in the protocol. 
All patients who have received at least one dose of study drug will be evaluable for safety
analysis. All patients who are registered into the study but fail to receive the first dose of
study drug and those who are lost to follow up before disease evaluation will be replaced. 
The primary reason for withdrawal will be clearly documented in the subject’s medical 
record and recorded in the CRF. A final evaluation will be completed at the time of
discontinuation from the study.
3.11. Clinical laboratory tests and procedures 
3.11.1. Pre-study 
Prior to study enrollment each patient will have the following assessments:
No more than 4 weeks before study enrollment:
Plain chest X-ray will be performed for baseline tumor assessment. Other imaging (ie CT 
scans, bone scan or skeletal X-rays) should be performed if clinically indicated, at the 
discretion of the investigator.  
No more than 2 weeks before study enrollment
Medical history and physical examination, including measurements of height, weight,
calculation of body surface area, blood pressure, and pulse rate. 
 Evaluation of performance status (Karnofsky scale)
 Concomitant medication notation 
 Tumor measurement of palpable lesions
 Tumor measurement of skin metastases
Within 7 days before study enrollment:
Haematology
Blood chemistries: bilirubin, ALT, AST, alkaline phosphatase (ALP), creatinine, calcium and
electrolytes (sodium, potassium) 
A serum pregnancy test for females with childbearing potential. 
3.11.2. During the study 
3.11.2.1. Efficacy assessment 
Prior to each cycle of treatment
Performance status evaluation 
Limited medical history and physical examination 
Clinical tumor measurement
Radiological assessment to be repeated every 6 weeks where appropriate.
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The following tests and procedures will be performed at specific intervals during the study to 
monitor study drug safety: 
 Limited physical examination to include blood pressure, heart rate, weight, height, 
and calculation of body surface area at each cycle.
 Concomitant medication notation and number of units required for transfusions at 
every cycle.
 Haematology within 4 days prior to the start of each cycle (except cycle 1 where the 7
days limit before study enrollment applies), and between days 10 to 16 of each cycle.
In addition, hematology on day 8 during the first cycle of each chemotherapy drug (ie 
adriamycin or docetaxel) will be performed as part of pharmacodynamic endpoints. 
 Blood chemistries (bilirubin, ALT, AST, creatinine, electrolytes) prior to the start of
each cycle.  
 Toxicity rating using the NCI CTC scale prior to each cycle.
3.11.3. Laboratory Tests and Results 
The local laboratory in National University Hospital will perform all laboratory tests.
Investigators must document their review of each laboratory report by signing or initialing
and dating each report. 
The investigator must evaluate laboratory values that fall outside the clinically accepted 
reference range or that differ significantly from previous values. Any such significant 
laboratory changes must be documented and commented on in the CRF. 
3.11.4. Post-Study follow-up 
3.11.4.1. Efficacy 
To obtain meaningful data on time-to-event variables, assessments of disease status will be
made at regular intervals after patients discontinue from study therapy. Assessments will 
continue until documented disease progression, death or 12 months after randomization,
whichever occurs first.  
During the post-study follow-up period, information will be collected regarding date of 
disease progression or death. The study will be closed when, in the opinion of the principal
investigator, sufficient data have been obtained for completion of the final study manuscript. 
3.11.4.2. Safety 
After a patient discontinues study therapy, the investigator should make every effort to 
continue to evaluate the patient for delayed toxicity by clinical and laboratory evaluations as
clinically indicated. Every attempt should be made to obtain haematology and chemistry
approximately 30 days after the last dose of study treatment. The patient must be followed
approximately every 30 days until toxicity resolves.
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4. Sample Size and Data Analysis Methods 
4.1. Sample Size
We expect 70% of all potentially eligible patients to have non-metastatic locally advanced
disease, and 30% to have metastatic disease. Among the patients with non-metastatic disease,
we expect approximately 20-25% to have complete clinical response following four cycles of
treatment. Therefore, core biopsy to obtain further tumor materials for gene expression
studies will no longer be possible. Accordingly, we estimate that we will be able to obtain
tumor tissues at all three planned time points in approximately 80-85% of the entire cohort. 
With this in mind, the target number of patients to be recruited has been set at 100, to ensure
that we will have approximately 40 patients in each treatment arm who are fully analyzable in 
the gene expression studies.
4.2. Data to be analyzed
Clinical Data 
Efficacy data that will be analyzed will include: 
1. Rates of good clinical response (complete clinical response, minimal residual disease, 
and partial clinical responses), including confidence intervals.
2. Rates of complete pathological responses. 
3. Time to progression 
The overall response of the entire patient cohort (Arms A and B combined) will be reported,
as we expect the clinical and pathological response rate to the two different treatment 
schedules to be comparable.  
The major analysis to be made include:
1. Comparison of acute gene and protein expression changes in tumor in response to the 
two different schedules of chemotherapy (ie Arm A versus Arm B).  
2. Correlation between clinical response (good clinical response, stable disease and 
progressive disease) and tumor gene expression and protein expression changes.  
3. Correlation between drug pharmacokinetics and treatment toxicity/tumor response. 
4. Correlation between patient genotype and drug pharmacokinetics. 
No interim analysis is planned. 
5. Clinical Pharmacy 
Pharmaceutical Information
Docetaxel will be sponsored in part by Aventis. Adriamycin and part of the docetaxel will be
purchased from the local manufacturer. 
The Cancer Centre pharmacist will be responsible for adequate storage of the study
medication according to the manufacturer’s recommendations and for dispensing the
treatment to the patients. 
The study medication must be used in accordance with the protocol and only by the 
investigator. 
The investigator and/or pharmacist must maintain adequate and accurate records, showing the 
receipt and distribution of all supplies of the study medication. 
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These records include: 
 All accompanying letters that list the batch number of the medication, the quantities 
received, and the date of reception. 
 The drug accountability form that includes the patient’s identification, the date of
dispensation, each quantity dispensed, and the identity of the dispenser.  
6. Special Tests 
6.1. Pharmacokinetics studies
Pharmacokinetic sampling will be carried out during the first cycle of administration of each
chemotherapy drug (ie adriamycin and docetaxel). A maximum of 8 blood samples for each 
drug will be taken.
Procedure for collection and processing of blood samples
Blood samples may be collected by venepuncture or via an indwelling peripheral venous line,
followed by rapid transfer into heparinised silicon treated glass tubes. The first 1ml blood
withdrawn from an indwelling venous line is discarded. Blood sampling that is carried out 
during chemotherapy infusion must be collected from the contralateral arm of the 
chemotherapy infusion. If a central venous line is present, blood sampling is allowed from it,
provided that this route is not being used for chemotherapy infusion. Care must be taken to
collect blood slowly without causing hemolysis. 
Blood collection tubes will be pre-labeled for the different time-points. If a sample cannot be
collected at the planned time, it will be taken as close as possible to the scheduled time and
the exact clock time will be reported in the pharmacokinetics form for computer fitting of the 
curve. 
Assay methods 
Docetaxel concentrations will be analyzed using a validated method developed in our HPLC
laboratory, using liquid-liquid extraction and reversed phase HPLC. Adriamycin
concentrations will be analyzed using fluorescence detection by HPLC methods that have
been previously established. 
Storage of samples and PK assays
Samples will be stored at -80C for subsequent bioanalysis. PK assays will be performed in 
the Department of Pharmacology, National University of Singapore. Individual parameter
estimates will be determined by standard compartmental and non-compartmental methods 
based on WINNONLIN software. 
6.2. Genotyping studies 
10ml blood will be collected from each subject prior to the start of treatment for genotyping. 
The blood will be collected into EDTA tubes and stored at 4C for no longer than 1 week
before DNA extraction is carried out. DNA is extracted using the Gentra DNA extraction kit 
(Gentra Systems, Inc., Minneapolis, USA) and stored at -20C for subsequent genotyping.
Known functional SNPs of Cyp3A, MDR-1 and GSTs will be characterized. More
comprehensive genotyping will be carried out in ‘outliers’ who have extreme 
pharmacokinetic parameters, experience exceptional toxicity or tumor response to identify
novel functional SNPs using high throughput sequencing techniques. 
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6.3. Gene expression and protein expression studies and cluster analysis
Core biopsy (Philip Iau) is carried out before chemotherapy, at the end of the first cycle of
each chemotherapy drug (adriamycin and docetaxel), and after completion of six cycles of 
chemotherapy (at lumpectomy or mastectomy, or with core biopsy if surgery is not 
performed), for a total of four tumor specimens for each patient. In the event that the patient
experienced complete remission with no palpable tumour, image-guided biopsy using either
mammography or ultra-sonography will be performed as appropriate. Tissues will be snap-
frozen for subsequent gene expression studies. Messenger RNA will be extracted from the 
tissues using standard methods, and subject to expression array analysis in the Genome
Institute of Singapore (Edison Liu) using a 15,000-gene oligonucleotide array. For clustering
analysis, we will utilise the system developed by Eisen et al that employs standard statistical
algorithms to arrange genes according to similarity in pattern of gene expression.54 Log
converted expression data from the cDNAs measured will be subjected to one-dimensional 
hierachical clustering to compute a dendrogram that assembles all elements into a single tree 
based on pair-wise calculation of the Pearson correlation coefficient of normalised 
fluorescence ratios as measures of similarity and average linkage clustering. Results of the
clustering will be displayed by TREEVIEW (software available at http://genome-
www4.stanford.edu/Microarray/SMD/restech.html). We expect to be able to develop a 
“training set” using the first 10 patients to establish a pattern of gene expression that can
predict response, and validate this using the next 10 patients. 
Proteins from tumor cores will be extracted from the elluent that is obtained during the RNA
extraction process. The proteins will be fractionated and profiled using the ProteinChip Array
SELDI MS. Changes in protein profiles in response to chemotherapy will be compared 
between the good and poor responders and correlated with gene expression changes.
6.4 Gene expression studies of peripheral mononuclear cells 
2.5 ml of peripheral blood from samples obtained during the pharmacokinetic sampling will 
be used for this part of the study. The blood will be collected into PAXgeneTM tubes
(PreAnalytiX), at 2 time points namely, before and 24 hours after exposure to adriamycin and 
docetaxel respectively (ie, first and second cycle of chemotherapy). RNA isolation would be 
done according to the manufacturer’s instructions (PAXgeneTM Blood RNA kit). The RNA
would then be quantified spectrophotometrically and aliqouted for storage at –800C. The 
expected RNA yield is 4-20g from each sample. A total of 2-5g of total RNA would then
be used to synthesize double-stranded cDNA using T7 dT primers and SuperScript II reverse 
transcriptase and polymerases (Affymetrix User Manual). cRNA would be synthesized and
biotinylated through an in vitro transcription assay and after cleanup (Qiagen) would be 
quantified spectrophotometrically and a minimum of 15g used for subsequent experiments.
cRNA would then be fragmented for hybridization on the Affymetrix HG-U133A 
oligonucleotide arrays according to an overnight protocol (Affymetrix User Manual). After 
washing, arrays would be stained with streptavidin-phycoerythrin (Molecular Porbes) and
scanned on a Hewlett Packard scanner. Intensity values would be scaled such that overall 
intensity for each chip of the same type is equivalent. Intensity for each feature of the array
will be captured using the default settings of Affymetrix Microarray Suite software version 5 
(MAS 5.0, Affymetrix, Santa Clara, CA) and a single raw expression level for each gene
derived from the 20 probe pairs representing each gene will be accomplished by using a 
trimmed mean algorithm. Raw signals will be log-transformed and probe sets filtered out as 
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deemed absent or no change by MAS 5.0. Standard analytical software will be used to 
perform the statistical analysis. Unsupervised (hierarchical clustering, principal component
analysis) or supervised learning methods (support vector machines, k-nearest neighbor, 
artificial neural network) would be used to select the most discriminating gene probe sets and
ranked according to their discriminating powers.  
7. Study monitoring and data collection
7.1. Data collection 
Case Record Forms (CRFs) 
All data obtained in the study described in this protocol will be recorded on CRFs. The CRF
for each subject will be presented in a folder. The CRF will be completed chronologically and 
updated regularly in order to reflect the most recent data on the patient included in the study.  
Prior to the start of the study, the Investigator will complete a “People authorized to
document CRFs” form, showing the signatures and initials of all those who are authorized to
make or change entries on the CRFs. 
Each CRF must be neatly filled in with a black-inked pen. For each page on which
information is entered, the subject number must be recorded. The registration form, the
treatment form and the follow-up status form must be dated and signed by an authorized
investigator. 
Errors must be corrected by drawing a single line through the incorrect entry and by writing
the new value as close as possible to the original. The correction must then be initialed and
dated by an authorized person. 
Although a research nurse may interview subjects, the investigator must verify that all data 
entries are accurate and correct, including verification that the subject fulfils the criteria for
entrance into the study before study medication is dispensed. Physical examinations have to 
be performed by a registered medical practitioner. 
The End of Treatment Form must be completed for each patient upon completion or 
withdrawal from the study.
The investigator will add to the subject trial file, after completion of the study, any relevant
post-trial information brought to his attention.
7.2. Data Management
Data entry
A data manager will enter data into an electronic database in a password protected, user-
designated computer in the office of the CTRG. 
Maintenance of patients records 
CTRG clinical report forms (CRF) will be used to record data for this study. A copy of the 
CRF will be kept in the CTRG Office. All records will be kept for a period of 6 years 
following the date of study closure according to Singapore GCP guidelines. 
7.3. Statistical Analysis
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To determine correlation between the pharmacokinetics and SNPs of DMEs/drug
transporters, two sets of models will be constructed: one to determine the effect of variant 
alleles on drug PK, and another to build PK-PD relationships. Gene expression and protein
expression data will be included in mathematical models with other covariates to generate 
hypotheses about the contributions of SNPs of DMEs and transporters to the inter-individual 
pharmacodynamic variability of anticancer drugs. 
8. Informed Consent, Ethical Review, and Regulatory Considerations 
8.1. Informed Consent 
The informed consent document will be used to explain the risks and benefits of study 
participation to the patient in layman terms before the patient is entered into the study.
The investigator is responsible to see that informed consent is obtained from each patient or
legal representative and to obtain the appropriate signatures and dates on the informed
consent document prior to the performance of any protocol procedures and prior to the 
administration of study drug.  
As used in this protocol, the term “informed consent” includes all consent and/or assent given
by patients and their legal representatives. 
8.2. Patient information 
The responsible physician will inform the patient about the background and current 
knowledge of the treatment under study with special reference to known activity and toxicity. 
The patient will be told about the investigative nature of this treatment and in particular, the 
randomization process involved in this study. The patient will be told of his or her right to
withdraw from the study at any time without any penalty with regards to the continuation of 
care at this institution and by the same physicians as he chooses. The patient will be told that
tissue and blood samples obtained for genetic studies will be assigned unique patient numbers
(UPN) to ensure patient confidentiality.
8.3. Ethical Review
Approval of the protocol and the informed consent document will be obtained from the 
institution’s ethical review board before the study may begin.
The investigator will supply the following to the study site’s ethical review board(s):
 The study protocol
 The current Clinical Investigator’s Brochure or package labeling and updates during 
the course of the study
 Informed consent document
 Relevant curricula vitae 
8.4. Regulatory Considerations 
This study will be conducted in accordance with the ethical principles stated in the most
recent version of the Singapore guidelines on good clinical practice (GCP).   
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10 Appendix 
10.1 AJCC Staging Criteria 
Breast cancer staging information
The American Joint Committee on Cancer (AJCC) staging system provides a strategy for grouping patients with
respect to prognosis. Therapeutic decisions are formulated in part according to staging categories but primarily
according to tumor size, lymph node status, estrogen- and progesterone-receptor levels in the tumor tissue,
menopausal status, and the general health of the patient.
The AJCC has designated staging by TNM classification.
TNM definitions
Primary tumor (T):
TX: Primary tumor cannot be assessed 
T0: No evidence of primary tumor
Tis: Carcinoma in situ; intraductal carcinoma, lobular carcinoma in situ, or Paget’s disease of the 
nipple with no associated tumor 
Note: Paget's disease associated with a tumor is classified according to the size of the tumor 
T1: Tumor 2.0 cm or less in greatest dimension  
T1mic: Microinvasion 0.1 cm or less in greatest dimension 
T1a: Tumor more than 0.1 but not more than 0.5 cm in greatest dimension
T1b: Tumor more than 0.5 cm but not more than 1.0 cm in greatest dimension 
T1c: Tumor more than 1.0 cm but not more than 2.0 cm in greatest dimension 
T2: Tumor more than 2.0 cm but not more than 5.0 cm in greatest dimension  
T3: Tumor more than 5.0 cm in greatest dimension 
T4: Tumor of any size with direct extension to (a) chest wall or (b) skin, only as described below
Note: Chest wall includes ribs, intercostal muscles, and serratus anterior muscle but not pectoral
muscle
T4a: Extension to chest wall
T4b: Edema (including peau d'orange) or ulceration of the skin of the breast or satellite skin
nodules confined to the same breast 
T4c: Both of the above (T4a and T4b) 
T4d: Inflammatory carcinoma*
* Note: Inflammatory carcinoma is a clinicopathologic entity characterized by diffuse brawny
induration of the skin of the breast with an erysipeloid edge, usually without an underlying palpable 
mass. Radiologically there may be a detectable mass and characteristic thickening of the skin over the
breast. This clinical presentation is due to tumor embolization of dermal lymphatics with engorgement
of superficial capillaries. 
Regional lymph nodes (N):  
NX: Regional lymph nodes cannot be assessed (e.g., previously removed) 
N0: No regional lymph node metastasis  
N1: Metastasis to movable ipsilateral axillary lymph node(s)
N2: Metastasis to ipsilateral axillary lymph node(s) fixed to each other or to other structures
N3: Metastasis to ipsilateral internal mammary lymph node(s) 
Pathologic classification (pN):
pNX: Regional lymph nodes cannot be assessed (not removed for pathologic study or previously
removed)  
pN0: No regional lymph node metastasis  
pN1: Metastasis to movable ipsilateral axillary lymph node(s)  
pN1a: Only micrometastasis (none larger than 0.2 cm) 
pN1b: Metastasis to lymph node(s), any larger than 0.2 cm
pN1bi: Metastasis in 1 to 3 lymph nodes, any more than 0.2 cm and all less than 2.0 cm in
greatest dimension 
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pN1bii: Metastasis to 4 or more lymph nodes, any more than 0.2 cm and all less than 2.0cm in
greatest dimension 
pN1biii: Extension of tumor beyond the capsule of a lymph node metastasis less than 2.0 cm 
in greatest dimension 
pN1biv: Metastasis to a lymph node 2.0 cm or more in greatest dimension 
pN2: Metastasis to ipsilateral axillary lymph node(s) fixed to each other or to other structures
pN3: Metastasis to ipsilateral internal mammary lymph node(s)  
Distant metastasis (M):  
MX: Presence of distant metastasis cannot be assessed
M0: No distant metastasis
M1: Distant metastasis present (includes metastasis to ipsilateral supraclavicular lymph nodes) 
AJCC stage groupings 
Stage 0 
Tis, N0, M0  
Stage I 
T1,* N0, M0





*T1 includes T1mic  









*T1 includes T1mic  
Stage IIIB 
T4, Any N, M0 
Any T, N3, M0 
Stage IV
Any T, Any N, M1 
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10.2. Karnofsky Performance Scale
Able to carry on normal activity; no special 
care needed
100 Normal, no complaints; no evidence of 
disease
90 Able to carry on normal activity; minor signs 
or symptoms of disease 
80 Normal activity with effort; some signs or 
symptoms of disease
Unable to work; able to live at home and 
care for most personal  




Cares for self; unable to carry on normal
activity or to do active work
Requires occasional assistance but is able to 
care for most of his needs 
50 Requires considerable assistance and frequent 
care 
Unable to care for self; requires equivalent 
of institutional or  




Disabled; requires special care and assistance
Severely disabled; hospitalization is 
indicated although death not imminent 
20 Very sick; hospitalization necessary; active 
supportive treatment is necessary
10 Moribund; fatal processes progressing rapidly 
0 Dead 
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10.3. Patient Information Sheet and Consent From 
INFORMATION TO THE PATIENT (original version – superceded by latest IRB-approved version)
Gene expression profiles of breast cancer treated with sequential adriamycin and 
docetaxel in relation to tumor response. 
Introduction
This document gives a description of the study in which you are being asked to participate.  
Purpose and Design of Study 
We would like you to take part in a research study using two drugs, called adriamycin and
docetaxel, in the treatment of breast cancer. Both adriamycin and docetaxel have been used 
successfully, either alone, or in combination in the treatment of breast cancer, with good 
results. A total of twenty-six patients in the National University Hospital, Singapore will take
part in the study over a period of about 18 months. 
By participating in this study, you will receive adriamycin alternating with docetaxel for a 
total of six cycles, starting with either adriamycin or docetaxel. The purpose of our study is to 
determine whether genetic changes in the cancer may be used to predict how your cancer will
respond to chemotherapy, and whether there is a difference to cancer response and gene
changes in your cancer when adriamycin or docetaxel is given before the other. We are also
studying how your body reacts to each of these two chemotherapy drugs and how these 
reactions relate to your genes.  
Description of study 
Chemotherapy is given once every 3 weeks, defined as a cycle. You will be receiving either
adriamycin or docetaxel during each cycle. If you agree to enter the study, you will be
‘randomised’ to either starting with adriamycin or with docetaxel. ‘Randomisation’ means 
that neither you nor your doctor will be able to choose which drug you would start with. You
will have the same chance of starting with adriamycin, or with docetaxel. Adriamycin will be 
administered as a 15-minute infusion, while docetaxel will be administered as a 1-hour 
infusion. The treatment will be given in the outpatient clinic. You will receive at least two
cycles of treatment unless your tumor progresses during treatment or you experience serious 
side effects.  
Your doctor will examine you before you enter this study and before each treatment. You will 
have the routine physical examinations, blood tests (before the treatment, before each cycle, 
once to twice during each cycle, and when clinically indicated); chest X-ray (baseline); CT-
scans (when clinically indicated). These tests are to ensure your safety and for the doctors to
monitor your progress during the treatment. 
About 8 samples of blood will be collected, each consisting of 1 teaspoon, when you receive 
the first cycle of each chemotherapy drug (ie, adriamycin or docetaxel). This is done through
a plastic tube inserted into one of your arm veins so that discomfort of needle pricks are 
minimised.  These studies would help us learn how your body handles the chemotherapy
drug. An additional tablespoonful of blood will be collected before you start the first cycle of 
treatment for gene studies. These are studies to understand genetic factors that may affect 
how your body reacts to the chemotherapy drugs. 
Protocol No.: HO B17/02
Version 6, 26 May 2004
Page 31 of 35






    
      
     

















    
   
   
 
 











    
  
      





A sample of your breast cancer will be obtained from you before treatment, after you receive 
the first cycle of each chemotherapy drug, and after you complete the treatment, through a
routine procedure in the clinic called a core biopsy. This is a procedure whereby a small
needle is used to take a sample of cancer tissue from you. This procedure is safe, and the 
main side effect is that of slight pain and bleeding. The purpose of taking these samples is to
allow doctors to determine your cancer response to treatment, as well as to obtain genetic 
materials to study changes.
Potential adverse effects
Both adriamycin and docetaxel have been used extensively in the treatment of advanced
breast cancer.  
Side effects will probably include: 
- temporary lowering of the white blood cells, sometimes accompanied by fever and
shivering. If these occur, you should immediately tell your doctor so that the necessary
treatment (antibiotics) can be started and so that the next administration of the medicine is
postponed, 
- total hair loss,
- allergic reaction, 
- nausea and vomiting; these side effects may be alleviated using anti-vomiting 
medications, 
- constipation, diarrhoea, 
- tingling in the limbs,  
- inflammation of the mucous membranes of the mouth,  
- pain at the place where the  injection needle was inserted, 
- impaired heart function with large cumulative doses of adriamycin; however, the total 
doses of adriamycin you will receive by participating in this study is low and is very
unlikely to result in this complication.
We advise you to check your body temperature regularly by taking your temperature by the 
mouth or under one arm. If you notice any of these symptoms or any other clinical signs such 
as a severe fatigue or fever, please phone your doctor. He/she will tell you what must be 
done and may, if the case arises, modify or change the treatment. Similarly, it will be
important to inform your doctor of any medicine that you take during this treatment, even if it 
seems insignificant to you. Women of childbearing potential must agree to have adequate 
contraception for the duration of the study and for 60 days after last treatment. 
Possible benefits
Both adriamycin and docetaxel have proven high activity against your cancer, and there is a 
high chance of shrinking your tumour. If your tumour was too large for surgery, this
treatment has a good chance of reducing the size to the point of being able to go for surgery.
However, although we know that chemotherapy can improve the evolution of your disease,
there is individual variation to response to this treatment, and we cannot guarantee with
certainty that you will have any benefit. In fact, we are hoping to be able to use the 
information derived from this study to predict who will benefit from this treatment most, and
what doses of drugs to give for optimum effectiveness and minimal side effects.  
Protocol No.: HO B17/02
Version 6, 26 May 2004
Page 32 of 35







   
   
     
 
 



























   
       
   
    
    
 
     
    
 
Alternatives
If you choose not to participate in this study, you may continue to receive standard regimens 
of chemotherapy for shrinking the tumour before surgery. Your decision not to participate in
this study will in no way affect your continued care in this institution with your physician.
Costs 
You will be responsible for paying 50% of the costs of docetaxel, full costs of adriamycin, 
routine blood tests, x-rays, scans, other laboratory tests and medical care.
You will not be paid for your participation in this study.
Confidentiality 
All data obtained during the study concerning you will be treated as confidential and only
revealed to the legal or health authorities if they so require. No information bearing your 
name will be supplied to any person whatsoever, apart from the doctors participating in the study.
You will not be individually identified in any report and/or publication based on this study. They
may be checked in accordance with the regulations currently in effect. Your genetic material will 
be kept safe in our academic institution and will not be released to industries for profit making
without seeking clearance from our ethical committees. On the other hand, if there is intellectual
property arising from this study, you will not have any claim on this. 
Patient’s protection
Protection of patient:
This study is organised in accordance with the International Consensus of Harmonization –
Good Clinical Practice Guidelines (ICH-GCP). If you follow the instructions of the doctor in
charge of this study and you are injured as a result of your participation in this study, the 
National University Hospital will pay for the treatment of that injury. Payment for 
management of the expected consequences of your treatment, including the management of 
severe nausea/vomiting or hospitalisation due to fever, will not be provided by the National 
University Hospital. 
Ethics Committee 
This protocol was submitted for examination by the National University Hospital Research
and Ethics Committee (NUH REC) whose task is to check that the conditions required for
your protection and the respect of your rights have been complied with. The Committee gave
its approval before the beginning of the study. 
Your rights
You are free to decide whether or not to participate in this study. You may refuse and, even if
you accept, you may withdraw from the study at any time without having to give the reason
for your decision. Your refusal or subsequent withdrawal will have no effect on the future
management of your disease with your doctor. If you so wish, your doctor will continue to
treat you with the best means available. Your relationship with the medical team will be
completely unaffected by your decision. 
Your doctor may also stop the study at any time without your consent if they feel there is a
reason to do this. If any important information becomes available during this study, you and
your hospital doctor will be informed of it. 
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Whatever your decision, we thank you for the attention you have paid to this information 
sheet. 
If you have any questions regarding this study, please ask your doctor.
For an independent opinion regarding the trial and your rights, please contact a member of 
the NUH REC (Attn: Ms Ms Emily Cheong) at telephone 772 5927.  
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_________________  _________________  _____________________ 
  
 
_________________  _________________  _____________________ 
 
    
 
_________________  _________________  _____________________ 
    
 
 
Patient Informed Consent 
Gene expression profiles of breast cancer treated with sequential adriamycin and 
docetaxel in relation to tumor response. 
 This trial has been explained to me in a language _______________ (state the language
used) I understand by ________________ (name of translator) on ________________ 
(date). 
 I have received, read and understood the Patient Information Sheet for the above study. I
have also received an adequate explanation of this clinical study, its purposes, risks and 
my rights as a patient and what is done to me. I have been given every opportunity to ask
questions before making my decision. I may request additional information at any time 
from the investigator. 
 I know that the decision to take part in this study is voluntary and that I have the right to
change my mind at any time during the course of the study without penalty or loss of 
benefits to which I am otherwise entitled. I shall then inform the investigator. 
 I also understand that access to relevant information from my patient notes may be 
required as part of the study, and that data collected during the study could be checked by
Health Authorities and sponsor’s representatives according to current legislation. 
I am aware that I will not be identifiable from such data extracted from my patient notes
and all data will be processed with the strictest confidence. 
 My consent does not relieve the investigator from his legal obligations.
 I agree to inform my doctor of any medicine that I take during this study. 
 I have been given a copy of this document and I was told that one copy will be held in
confidence by the investigator of this study.
On this basis, I consent to take part in this study. 
Name of subject Name of Investigator/ Name of witness 
Research staff 
Signature of subject Signature of Investigator/ Signature of witness 
Research staff 
Date Date Date 
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10.4. Evaluation and visit schedule
Pre-
treatment





(30 Days  
 post last
dose) 
Day 1 Day 8 Day 15 Day 1 Days  
10 -16
Inclusion/Exclusion criteria X
Informed consent X 
Medical history a X 
Physical examination
BSA, KPS, V/Signs a 
X X 
Limited medical history, physical
examination, BSA, KPS, V/signs b
 X X 
Concomitant medications a X X X X X X X 
Adverse events evaluation a
 (NCI CTC grading)
X X X X X X X X h 
Clinical tumor measurement c 
(Palpable lesions and skin metastasis) X X X 
Chest x-ray d X 
CT scans, bone scan & skeletal x-ray d X X e 
Haematology (FBC) f X X X X X X X 
Chemistries (Sp#1, CAP#1) f X X X X 
-HCG (patient with child bearing 
potential) f 
X 
Tumor core biopsy g X X X 
Genotyping 
adriamycin & docetaxel sampling X 
a not more than 2 weeks before study enrollment. 
b to be performed prior to each cycle, from cycle 2 onwards. 
c within 2 weeks of study enrollment.  Subsequent assessments to be done every 3 weeks. 
d within 4 weeks prior to study enrollment. Chest x-ray is mandatory, all other imaging studies (CT scans, bone scans, skeletal 
    x-rays should be performed if clinically indicated, at the discretion of the investigator.  The same clinical evaluation and  
    radiological studies must be consistently used for subsequent tumour assessment.
e radiological assessment to be repeated every 6 weeks, where appropriate. 
f within 7 days prior to study enrollment. From cycle 2, haematology to be done within 4 days prior to the start of cycles. 
g  to be performed before treatment, after cycles 1 and 2 (post nadir, prior to the next cycle), and at withdrawal or completion of the
Treatment, for a total of four biopsies. The final biopsy may be obtained at surgery.
h all study drugs related toxicities must be followed appropriately every 30 days till resolved. 
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